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Abstract 
Since the advent of structure-activity relationship (SAR) by nuclear magnetic resonance (NMR) in the 90s, 
NMR has become an essential tool in drug discovery. Though ligand observed NMR is used routinely in 
drug discovery pipelines, protein-observed NMR is more challenging to apply, but provides more 
functionally relevant information on ligand binding. This thesis describes the application of protein-
observed NMR to two targets with relevance to drug discovery – adenosine 2A receptor (A2AR) and alpha-
1-acid glycoprotein 2 (AGP2). 
The A2AR is a G-protein coupled receptor that has been investigated as a target for novel Parkinson’s 
disease treatments. These efforts have been directed towards developing novel antagonists to improve 
dopamine signalling, which the A2AR supresses. Here site directed mutagenesis and chemical conjugation 
are used to incorporate 19F tags for NMR analysis. NMR demonstrated that a novel A2AR antagonist 
induced a distinct inactive state of the A2AR. This study extends previous 19F NMR work on GPCR 
activation using a combined in silico and in vitro approach to investigate alternative inactive states to 
integrate the technique more directly into drug discovery pipelines. 
The AGP2 is a lipocalin that has a marked detrimental effect on the pharmacokinetics of a broad range of 
small molecules. Among them, the kinase inhibitor UCN-01, which has been investigated as an anti-cancer 
treatment, binds AGP2 with affinity of 3.5 nM. Here protein-observed NMR is used in conjunction with 
X-ray crystallography to elucidate this interaction and facilitate future efforts to re-design UCN-01, 
abrogating its affinity for AGP2, but maintaining its affinity for its intended target. The NMR data also 
revealed that a drastic structural change occurs in AGP2 during ligand binding, that may explain AGP2’s 
promiscuity.  
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NMR as a Drug Discovery Tool 
Nuclear magnetic resonance (NMR) spectroscopy measures the spin excitation in samples containing 
certain nuclei. The utility of NMR has been exploited for decades across several disciplines including 
geology, organic chemistry, and structural biology (Timur, 1969; Arnold, Dharmatti & Packard, 1951; 
Wüthrich, 2001), and continues to be a cutting-edge tool in structural biology today (Alderson & Kay, 2020; 
Barret et al, 2013). NMR is particularly useful as a biophysical tool because it yields parameters describing 
biochemical properties whilst observing a sample non-destructively. The simplest outputs of an NMR 
experiment are signal intensity and chemical shift. Electrons experiencing an external magnetic field form 
a local magnetic field around a nucleus and this local magnetic field modifies the external field experienced 
by that nucleus altering the observable Larmor frequency (ω) of its spin (Keeler, 2010). The size of this 
change is expressed as the relative shift from a reference compound in units of ppm and it may be used to 
infer changes in chemical environment of an atom. Other experimental parameters include rates of re-
equilibration of magnetisation (R1 and R2), the size of coupling between nuclei through space or bonds, and 
simple changes in intensity over time (Keeler, 2010).  
NMR has become a routine tool for in the pharmaceutical industry to generate and characterise leads in 
drug discovery. NMR experiments in drug discovery pipelines may be divided into two categories: Ligand-
observed NMR and protein-observed NMR. Ligand-observed NMR experiments are comparatively fast, 
easy to automate and analytically simple due to the lower complexity of small molecules relative to 
macromolecules (Villar et al, 2004). Experiments in this category are workhorses within drug discovery 
programs and some of the most common types are summarised briefly below. Protein-observed NMR is 
generally more resource-intensive than ligand-observed NMR. The advantage of observing proteins directly 
is that they are the usually the targets of drug discovery and so the information gained is more directly 
relevant to the therapeutic axis and less prone to misinterpretation (Li & Kang, 2017). 
This thesis describes the application of protein-observed NMR to two targets relevant within drug 
discovery: The adenosine 2A receptor (A2AR) and human alpha-1-acid glycoprotein (AGP). Protein-
observed NMR has been applied across a wide range of targets and includes a number of experiments. To 
highlight the utility of different protein-observed approaches, their application to the Bcl-2, M2 channel 
and β2 adrenergic receptors are described in this section. Through these examples three advantages of 
protein-observed NMR applied to drug discovery are described: 
1. The broad applicability of protein-observed NMR to provide detailed information all the 
way from hit identification to lead optimisation 
2. The flexibility of protein-observed NMR to observe the same target in different 
environments 




Ligand-observed NMR is first summarised briefly to contrast it to protein observed techniques and draw 
out the key advantages of each approach. 
Ligand-observed NMR in Drug Discovery  
Ligand-observed NMR has a great tractability advantage over protein-observed NMR, as isotopically 
labelled protein, which is most easily generated in bacterial expression systems, may be difficult to produce 
and the protein may not be soluble at high enough concentration to allow its observation (Cala, Guillière 
& Krimm, 2013). Typical small molecules found in the compound libraries of pharmaceutical companies 
contain sufficient 1H spins to be observed easily by simple 1D NMR experiments (Liu et al, 2012). 
Furthermore, 19F-containing compounds are increasingly being used in fragment-based drug discovery 
processes, thus expanding the scope of NMR applications (Norton et al, 2016). 
Some of the most common ligand-observed NMR methods used in drug discovery are: 
• Saturation transfer difference (STD) 
• Water-ligand observed via gradient spectroscopy (WaterLOGSY) 
• T2 relaxation filtering 
• Fluorine chemical shift anisotropy and exchange for screening (FAXS) 
Saturation Transfer Difference 
STD experiments, shown schematically in Figure i.1, use saturation transfer of magnetisation from the 
protein to a small molecule to distinguish ligands from non-binders (Mayer and Meyer, 1999). 
A STD spectrum is the calculated difference between two spectra, the first in which protein spins are not 
saturated and a second where they are saturated. In the saturated spectrum the protein spins are excited by 
a series of on-resonance narrow bandwidth NMR pulses (typically 1H methyl spins between 2 and -1 ppm, 
purple bolt in Figure i.1). Over a period of seconds, these saturated spins transfer magnetisation to 
neighbouring spins and will eventually transfer to proton spins of a ligand interacting with the protein. The 
2 to -1 ppm region is chosen to exclude shifts that commonly occur on ligands found in fragment decks 
whilst allowing protein methyls to be excited (Pellechia et al, 2008; Harner et al, 2017). The fast exchange of 
ligands on and off the protein leads to an accumulation of saturated ligand spins in solution, which then 
display a lower amplitude free induction decay after a 90° pulse. The off-resonance spectrum uses selective 
irradiation of some irrelevant part of the spectrum away from both protein and ligand shifts. A subtraction 
of the on-resonance spectrum from the off-resonance spectrum then reveals which ligands associate with 
the protein as saturation transfer from the protein to the ligands supresses ligand spin longitudinal 
magnetisation leaving behind small positive peaks after a 90° pulse. Conversely, there is no effect on non-
binding compounds whose signals are therefore removed in the subtraction. This technique typically uses 
only 0.5-3 µM target protein samples with an excess of the ligand, typically up to 100-fold, to yield a sensitive 




including less tractable integral membrane proteins such as Integrin αIIbβ3 (Meinecke & Meyer, 2001), 
demonstrating its broad utility. 
At its most basic level, an STD experiment can confirm binding or non-binding of a ligand. When applied 
to small molecules with sufficient observable spins some information on ligand binding pose may even be 
deduced (Mayer and Meyer, 2001). Spins from ligand motifs more closely associated to the protein receive 
more magnetisation transfer and so are more intense in the difference spectrum than other spins within the 
same ligand. This methodology is not, however, reliable, or fast enough to be routinely used in screening 
pipelines. One source of unwanted variation is that different spins within a small molecule may have 
significantly different longitudinal relaxation rates that may impact the magnitude of the STD effect and so 
yield a misleading epitope map (Yan et al, 2003). 
A limitation of STD is that it cannot be applied to ligands that are not soluble enough to be observed in an 
excess ratio to the protein. Ligands must also have affinities to the protein of between 10-3 M and 10-8 M, 
as weaker binders will not be on the protein for enough time to allow magnetisation transfer and tighter 
binders will not exchange fast enough into solution to allow magnetisation transfer to spread across the 
entire ligand population (Mayer and Meyer, 1999). The technique is nonetheless widely employed to screen 
fragment libraries for initial binders as fragments are typically more soluble and have lower affinity than 








Protein binder exchanges in and 
out of  binding site
Off-resonance pulses do not 
excite protein 1H spins
Ligands associating with 
the protein show peaks 
in the difference 
spectrum whereas non-
binders are absent
On-resonance excite protein 
1H spins
Non-binder
Difference between on-resonance and 
off-resonance spectra is calculated
Non-bound small molecules maintain the same
intensity, whereas bound ligands cannot be excited
due to a loss of Z magnetisation by transfer from
the protein
Figure i.1 Schematic of STD experiments to detect weak binders to target proteins. This method is suitable for 





WaterLOGSY (Shown schematically in Figure i.2.) is an alternative difference spectrum method which uses 
magnetisation transfer from 1H spins in water to small molecules (Dalvit et al, 2000). As with STD 
experiments the final output is a difference spectrum in which the off-resonance spectrum is subtracted 
from the on-resonance spectrum.  
 
Prior to excitation of the small molecule spins bulk water is saturated in the on-resonance spectrum or not 
in the off-resonance spectrum.  
Negative NOE enhancement between protein-bound water molecules and protein-bound ligands reduces 
the population of excitable ligand spins at equilibrium, due to the slow tumbling of the complex. Conversely 
NOE effects from free water to solvated small molecules increases the proportion of excited spins that are 
then observed in the resultant 1D spectrum. The difference spectrum from the off-resonance control 
experiment and the on-resonance spectrum gives negative peaks for non-binders and positive peaks for 
binders. 
This method has many of the same advantages and drawbacks as STD and may be run with similar 
concentrations of small molecules and protein (Harner et al, 2017), but with the added convenience of the 
non-hits being observable in the final spectrum. This can help rule out a supposed hit being due to 






does not affect spins
Binders and non-binders
show small positive or
negative peaks respectively in
the difference spectrum
Non-binder
Difference between on-resonance and
off-resonance spectra is calculated
On-resonance pulses
excite water 1H spins
NOE effects boost longitudinal magnetisation for
non-binders, whereas NOE transfer between bound
ligand and bound water supresses magnetisation
leading to a smaller signal
Figure i.2 Schematic representation of fragment screening by WaterLOGSY. Excitation of 1H spins in water 
causes NOE transfer to protein-bound ligands from protein-bound water which supresses longitudinal 
magnetisation and yields smaller signals, whereas transfer from free water to unbound ligands increases 
longitudinal magnetisation due to the faster tumbling rate and so the resultant ligand peaks are larger. Therefore, 




WaterLOGSY has also been reported to enjoy an advantage over STD in sensitivity (Antanasijevic, Ramirez 
& Caffrey, 2014), although STD may still be advantageous as it reports directly on magnetisation transfer 
from target to ligand rather than from associated water.  
T2 Relaxation Filtering 
The T2 relaxation rate of a spin changes with the tumbling rate of that spin in solution. This may be exploited 
to screen ligand binding events to proteins by a method shown schematically in Figure i.3 (Dalvit, 2009). 
 
A delay containing a Carr-Prucell-Meiboom-Gill (CPMG) pulse train (Carr & Purcell, 1954; Meiboom & 
Gill, 1958) between initial excitation and signal observation allows spins with fast relaxation rates to relax 
to equilibrium and so are reduced or not observed in the test spectrum. This method requires a control in 
the absence of protein for each test to ensure that ligand signals are broadened/removed significantly 
relative to signals from solvated ligand.  
Variations on T2 relaxation filtering include target immobilised NMR screening (TINS). This method is 
employed to reduce the target material consumption of a screening campaign by tethering the target to solid 
material within the NMR tube, allowing the target protein to be washed and re-used (Vanwetswinkel et al, 
2005). As in the standard un-tethered methodology the broadening effect of a slowly tumbling complex 
leads to a reduction in intensity of protein-bound small molecules due to an increased transverse relaxation 
rate. This effect is intensified when the tumbling of target proteins is restricted further by tethering to a 
solid substrate within the NMR sample. This method was applied to the A2AR which is the subject of 




1D relaxation filtered control in
absence of protein
All small molecules display slow T2
relaxation in the absence of protein
Faster T2 relaxation broadens the
peaks of protein binders, allowing
their identification whereas non-
binders are unaffected
Binders experience slower
tumbling when on the protein
Figure i.3 Schematic representation of fragment screening by T2 relaxation filtering. The experiment requires two 




The advantages of T2 relaxation filtering are that it may be carried out with concentrations of ligand and 
protein as low as 10 µM (Dalvit, 2009) in each experiment, which allows the technique to be applied to less 
soluble ligands, and it may be applied to stronger binders than saturation transfer or NOE experiments.  
FAXS 
FAXS (described schematically in Figure i.4) circumvents several limitations of the other ligand-observe 
techniques by observing 19F in a known binder that acts as a “spy molecule”. This molecular probe can 
then be monitored for changes in behaviour if it is competed out of the protein binding site by the addition 
of a second ligand (Dalvit et al, 2003).  
A FAXS experiment is a 19F-detection experiment run by the same principle as T2 relaxation filtering; 
experiments consist of 90° excitation pulses followed by a time delay containing a refocusing CPMG pulse 
train. The time delay between excitation and observation of 19F spins on the spy molecule removes fast-
relaxing signals. Chemical shift anisotropy makes a major contribution to 19F transverse relaxation resulting 
in significant line broadening when the tumbling rate of the spin slows down, such as when the ligand is in 
complex with a protein. This effect may be strong enough to entirely remove the peak of the bound spy 
molecule in a 1D spectrum. 
To determine if a test compound binds the protein T2-filtered signal of the spy molecule in the presence 
and absence of test compound are collected. The re-appearance of the spy-molecule peak as it is competed 
out of the ligand binding sight is followed to report on binding events by the ligands being screened.  
Observing a spy molecule removes some limitation from ligand properties that may vex other experiments. 




Non-binders do not compete
out the spy molecule
Bound spy molecule gives a
broad peak
Free spy molecule exhibits a reduced 
R2, sharper signal and may shift from 
the bound spectrum
Therefore test compound
deduced to be non-binder
Therefore test compound
deduced to be binder
Figure i.4 Schematic representation of fragment screening by FAXS. In the absence of fragment hits the spy 





out of the specific binding site. It also shares the advantages of T2 relaxation filtering in allowing tight 
binders to be observed and, as it observes 19F spins, eliminates problems with signal overlap.  
On the other hand the observation of a specific binder removes the possibility of finding or probing 
allosteric hits in sites outside of the known orthosteric binding site and limits the possibility of screening 
fragment cocktails as spy molecule displacement by a single binder may not be distinguished from 
displacement by multiple binders. It is of course also necessary to possess a known fluorine-containing 
ligand for the target molecule. 
Shared Problems with Ligand Observed Approaches 
Although ligand-observed NMR experiments provide efficient methods for screening small molecules for 
binding to a target, they all have certain limitations. Other than in specific and very favourable circumstances 
they do not give precise information on ligand binding mode. As noted, STD experiments with ligands that 
have multiple observable groups can give information on orientation and FAXS by its nature reports on a 
binding to a particular site. This information, however, falls short of atomic resolution 3D mapping of a 
binding site that is necessary for rational lead optimisation. The compound decks must also be carefully 
curated to exclude compounds that aggregate or associate non-specifically with the protein as all the 
experiments described above other than FAXS are prone to report such compounds as false positives.  
To obtain maximum value from NMR as a drug discovery technique protein observation must be employed 
to transcend the limitations of ligand observed NMR.  
In-Solution NMR of Isotopically Labelled Proteins with Bcl-2 as a Case Study 
In solution observation of isotopically labelled proteins is a well-established methodology in structural 
biology with the first NMR structure of the bull proteinase inhibitor IIA published over 30 years ago 
(Williamson, Havel & Wüthrich, 1985). Observation of the protein target itself is a significantly more 
powerful approach than ligand-observed NMR in drug discovery, applicable from hit identification through 
to lead optimisation. This point is illustrated well by work on the Bcl-2 protein family. 
The Bcl-2 family members are a set of proteins containing a variable number of Bcl-2 homology 3 domains 
(BH3) (Kale, Osterlund & Andrews, 2018). These proteins form a signalling network based on BH3 domain 
dimerization that controls apoptosis. As evasion of apoptosis is a hallmark of cancer anti-apoptotic 
members of the Bcl-2 family are often upregulated in tumour cells and are therefore a target for small 
molecule inhibitors (Kale, Osterlund & Andrews, 2018). 
HSQC in Drug Discovery 
Bcl-2 itself was the target of an extensive fragment screening effort using heteronuclear single quantum 
correlation (HSQC) monitoring chemical shift perturbation (CSP) using a minimal shift analysis (Petros et 




shift of the indirectly observed, less sensitive nucleus (typically 13C or 15N) and the signal of the directly 
observed nucleus (usually 1H) generate a two-dimensional plot described schematically in Figure i.5. 1H-15N 
HSQC experiments are a common variant of HSQC in structural biology as each protein may ideally yield 
a predictable and manageable number of well-resolved peaks based on its primary structure, one signal for 
each backbone amide with the exception of proline. 1H-13C HSQC spectra are also employed, but are 
generally less well-dispersed unless 13C labelling of specific groups is used (Williamson, 2013). Dispersion 
of the signals in the 2D plane is determined by the secondary and tertiary structure of the protein in addition 
to other factors such as pH, temperature and buffer used. Chemical shift is dependent on the chemical 
environment of a spin, and so the binding of a small molecule ligand close to a protein 1H-Heteroatom pair 
causes a change in the chemical shifts of those spins known as chemical shift perturbation (CSP). CSPs can 
arise directly at the ligand binding interface and also from conformational changes induced elsewhere in the 
protein. CSPs therefore readout on two important mechanisms of action: Orthosteric mechanisms and 
allosteric mechanisms. Orthosteric binding is the direct blocking of the natural protein binding epitope, the 
BH3 cleft in the case of the Bcl-2 family (Petros et al, 2010). Allosteric binding is the distal binding of a 
ligand causing a conformational change in the protein’s functional site (Manley & Loria, 2012). In fragment 
screening backbone chemical shift assignments of the 1H-15N HSQC spectrum for the apo protein are 
typically sufficient. CSPs can then be mapped onto the protein sequence or structural model by assuming 
that the peaks in a ligand-bound spectrum with the minimum shift from a peak in the assigned apo spectrum 
correspond to the same residue. There are several methodologies by which CSPs are categorised as 
significant or insignificant; the application of these methodologies may vary between different research 
groups. The decision on setting a threshold value for significance may be considered a trade-off between 

























































spin pair yields a
peak in the 2D
spectrum
Figure i.5 (A) Apo protein yields a peak for each 1H-Heteroatom pair environment in the sample. The number 
of peaks may be predicted from the protein primary structure and their identities may be determined from triple 
resonance experiments. (B) An HSQC may be used to screen and characterise the binding of small molecules to 
the protein targets. By comparing the chemical shifts of the protein before and after addition of small molecules 
it may be determined whether or not they are binders. Further, the binding site of a ligand may be identified as 








sensitivity and specificity. One method is to select those residues whose peaks move by more than 1 or 2 
standard deviations of the total chemical shift changes (Williamson, 2013). Another method is to iteratively 
calculate a standard deviation of the maximum number of peaks in a spectrum that all fall within their own 
standard deviation and to identify those peaks which fall outside of that value as shifting significantly (thus 
not raising the threshold due to some highly significantly shifted peaks)(Williamson, 2013).  
CSP has advantages over previously discussed ligand-observed techniques. The fact that the protein is 
observed directly serves to rule out ligand aggregation artefacts that may plague STD and WaterLOGSY 
experiments and the binding site of a small molecule is identified concomitantly with screening. CSP also 
rules out non-specific association with the protein that may affect STD, WaterLOGSY and T2 screening. 
Furthermore, as a screening technique CSP may immediately categorise hits as orthostatic or allosteric 
which ligand-observed techniques cannot do, indeed FAXS may discard allosteric binders altogether by 
registering allosteric binders as false negatives.  
Bcl-2 binders were identified in a 1H-13C HSQC screen (Petros et al, 2010). As protein aliphatic sidechains 
(which are visible in a 1H-13C HSQC) often form the direct contacts between ligands and proteins this 
screening method is likely to yield more direct evidence of binding than a 1H-15N HSQC which monitors 
only backbone perturbations, but the spectra are likely to be more crowded in a uniformly labelled spectra 
(Hajduk et al, 2000). Chemical shift assignments, a prerequisite for mapping binding epitopes, were based 
on the authors’ previous structural study that resulted in a full solution structure (Petros et al, 2000). Hajduk 
and co-workers initially screened 17000 fragment-sized small molecules and identified a potent 
diphenylmethane hit.   
As discussed above a drawback of protein-observed NMR is the large quantity of protein consumed. This 
Bcl-2 screen, for example, required 50 µM protein samples, and all 17000 fragments most likely had to be 
screened individually. For a 5 mm NMR probe, as used in the study (Petros et al, 2010), 200 μl samples are 
likely, assuming that 3 mm NMR tubes were used to conserve material. With a 19.23 kDa Bcl-2 construct 
the full screen would have required more than 3 g of protein from 13C-glucose labelled minimal media, even 
without including the material necessary for generating the structure and assignments in the first place. Such 
an expense may be out of reach for many academic groups, but is feasible for a project that may pay large 
commercial dividends. The success of this method also relies on the protein being stable in the 
concentration of DMSO necessary to solubilise the fragment in a large excess. 
Following the identification of binders to Bcl-2, CSP was further used to determine the affinities of the 
fragment hits. Under conditions of fast exchange between two states (in this case bound and unbound) an 
NMR spectrum will represent a population-weighted average chemical shift of those states rather than 
resolving them as separate signals. By collecting titration data with increasing ligand concentrations the 
chemical shift variation may be fitted to standard ligand binding equations to determine a KD (Fielding, 
2007). This approach to measuring KDs is limited by the kinetics of the binding event as shown schematically 




effect on the peaks makes fitting an accurate titration curve difficult. Unfavourable chemical exchange 
timescales may also hinder structural NMR studies of ligand-protein complexes if regions of the protein 
are in exchange between multiple conformational states. In the case of the Bcl-2 study under consideration 
the affinity of the primary fragment hit was determined to be 20 µM and so this was not a limitation. 
However, a drug discovery effort on the related Mcl-1, a member of the Bcl-2 family, illustrates the problem 
as the experimental temperature had to be altered to improve the chemical exchange conditions (Caenepeel 
et al, 2018). In a robust system modifying temperature to achieve favourable chemical exchange may not be 
an obstacle, however when less stable targets, such as membrane proteins, are studied these modifications 
may not be possible and so may limit the application of NMR methods.   
NMR Structures in Drug Discovery 
Having identified a hit to Bcl-2, NMR was employed to carry out a full structural characterisation of the 
binding of the diphenylmethane fragment to the protein. A solution NMR structure of Bcl-2 (modified 
with some Bcl-xL residues to improve solubility) was available before the study and is shown in Figure i.7. 
(Petros et al, 2000). 
Although structural determination by NMR has declined in popularity since its peak in 2007 when 965 
NMR structures were deposited, it is still an important technique in structural biology with 380 structures 
deposited to the protein data bank in 2019 (Berman et al, 2000). The increasingly routine nature of X-ray 
crystallography may be part of the reason. NMR is perhaps best applied to those targets, or parts of targets, 
with particular characteristics that make them intractable to crystallography. Work on the Bcl-2 family 
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Peak shifts from apo to fully
bound state with increasing
ligand concentration.
In intermediate exchange peaks
become broader as a mixture
bound and unbound forms are
present.
Figure i.6 (A) For binding events in fast exchange, a peak is observed at the weighted average shift between the 
bound and unbound form. By tracking this average peak, a titration curve may be used to determine the KD of the 
ligand to the protein. (B) In slower exchange regimes peaks become broadened when a mixture of states is present 
rather than allowing the observation of an average chemical shift. This may hinder the calculation of an accurate 
KD, but for very slow exchange a KD may be determined by fitting the relative intensities of the 2 peaks to a 




illustrates this as the first structures of the Bcl-2 
homologue Bcl-xL were solved by NMR and X-ray 
crystallography and described in a single publication 
(Muchmore et al, 1996) with the helix I/II loop 
observable by NMR, but not by crystallography. 
Unstructured loops in fast conformational exchange 
are often visible in NMR spectra giving rise to 
sharper resonances than the bulk of the protein and 
so may be observed in solution; on the other hand 
the conformational heterogeneity of loop regions 
hinders repeatable crystal packing necessary for their 
observation by crystallography. NMR is therefore 
best applied to solving structures of proteins whose 
functions require them to be dynamic in solution and undergo conformational rearrangement.  
Beyond the 1H, 15N and 13C chemical shift assignment of the protein backbone and side chain resonances 
the main type of data needed to solve NMR structures is a set of nuclear Overhauser effect (NOE) 
constraints. NOE constraints for protein structural determination arise from dipolar couplings between 
nuclei, usually protons, that are proximal in space and not J coupled, resulting in NMR peaks in the off 
diagonal spectral region with intensities dependent on the proximity of individual nuclei to the power of 6 
(Keeler, 2010). The form of a protein NOE experiment is shown schematically in Figure i.8. The peak 
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other protein peaks provide
distance restraints for protein
structure determination
Figure i.8 (A) The structure of a protein may be calculated from distance restraints derived from 1H-1H 
intramolecular protein cross peaks, which allow the distance between two spins to be calculated. Protein-ligand 
NOEs appear as cross peaks that are not correlated to any observed diagonal peaks in the indirect dimension. (B) 
When 12C filtering is applied to the indirect dimension crosspeaks solely between 1H spins attached to 13C are not 
observed and so protein-ligand NOE peaks between 1H-13C and 1H-12C may be identified unambiguously and 
used to calculate distance restraints for the protein:ligand complex. 
 
Figure i.7 NMR structure Bcl-2-Bcl-xl hybrid 
[PDB:1G5M] (Petros et al, 2000) The authors went on 
to use NMR to determine the binding conformations 




intensities can be used to calculate a series of distance constraints between assigned spins. An ensemble of 
protein structures that violate the minimum number of NOE distance constraints is generated as a 
structural model.  
Further, if the spins in a protein are assigned, NOE data sets may be used to determine the structure of a 
ligand-protein complex as NOE signals between the protein and the ligand appear as new peaks in the 
NOE spectrum and can be used to introduced distance constraints of the ligand:protein complex. Protein-
ligand NOE’s are often, however, more easily identified by using filtered experiments to observe the ligand 
1H resonances in the indirect dimension whilst removing intramolecular protein NOE peaks (Otting & 
Wüthrich, 1990). 
Hajduk and co-workers used this methodology to identify the binding site of their diphenylmethane 
fragment and found it to be in a different part of the Bcl-2 binding pocket compared to known biaryl 
binders to the homologous Bcl-xL (Petros et al, 2010). NMR was further used to generate distance restraints 
for a complex of both a biaryl ligand and the diphenylmethane demonstrating that both ligands could bind 
to Bcl-2 concomitantly.  
To produce a ligand with a higher affinity for Bcl-2 the previously known biaryl and newly identified 
diphenylmethane fragments were joined by an alkyl linker as shown in Figure i.9. The rational assembly of 
fragment sized ligands, based on NMR data, to form larger molecules is a common approach in fragment-
based screening as initial hits that do not have the necessary affinity for their target to act as a drug can be 
rapidly expanded (Harner, Frank and Fesik, 2013).  
The complex of the newly designed ligand bound to Bcl-2 was solved by NMR and confirmed to occupy 
the two adjacent binding pockets of the individual fragments as shown in Figure i.10 overlaid with the 
position of the novel diphenylmethane ligand. 
The affinity of the Bcl-2 ligand after optimisation 
was 40 nM (Petros et al, 2010). The limitation of 
NMR in determining ligand affinities is 
highlighted by need for a fluorescence polarisation 
assay to determine the affinity of this last 
compound as the binding exchange rate would 
likely be slow enough to require a potentially less 




Figure i.9 The diphenylmethane compound (top 
left) was linked with a previously known biaryl 





Before and since this work Abbott has developed other ligands that target the Bcl-2 family of anti-apoptotic 
proteins. The experimental drug Navitoclax (shown in Figure i.11.), which inhibits Bcl-2 and Bcl-xL, has 
been the subject of 16 completed clinical trials and 5 ongoing ones at the time of writing according to the 
U.S. National Institute of Health (clinicaltrials.gov). Hajduk and co-workers expressed their hope that the 
compound derived from the described structure activity relationship (SAR) by NMR approach would 
inform future efforts to develop anti Bcl-2 compounds (Petros et al, 2010). 
Although the described NMR techniques were applied very effectively to Bcl-2, it should be noted that the 
Bcl-2 constructs used in these studies were small and soluble, making them well-suited to these NMR 
techniques. Many targets of drug discovery do 
not fall within these parameters and so 
alternative NMR methods must be applied. 
Membrane proteins, for instance, are not soluble 
without associated amphipols and so NMR 
techniques must be adapted for drug discovery 
studies on these targets. An example of such a 
protein investigated using alternative NMR 
techniques is described in the next section.  
To summarise: In solution observation of 
proteins is a versatile technique across the entire 
span of a drug discovery project from screening, 







Figure i.10. The optimised compound derived from fragment linking (orange) is shown binding across 
both the known biaryl pocket and the novel binding pocket. The biphenylmethane moiety of the 
optimised compound binds in a similar position to the original biphenylmethane ligand (purple) 
(Adapted from Petros et al, 2010). 
Figure i.11. Structural representation of the 




increased time and resource cost relative to ligand-observed NMR means that protein-observed techniques 
are often reserved for validation and characterisation of initial hits. However, as this Bcl-2 study 
demonstrates, protein-observed NMR can be applied to both fragment-sized and drug-sized compounds 
to generate a valuable output, if the target is tractable to the relevant NMR techniques. 
Protein-Observed NMR of Membrane Protein Targets with M2 Influenza A Channel as a 
Case Study 
Drug discovery efforts must often target proteins that are significantly less tractable than Bcl-xL or Bcl-2. 
In these cases, the greater flexibility of NMR relative to crystallography in terms of experimental conditions 
becomes important. Structural biology studies of the influenza A M2 proton channel transmembrane 
domain illustrate this point. 
Membrane proteins include some of the most attractive drug targets in medicine. These proteins are 
inherently less tractable to biochemical and biophysical techniques than their soluble counterparts due to 
their extensive hydrophobic transmembrane domains that must be associated with lipids or lipid mimics to 
maintain the conformational stability, and therefore functional status, of the protein.  Membrane proteins 
are targeted by an extensive range of drugs many of which, such as bisoprolol and morphine, are included 
in the World Health Organisation’s list of essential medicines (World Health Organisation, 2019). It is 
therefore inevitable that further study of these difficult protein targets must be undertaken to develop new 
drugs and better understand the mechanisms of existing therapeutics.  
The pseudo tetrameric M2 channel from influenza A virus is the target of antiviral drugs to treat influenza, 
reducing the duration of symptoms and minimising complications (Shen, Lous and Wang, 2015). During 
cell infection, the influenza virus triggers invasion of the cytoplasm by an internal drop in pH mediated by 
the M2 proton channel. The adamantane-based drugs for treatment of influenza inhibit the M2 proton 
channel thus preventing the virus from infecting the cell. The admantane drugs amantadine and rimantadine 
(shown in Figure i.12) were used as treatments for influenza. The evolution and almost universal spread of 
mutant influenza viruses resistant to these drugs necessitates the design of new compounds to treat resistant 
strains (Shen, Lou & Wang, 2015). Rational modification of amantadine and rimantadine necessitates an 
atomic-level understanding of their mechanism of action, which has been provided by structural studies. 
The fact that M2 is a membrane protein complicated crystallisation efforts. Detergent micelles used to 
solubilise membrane proteins do not form consistent crystal contacts easily and may occlude hydrophilic 
parts of the protein that are able to mediate such interactions. Therefore, careful detergent selection or 
extensive screening is necessary. Perhaps as a result of this, the first structural model [PDB: 1NYJ] of M2 




ssNMR samples constitute a form of the target protein that is 
fixed in solid rather than being solubilised. An advantage of 
this technique for membrane proteins is that the proteins may 
be prepared in lipid bilayers which more closely replicate 
physiological membranes than detergent micelles do, although 
the sample preparation, often in anhydrous conditions, may 
stress the sample more than solution state sample preparation. 
For the initial M2 structural study 1,2-dimyristoyl-sn-glycero-
3-phosphocholine (DMPC), a lipid that spontaneously forms 
bilayers, was used as a membrane mimetic. The lack of in-
solution tumbling in such a sample results in extreme 
broadening of NMR signals from the effects of CSA. 
Fortunately, ssNMR samples yield well-dispersed sharp 
spectra when spun at several thousands of kilohertz at the “Magic Angle” of 54.74° to the B0 field which 
averages out the direction-dependant chemical shift anisotropy, allowing data for the determination of 
protein structures to be collected (McDermott, 2009). This spinning also supresses the structurally useful 
dipolar couplings between nuclei, but they may be reintroduced by the application of specific 
radiofrequency pulses to the sample to generate data for structural restraint determination. 
The derivation of structural restraints from dipolar couplings allowed a model of the M2 channel to be 
proposed (Nishimura et al, 2002). This structural model indicated that the pore of the proton channel was 
sufficiently large to allow the binding of amantadine, supporting this as a mechanism of drug action against 
the virus. 
Subsequently, atomic resolution structures of the M2 
tetramer in complex with adamantane drugs were 
determined by crystallography and solution NMR(Schnell 
& Chou, 2008; Stouffer et al, 2008). The crystal structure 
of the M2 tetramer contained a single amantadine 
molecule bound in the channel pore close to the 
extracellular face, as hypothesised from the ssNMR 
model. Conversely the solution NMR structure contained 
4 rimantadine molecules bound around the internal face 
of the M2 channel. These alternative structures are shown 
in Figure i.14. 
These alternative binding modes of adamantane drugs 
were not necessarily in conflict with one another and were 
both published in the same issue of Nature. Subsequent 
 
Figure i.13 Structural model of M2 protein 
channel [PDB: 1NYJ], based on limited set of 
dipolar couplings, viewed from extra-viral face. 
From this model, amantadine binding in the 
centre of the pore was hypothesised 
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Figure i.12 Adamantane drugs act by 
inhibiting the influenza A virus M2 proton 
channel (A) Structure of amantadine. (B) 




reviewers have suggested that both structures are possible and consistent with other functional data 
(Kozakov et al, 2010). The X-ray and NMR structures were solved in open and closed conformations 
respectively, likely due to the different conditions under which they were obtained. The crystals were 
generated in octyl-β-D-glucopyranoside as a membrane mimetic system with polyethylene glycol (PEG) as 
a precipitant at pH 5.3 (Stouffer et al, 2008). By contrast the solution NMR structure was solved in DHPC 
micelles, without PEG at a pH of 7.5 (Schnell & Chou, 2008). Differences in membrane mimetic systems 
between studies are a concern in the study of all membrane proteins, including the A2AR as will be discussed 
in Chapter 1. 
The M2 NMR sample also contained 40 mM of rimantadine whereas the M2 was crystallised with only 0.6 
mM amantadine whilst the protein concentrations were comparable at 0.75 mM and 0.5 mM, respectively. 
The excess ligand in the NMR structure may be necessary to drive occupancy of the putatively lower affinity 
binding sites around the internal base of the channel. Another possible contributing factor to the difference 
is the construct used in the NMR structure, which was not truncated to the same extent as the 
crystallography constructs (Schnell & Chou, 2008). There are, however, no subsequent NMR studies using 
constructs as large as that used by Chou & co-worker and so it is difficult to draw conclusions relating to 
this factor. The effects of differences in protein constructs have been investigated in the GPCR field as will 
be discussed in Chapter 1 (Eddy et al, 2016). The discrepancy in the M2 may also be due to the different 
structures of amantadine and rimantadine.  
Although the binding site identified by crystallography was the higher affinity site there is value in 
identifying alternative sites as they may be 
explored in further drug discovery efforts. In 
this respect the flexibility of NMR is a 
significant advantage in being able to observe 
transient or less populated conformations 
which may be present under different 
conditions from those required for 
crystallography.  
Following the initial ligand binding studies, the 
flexibility of NMR as a technique is highlighted 
by the relative frequency (compared to 
crystallography) with which new binding 
studies were published following the initial 
effort. In 2010 a ssNMR structure of 
amantadine bound in the channel pore of the 
M2 protein, was published, as in the crystal 
structure (Cady et al, 2010). The ssNMR study 
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Figure i.14 (A) Solution NMR structure of M2 
transmembrane domain in complex with rimantadine 
bound outside the helical bundle [PDB: 2RLF] (B) Crystal 
structure of M2 transmembrane domain in complex with 




did also observe a low affinity binding event in the presence of a large excess of amantadine towards the 
C-terminus of the M2 protein, as observed in the solution state structure. The 2010 structure [PDB: 2KQT] 
was solved in DMPC bilayers at pH 7.5 and revealed a more tightly packed helical bundle (similar to the 
“closed” conformation of helices shown in the 2008 solution state structure). By allowing the observation 
of the M2 channel at a higher pH the NMR studies provide a more complete picture of the M2’s structure 
and interaction with its inhibitors.  
Subsequent studies of novel M2 inhibitors exploited the flexibility of 
NMR to investigate the binding of ligands designed to overcome 
resistance. Resistant influenza channels contain the mutation S31N 
(situated close to the in-channel drug binding site) and this mutant 
was investigated with solution NMR (Wang et al, 2013; Wu et al, 
2014). These studies determined the structures of the potential anti 
influenza drugs M2JW332 and a compound referred to as 
“compound 11” (a modified amantadine shown in Figure i.15) in 
complex with the mutant S31N M2 proton channel transmembrane 
domain.  
In illustrating the flexibility of NMR these studies are significant as 
no further crystal structures of the M2 channel in complex with its 
inhibitors were published in the 10 years between 2008 and 2018, 
when structures of the channel with 3 adamantanes were solved in 
lipidic cubic phase crystals, thus highlighting the superior flexibility of 
NMR in conducting follow-up studies of compounds related to the 
initially investigated drug (Thomaston et al, 2018). Although all the M2 studies discussed in this section were 
carried out in academia, the analogy to a commercial context highlights that in some cases rational drug 
design is enabled by taking advantage of the adaptability of NMR to varied experimental conditions to 
expedite progress where the target is less tractable to crystallography. Although, as discussed in this 
example, crystallographic studies may often deliver a structure of a target before or concomitantly with 
NMR, it may be difficult to explore the effects of alternative experimental parameters on the system. Crystal 
conditions must necessarily be chosen primarily by whether they generate crystals. In the case of the M2 
channel, amantadine co-crystallisation conditions were screened by pH and a hit was found at a pH of 5.3 
(Stouffer et al, 2008). On the other hand, although NMR often benefits from specific pH conditions, these 
may be varied in a continuous way to explore a greater range of protein environments.  
In co-crystallisation studies (such as those of the M2 channel), the presence of a particular ligand itself may 
be essential for crystal formation, in that certain ligands promote crystallisation whereas others do not. 
Many apo crystal structures may in fact contain additives which may compete with ligands for the active 
site. Some protein crystals are sufficiently stable to allow ligands to be soaked in after the fact without 
 
Figure i.15. Structural 
representation of “compound 11” 
– a modified amantadine solved in 




disrupting the lattice indicating that the protein has crystallised in a conformation pre-disposed for ligand 
binding. If a large conformational change is required to accommodate the ligand crystals may crack and not 
yield useable diffraction data. Further, the crystallised form may represent only one conformational state of 
a dynamic protein, and so provide an incomplete understanding. 
High resolution NMR is more flexible with respect to studying new ligands as they may simply be added to 
a protein solution allowing the protein to sample its natural conformational repertoire unimpeded. A 
drawback of traditional NMR methods is the requirement for isotopically labelled protein and, minimally, 
assignment of the backbone amide resonances to specific amino acids. Novel selective labelling and tagging 
approaches have extended the range of protein systems amenable to NMR to new targets such as the one 
described in the next section.  
To summarise: The advantage in adaptability allows NMR to accelerate drug discovery lead optimisation, 
in many cases faster than other methods, thus saving resources and leading to efficiency in drug 
development pipelines. 
19F Tagging for Conformational Landscape Mapping with β2-adrenergic Receptor as a 
Case Study 
Studies of the β2-adrenergic receptor illustrate that alternatives to standard NMR approaches (standard 
NMR approaches relying on protein backbone assignment) widens the scope of the technique to more 
challenging drug discovery targets. Interest in the β2-adrenergic receptor stems from its importance as a 
target of cardiovascular drugs such as carvedilol (Velmurugan, Baskaran & Huang 2019). 
The specialist equipment necessary for solid-state NMR and the challenge of generating isotopically labelled 
material for difficult-to-express membrane proteins limits the application of NMR to difficult targets. 
Although chemical shift analysis has been applied to a protein complex in excess of 900 kDa (Fiaux et al, 
2002) structural determination has generally been considered to be limited to proteins of around 25 kDa 
(Sugiki, Kobayashi & Fujiwara, 2017). Many drug discovery targets fall outside of this range and so many 
of the techniques described above are difficult to apply, either because of issues with spectral quality, such 
as excessive line broadening due to slow molecular tumbling, or the assignment problem associated with 
severely overlapping signals in uniformly labelled samples.  
G-protein coupled receptors (GPCRs), which are described in greater depth in Chapter 1, are 7-
transmembrane helical proteins that long eluded structural characterisation due to their intractability in 
expression, conformational plasticity and instability when extracted from their native membrane 
environment. However, in recent years advances in NMR and crystallography methods have provided 
complementary approaches to advance our understanding of the protein family (Shimada et al, 2018). The 
β2-adrenergic receptor (a structure of which [PDB: 2R4R] is shown in Figure i.12) is an archetypal member 




first crystal structure that did not contain a bacterial 
fusion protein (as displayed in Figure i.16), despite 
being truncated, had a mass of around 41 kDa 
(Rasmussen et al, 2007), potentially outside of the 
mass range of classical NMR techniques.  
Advances in understanding the effects of small 
molecule drugs on the GPCR protein family were 
made by applying residue specific 19F tagging NMR 
to study the β2-adrenergic receptor.  
From a spectroscopic perspective 19F experiments 
with tagged proteins are extremely simple, even 
when compared to basic ligand-observed 
techniques. The studies rely on simple 1D 
experiments to observe changes in chemical shifts 
of 19F nuclei between different samples, taking 
advantage of the exquisite sensitivity of this nucleus to small changes in magnetic environment conferred 
upon it by its large CSA. 19F atoms do not occur naturally in the translated sequences of proteins. This fact 
is an advantage as it circumvents the need to assign the 15N, 13C and 1H nuclei, which occur throughout a 
uniformly labelled protein. The lack of natural 19F in proteins also presents a biochemical challenge, 
however, as the 19F nuclei must be introduced without disrupting the function of the receptor. 
Although 19F-containing non-natural amino acids do exist, the most common method for studying GPCRs 
using 19F probes is by chemical tagging of protein thiol groups, which are either native or introduced by 
point mutations. Sulphur atoms possess lone pairs that may react with specific groups of 19F-containing 
compounds, thus covalently attaching these tags to the protein. The first β2-adrenergic receptor 
investigation using 19F NMR tagged native intracellular cysteine residues with the compound 2,2,2-
trifluoroethanethiol (TET) (Liu et al, 2012) shown in Figure i.17 (A). Wüthrich & co-workers assigned the 
tagged cysteine residues as Cys2656.27, Cys3277.54 and Cys341, the locations of which are shown in Figure 
i.16, by sequential alanine mutations (superscripts refer to Ballesteros/Weinstein numbering of GPCRs 
(Ballesteros & Weinstein, 1995)). Such an approach would be highly impractical and unnecessary to assign 
the signals in a 2D spectrum of a uniformly labelled protein, such as Bcl-2, but with only three mutations 
to make and no multidimensional experiments to assign the 19F signals the mutagenesis approach is 
appropriate. When making observations of a tag on 1 helix this method requires the other cysteine residues 
be mutated to alanine so as to observe only 1 tag at a time.  
It was found that TET tagged on Cys341 was unresponsive to ligand binding, but chemical shift changes 
of TET bound to Cys2656.27 and Cys3277.54 were observed. In this study, and typically across 19F tagging 




Figure i.16 Ribbon representation of the β2-
adrenergic receptor [PDB: 2R4R] displaying 7-
transmembrane helix architecture. The native cysteine 





states in slow exchange with each other, resulting in a change in the proportions of their populations as 
ligand was added (described schematically in Figure i.17(B)). This method is in principle the same as the 
CSP method for ligand screening and affinity calculation discussed in the Bcl-2 section of this introduction, 
but only a one-dimensional spectrum is required due to the low number of or single 19F spin(s).  
Wüthrich & co-workers found that the population of the active-associated chemical shift of TET at 
Cys2656.27 was correlated with agonist efficacy. In the same paper the authors had identified this site as 
exhibiting a large deviation between crystal structures of the receptor bound to agonists and to antagonists, 
making their results consistent with past studies (Liu et al, 2012). Perhaps the more interesting result of their 
experiments was the observation that TET bound to Cys3277.54 could report on changes in conformational 
state population correlated with the biased agonism of the relevant ligand. A change in the populations of 
TET bound to Cys3277.54 could be observed independently from those associated with the activated state 
of Cys2656.27; this is consistent with a model of receptor activation by certain ligands occurring 
independently in helix VII without movement of helix VI. It had already been observed pharmacologically 
that some ligands specifically activate only one or other downstream signalling pathway in a phenomenon 
referred to as “biased agonism” (Urban et al, 2007). Standard agonists primarily activate the G-protein 
pathway whereas biased agonists activate the β-arrestin pathway more strongly. Carvedilol is one such ligand 
which was observed to cause the β2-adrenergic receptor helix VII to populate an active state rather than 
helix VI. The 19F NMR experimental observations of these structural rearrangements revealed the molecular 
mechanism that underpins the biased agonism property of some ligands.  
The development of drugs exploiting this property has been of particular interest in the GPCR field, given 
the diverging downstream effects of this protein family. One example is the development of the drug 
oliceridine by Trevena inc., targeting the µ-opioid receptor (DeWire et al, 2013). In opioid signalling the β-
arrestin pathway leads to negative side-effects such as respiratory suppression and gastrointestinal 
dysfunction whereas G-protein signalling causes the analgesic effects. The Trevena group used in vivo 
cAMP assays to characterise the G-protein signalling of their hits and in vitro complementation assays by 
chemiluminescence to characterise biased arrestin signalling. Oliceridine is effective in attenuating negative 
arrestin-induced side-effects (Ok et al, 2018) by the mechanism revealed in the described 19F NMR 
experiments.  
Following the observation of structural changes that underpin biased agonism, 19F NMR was further used 
to identify the thermodynamic parameters of the changes in conformational state of the β2-receptor by 
observation at different temperatures (Horst et al, 2013). Subsequently the technique was used to 
hypothesise the existence of an intermediate activation state using the same tagging protocol (Kim et al, 
2013). Some care must be taken, however, in extrapolating this finding to physiological membranes, since 
membrane mimetic systems (such as dodecyl maltoside used in the first study and maltose-neopentyl glycol 




imperfect physiological membrane mimics may stabilise conformational states that are not physiologically 
relevant or result in non-physiological population proportions of conformational states.  
Whilst the translatability of in vitro work limits the insights that may be derived from NMR to a degree, the 
translatability is itself also an area that 19F NMR can explore. The β2-adrenergic receptor provides an 
example of how the flexibility of NMR, which has been discussed above as a great advantage, allows it to 
compare the effects of in vitro experimental conditions themselves. Wüthrich & co-workers used the TET 
tagging system to investigate the effect of fusing T4 lysozyme into the helix V/VI intracellular loop on the 
conformational dynamics of the β2 receptor (Eddy et al, 2016). This fusion was present in the first non-
rhodopsin GPCR structure. Wüthrich & co-workers compared the 19F NMR spectra of the receptor with 
and without the fusion protein in intracellular loop 3 and found that with the lysozyme fusion the 19F signal, 
regardless of the ligand applied, populated exclusively the active state, the chemical shift of which was not 
affected by the new construct. This result indicates that in vitro experiments in general on the β2-adrenergic 
receptor (and perhaps other GPCRs) with the lysozyme fusion would artificially favour the receptor to 
occupy a more active conformation than would naturally be present if the less rigid wild type intracellular 
loop sequence were used. The NMR approach was thus able to explore a variety of experimental conditions 
and provide insight into the most physiologically relevant constructs of the receptor for future experiments 
potentially stabilising transient conformational states to enable detailed study of them.  
To summarise: The example of 19F tagging of the β2-adrenergic receptor demonstrates how NMR 
techniques may be extended to more difficult targets than would be possible simply by applying standard 
uniform isotope labelling. 19F NMR nonetheless, has the same advantage of experimental flexibility as NMR 
of isotopically labelled proteins, as discussed for the M2 channel, in being able to investigate a wide variety 
of ligands under different experimental conditions in a way that is difficult to achieve with other structural 
techniques. 19F NMR applied to membrane proteins is a relatively recent development, however, and so it 
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Figure i.17 (A) Structure of TET, a commonly used 19F tag, including in the initial β2-receptor discussed in this 
section (Liu et al, 2012) (B) Schematic of chemical shift change observation of protein tags in 1D 19F spectra. The 
relative populations of two states, typically in slow exchange, are observed to change when a ligand is added, 




has mainly been applied to rationalise existing pharmacological observations of the action of known 
compounds. The protein-observed techniques described for Bcl-2 and the M2 receptor were applied in 
active lead optimisation efforts in a way that has not been done with 19F tagging to date. 
Aims 
Chapter 1 of this thesis describes the application of 19F NMR to investigate the effect of a compound in 
development to treat Parkinson’s disease on the Adenosine 2A receptor (A2AR). This receptor is a GPCR, 
like the β2-adrenergic, and a crystallography study found that the receptor occupies a distinct inactive 
conformation when bound to the novel ligand Cmpd-1(Sun et al, 2017). However, crystallisation required 
the replacement of an intracellular loop with a bacterial cytochrome, limiting the conclusions that could be 
drawn from the study. 19F NMR has, as discussed, already demonstrated that fusion proteins can drastically 
affect the conformational landscape of GPCRs and so further evidence was required draw conclusions 
about Cmpd-1’s effects on the A2AR (Eddy et al, 2016). Here 19F is used provide evidence for the existence 
an alternative inactive state of the A2AR in the presence of Cmpd-1 using a tagging site rationally designed 
by molecular dynamics simulations. It is hoped that this work is a step towards integrating protein-observed 
19F NMR into the drug discovery process to address less tractable targets. 
Chapter 2 of this thesis describes a structural study of the binding of the anti-tumour compound UCN-01 
to alpha-1-acid glycoprotein 2 (AGP2) using more classical NMR techniques more similar to those 
described for Bcl-2. AGP2 is a blood plasma lipocalin that is a carrier for a broad range of basic drugs 
(Hervé et al, 1998). The strong affinity of AGP2 for small molecule drugs has been implicated in the poor 
pharmacokinetic properties of those compounds (Fuse et al¸1998). In particular, the anti-tumour compound 
UCN-01, which is a kinase inhibitor that has been investigated for the treatment of cancer, has an affinity 
of 8 nM for AGP (Welch et al, 2007; Kurata et al, 2000). Here uniform isotope labelling of AGP2 is used to 
study UCN-01 binding by NMR in conjunction with the first X-ray crystallography structure of UCN-01 
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Turnitin Note: This chapter deals with the G-protein coupled receptor project done by this author at UCB 





G-protein coupled receptors (GPCR(s)) are a protein family of seven-transmembrane (7-TM) helical 
receptors that is targeted by a larger number of small-molecule drugs than any other single family (Santos 
et al, 2016). GPCRs found in mammals may be divided into five types – rhodopsin family (class A), secretin 
family (class B), metabotropic glutamate (class C), the adhesin family, and frizzled family (class F) 
(Alexandere et al, 2016). The largest of these is the rhodopsin family (class A) with 719 members. The 
rhodopsin family has been studied extensively with crystal structures available for many of the class such 
as rhodopsin, β2-adrenergic receptor and µ-opioid receptor (Palczewski et al, 2000; Cherezov et al, 2007; 
Rasmussen et al, 2007; Manglik et al, 2012).  
GPCR signalling is known to occur mainly via a conserved pathway (Rosenbaum, Rasmussen and Kobilka, 
2009).  As shown in Figure 1.1, GPCRs receive extracellular stimuli that may be as a result of interaction 
with drugs such as morphine, endogenous ligands such as adrenalin, activation by light or from proteolytic 
cleavage. Upon activation the GPCR is stabilised in a conformational state that allows the binding of a 
heterotrimeric G-protein complex. A single GPCR may be capable of binding to multiple intracellular G-
proteins and so their downstream effects may depend upon the G-proteins present at that time in the cell 
or the receptor’s post translational modifications. For example: The β2-adrenergic receptor has been shown 
to couple to both the adenylate cyclase activating the G-protein Gαs and the inhibitory G-protein Gαi 
depending on the modulation of its phosphorylation status by protein kinase A (PKA) (Daaka, Luttrell and 
Lefkowitz, 1997). Therefore, GPCRs may transduce the same signal into multiple outputs depending on 
their cellular context.  The G-protein itself is a heterotrimer composed of a Gα, Gβ and Gγ subunit. The Gα 
subunit has intrinsic GTPase catalytic activity and forms most of the intermolecular contacts with a GPCR 
in its active conformation (Rasmussen et al, 2011). Prior to activation the Gα subunit is bound to GDP and 
exists in complex with the Gβ and Gγ. Upon GPCR activation the entire heterotrimeric G-protein binds to 
the GPCR and exchanges GDP for GTP. The GTP bound heterotrimeric complex then dissociates from 
the GPCR and itself dissociates into a lone GTP-bound Gα and Gβγ complex. Each of these components 
has multiple downstream signalling partners. Gαs downstream of the β2 adrenergic receptor may, for 
example, upregulate adenyl cyclase leading to an increase in cyclic adenosine mono phosphate (cAMP) and 
therefore activation of PKA (Rosenbaum, Rasmussen and Kobilka, 2009), however the same GPCR can 
also couple Gαi that inhibits adenylate cyclase activity thus having the reverse effect (Daaka, Luttrell and 
Lefkowitz, 1997). In the case of the β2 adrenergic receptor these two signalling cascades may even be present 
in the same cell with the inhibitory Gαi protein binding to the GPCR after it has been phosphorylated by 
PKA upregulated by the earlier Gαs signalling. Coupling sequentially to two antagonistic G-proteins 







Historically GPCRs have been recalcitrant to investigations of their structure due to their instability and 
difficulty in forming crystals of sufficient quality for X-ray diffraction. The first direct evidence of their 
structure came from an electron diffraction projection of bovine rhodopsin in crystalline bilayers (Schertler, 
Villa and Henderson, 1993). These experiments produced electron density projections consistent with the 
presence of 7-transmembrane helices as hypothesised prior to that time, which, combined with knowledge 
of the protein sequence, could be used to assign seven hydrophobic stretches in the sequence to the putative 
seven α-helices (Baldwin, 1993). An improved projection of frog rhodopsin yielded an improved 
understanding of GPCR structure (Unger et al, 1997), but the first high-resolution structure of a GPCR was 





Figure 1.1 Cartoon of generic GPCR signalling pathways. GPCRs are activated by an extracellular stimulus – 
often the binding of an agonist to the extracellular face of the receptor. Agonist binding stabilises active 
conformational states of the receptor that allow the heterotrimeric G-protein to bind and exchange GDP for 
GTP. The GTP-bound G-protein then dissociates into a lone Gα subunit and a heterodimer of Gβ and Gγ. Each 
of the two components of the G-protein heterotrimer can then activate downstream effectors. The GPCR is 
inactivated both by ligand dissociation and by clathrin mediated endocytosis that is triggered by arrestin binding 
to the phosphorylated intracellular surface of the GPCR. Arrestin itself also starts a signal cascade leading to 
changes in gene expression via the mitogen activated protein kinase pathway (Rosenbaum, Rasmussen and 
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The structure of inactive bovine rhodopsin (shown in 
Figure 1.2) confirmed the 7-transmembrane α-helical 
architecture of GPCRs. The 348-residue receptor is 
similar in length when compared to other members of 
the GPCR family and so could be used to provide 
strong evidence for the secondary structure of other 
GPCR sequences.  
One important structural feature of bovine rhodopsin 
that proved informative for the mechanism of 
activation of other GPCRs was the function of the 
highly conserved (D/E)R(Y/W) motif. This motif 
exists on TM3 of GPCRs. In the published structure 
Arg1353.50 formed a salt bridge to Glu2476.30 on TM6 
and an additional H-bond to Glu1343.49 which was 
hypothesised to retain the receptor in the inactive state 
(the superscript refers to the Ballesteros-Weinstein 
number of the residue; a numbering scheme where 
the most conserved residue in a helix is assigned to 
#TM.50 and  subsequent residues are counted 
backwards and forwards from it )(Ballesteros and Weinstein, 1995; Palczewski et al, 2000). Further 
mutational studies on the β2-adrenergic receptor demonstrated that mutation of the equivalent residues in 
this receptor resulted in constitutive G-protein signalling, demonstrating the importance of the ionic lock 
in stabilising the inactive state of GPCRs across the family (Ballesteros et al, 2001). 
Bovine rhodopsin had several properties that made it more tractable to structural studies; the receptor could 
be purified in large quantities from bovine retinas and it did not exhibit basal activity. It took the GPCR 
field seven years to overcome these challenges and crystallise the first non-rhodopsin GPCR (Cherezov et 
al, 2007; Rasmussen et al, 2007). The structures of the human β2-adrenergic receptor were obtained using 
either the fusion of T4 lysozyme into intracellular loop 3 or an antibody antigen binding fragment (Fab) 
raised against the native β2-adrenergic receptor and in complex with the ligand carazolol. The 
conformational plasticity of the β2-adrenergic receptor likely necessitated the presence of the fusion protein 
or Fab to lock the cytoplasmic ends of the transmembrane helices in a particular conformation. 
The architecture of the β2-adrenergic receptor was found to be broadly similar to that of rhodopsin, but 
with a more open structure. The putative ionic lock of Arg1313.50 and Glu2476.30 was not closed in either 
structure of the receptor as the residues were separated by 4.1 Å or 10 Å in the Fab and T4 fusion structures 
respectively – too distant for a hydrogen bond (Cherezov et al, 2007; Rasmussen et al, 2007). This makes 
 
Figure 1.2 Cartoon representation of the X-ray 
structure of bovine rhodopsin (purple) with its 
physiological ligand retinal (red) [PDB:1F88] 




the β2-adrenergic receptor complexed with carazolol structure intermediate between the dark-state structure 
of rhodopsin and the light-activated structure of rhodopsin (Salom et al, 2006). 
A structure of a non-rhodopsin GPCR in a fully inactive state was not solved until 2010 with the structure 
the dopamine D3 receptor in complex with the antagonist eticlopride (Chien et al, 2010). This structure 
[PDB: 1U19] revealed a “locked” conformation of Arg1283.50 and Glu3246.30 with a hydrogen bonded, as 
was the case with dark state rhodopsin. It was thought that the T4 lysozyme fusion protein replacing ICL3 
used in previous crystal structures impeded the closing of the ionic lock, but new distinct crystal structures 
of the turkey β1 adrenergic receptor (Moukhametzianov et al, 2011) with the antagonists carazolol, 
cyanopindolol and iodocyanopindolol revealed that under the right conditions these constructs could also 
be crystallised in a fully inactive form. The shifting of the receptor conformation to a more active state by 
the T4 fusion is supported by the 19F NMR study discussed in the introduction.  
The GPCR investigated in this study is the adenosine A2A receptor (A2AR) which is shown in Figure 1.3. 
This receptor is currently the target of two FDA-approved specific small molecule drugs; Regadenoson, 
developed by Astellas Pharma, is a vasodilator used in cardiac stress tests, (Chen, Eltzschig & Fredholm, 
2013) and Istradefylline, developed by Kyowa Hakko Kirin Inc., is a Parkinson’s drug approved for use as 
an add-on treatment with levodopa and carbidopa (Chen & Cunha, 2020). The A2AR has also been the 
subject of extensive efforts to develop further small molecule treatments to Parkinson’s disease (Shook and 
Jackson, 2011).  
The rationale for targeting the A2AR for Parkinson’s treatment is supported by studies of the long-term 
effects of caffeine. Caffeine is one of humanity’s most widely consumed psychoactive drugs and has been 
linked epidemiologically to a reduced risk of Parkinson’s disease (Hernan et al, 2002). The neuroprotective 
effect of caffeine as an A2A antagonist has also been supported by studies on the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-treated rodent Parkinson’s disease models (Chen et al, 2001). Mice treated with 
the neurotoxin MPTP display comparable symptoms to humans with Parkinson’s disease and display 
improved motor function in response to human treatments such as the dopamine precursor levodopa. 
These experiments demonstrated that caffeine administration increased residual dopamine levels relative to 
the non-caffeine-administered control group. Furthermore, this effect is only reproduced with selective 
A2AR antagonists, thus ruling out caffeine’s binding to other adenosine receptors as the mechanism of 





In addition to their neuroprotective effect A2AR antagonists also improve existing dopamine-depleted 
symptoms. A2AR agonists have been shown by radioligand binding experiments to decrease the affinity of 
the dopamine D2 receptor for its ligands in membranes expressing both receptors (Ferré et al, 1993). This 
leads to suppression of dopamine signalling when the A2A is active due to the weakening of the dopamine 
D2 receptor’s affinity for its agonists. Furthermore, the A2AR is coupled to stimulatory Gs proteins, whereas 
dopamine D2 receptors are coupled to inhibitory Gi proteins and so the receptors also oppose one-another 
during intracellular signalling (Ferré et al, 1993). The A2AR has also been shown to act via dopamine D2 
independent pathways. Dopamine D2 knockout mice exhibit improved behavioural symptoms when treated 
with A2A antagonists implying that the A2AR acts in part via an independent pathway. 
Taken together these data provide a rationale for treating Parkinson’s disease using A2AR antagonists that 





Figure 1.3 Ribbon representation of the A2AR viewed from two positions at 180° relative to each other derived 





One of the drug discovery campaigns targeting the A2AR led to the development of a novel dual antagonist, 
which is shown in Figure 1.5(A), to both the A2A receptor and the N-methyl D-aspartate receptor subtype 
2B. This antagonist (hereafter referred to as Cmpd-1) was crystallised in complex with the A2AR fused to a 
cytochrome b562-RIL in intracellular loop 3 (ICL3) (Sun et al, 2017). The crystal structure revealed that the 
methylphenyl and aminotriazole rings of Cmpd-1 occupied a similar position to the heterocycle and furan 
groups of the well-characterised antagonist ZM 241385. The structure of ZM 241385 is shown in Figure 
1.5(A)). In contrast, the o-methoxyphenyl group of Cmpd-1 occupies a conformation similar to the phenol 
group of ZM 241385 when bound to one published thermostabilised A2AR structure [PDB: 3PWH], but 
different to the conformations of ZM 241385 typical in other structures as seen in Figure 1.5(B)(Doré et al, 
2011; Segala et al, 2016 ). Cmpd-1 interacts with a unique arrangement of amino acid sidechains from helices 
I, II and VII. As a result, in the complex with Cmpd-1 the A2AR itself exhibits a distinct conformation when 
compared to the structures bound to ZM 241385: Notably an outward movement of helices I and V away 
from the helical bundle as shown in Figure 1.5(C/D). It could not be definitively inferred from this structure 
that Cmpd-1 causes these rearrangements since the crystallisation of the complex required a different set 
of crystallisation conditions to those in the complexes with ZM 241385. Previously antagonist-bound 
crystals were generated in lipidic cubic phase causing the receptor to associate in bilayers. Crystals of the 
Cmpd-1/A2AR complex, however, required crystallisation using vapour phase diffusion which caused the 





























Figure 1.4 Diagrammatic representation of dopamine D2 signalling in a healthy, Parkinson’s disease or treated 
Parkinson’s disease scenario. Dopamine signalling is insufficient in Parkinson’s disease, but relieving the inhibition 




To address the question of whether the conformational changes observed in the crystal structure are due 
to artefactual crystal contacts or reflect genuine Cmpd-1 induced changes relative to other antagonists we 
have used a rationally designed 19F NMR tagging approach. Establishing whether Cmpd-1 acts by a novel 
mechanism to inactivate the A2AR is important commercially as it may raise the value of the patent space 
of Cmpd-1 and related ligands. 
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Figure 1.5 (A) The structures of the dual A2A and NRB2 antagonist Cmpd-1 (top) and ZM 241385 (bottom)(Doré 
et al, 2011; Sun et al, 2017). (B) Structures of ZM 241385 (cyan) in its most common conformation overlaid based 
on protein backbone alignments, ZM 241385 bound to thermostabilised A2AR (purple), and Cmpd-1 (orange) all 
shown in a ribbon representation of the A2AR fused to cytochrome bRIL [PDB: 5IU4; 3PWH; 5UIG].  (C) 
Structure of A2AR-bRIL in complex with ZM 241385 (blue) and in complex with Cmpd-1 (green) shown with 
helix V in the foreground (D) View of A2AR from the intracellular face with bRIL residues removed. The 
intracellular terminus of helix V (indicated by the arrows) is displaced in the crystal structure with bound Cmpd-1 




As discussed in the introduction, the first GPCR to be 
investigated by 1D 19F NMR was the β2 adrenergic 
receptor (Liu et al, 2012). The authors tagged native 
cysteine residues with the compound trifluoroethanethiol 
(TET). Since 2012, work has been done comparing the 
chemical shift sensitivity of various 19F tags to solvent 
polarity (Ye et al, 2015). The most sensitive tag tested in 
this investigation was 2-Bromo-N-[4-
(trifluoromethyl)phenyl]acetamide (BTFMA) as shown 
in Figure 1.6. The same authors subsequently used this tag to investigate the conformational dynamics of 
the A2AR (Ye et al, 2016). In contrast to previous work on the β2 adrenergic receptor, a site on helix VI at 
Val2296.31 was selected for tagging based on differences in predicted Cα chemical shift derived from 
antagonist and agonist structures [PDB: 3EML; 2YDV] respectively calculated by PROSHIFT (Ye et al, 
2016). This was necessary as, unlike the β2 adrenergic receptor, the A2AR does not contain native reduced 
cysteine residues on its intracellular face that could be tagged without mutagenesis. Val2296.31 was modified 
to cysteine and tagged with BTFMA for 19F NMR. These experiments revealed that the A2AR populates 
multiple active and inactive conformations which are then biased by the addition of appropriate ligands, as 
schematically shown in Figure 1.7. Prosser & co-workers observed peaks centred on 3 chemical shifts; 61.08 
ppm corresponded to the fast exchanging inactive states S1/2 (S1 hypothesised to contain a closed ionic lock 
and S2 a broken one) , 61.60 corresponded to the partially active state S3, and 61.80 corresponded to the 
fully active state S3’ (Ye et al, 2016). Curiously, the potent antagonist ZM 241385 yielded spectra with a 
~50% population of partially active S3 state, suggesting that the inactive complex populated an active 
conformation to some degree. This model of A2A activation is in keeping with the current understanding 
of GPCR activation in general. A 
GPCR is not to be understood as a 
binary switch, but rather signal 
transducer with multiple outputs that 
may be affected in different 
proportions by different ligands 
(Smith, Lefkowitz and Rajagopal, 
2018). 
The A2AR ligand binding activity has 
also been investigated by protein 
observed NMR. One investigation 
(Clark et al, 2017) fed isotope-labelled 
isoleucine to yeast expressing the 
receptor and the authors were able to 
 
Figure 1.6 The structure of BTFMA, a very 
chemical shift-sensitive tag that reacts with 
exposed cysteines via the bromo-alkane group.  
 
Figure 1.7 Schematic representation BTFMA signals tagged on 
V229C of helix VI by Prosser & co-workers (Ye et al, 2016). Peaks at 
-61.08, -61.60 and -61.80 were assigned to the inactive S1/2 states, 




assign four of the protein’s native isoleucine residues (Ile923.40, Ile2386.40, Ile2747.39, Ile2928.92) by 
mutagenesis of individual isoleucine residues. Three of these showed greater conformational flexibility in 
the agonist bound form relative to the antagonist bound form with the reverse being true for Ile923.40. A 
further study (Eddy et al, 2018) used uniformly 15N, 2H labelled expressed A2AR to observe chemical shift 
changes in several assigned glycine and tryptophan residues. It was determined that a central tryptophan 
Trp2466.48 (often called the “toggle switch”) is functionally coupled to the nearby aspartate Asp522.50 which 
forms an “allosteric switch” that communicates ligand binding in the extracellular domain to the 
intracellular domain which adopts different conformations to allow G-protein binding.  
In principle it would be possible to conduct our study of the allosteric interactions of Cmpd-1 using isotope 
labelling of the A2AR, rather than a 19F tagging approach, however there are several good reasons to use 19F 
tagging from both a practical and method development point of view. Isotope labelling requires specialised 
yeast or insect cell expression systems that can grow in minimal (and deuterated) media. They also require 
more time for construct preparation by selecting transformed yeast clones or generating new baculovirus 
stocks respectively. In contrast, the expression of recombinant proteins in mammalian cells can be done 
easily by lipid-based transfection. This process uses standardised vectors that may be modified by simple 
site-directed mutagenesis and amplified in bacteria, the vector is then transfected directly into the 
mammalian cells for high levels of protein expression (Takahashi et al, 2010). Improving NMR techniques 
for systems less tractable to isotope labelling, as discussed in the introduction chapter, is also in itself 
worthwhile.  More recently there have been advances in membrane mimetic systems for GPCRs. These 
include reconstituting solubilised receptors in nanodiscs (lipid discs bounded by a protein scaffold) and 
lipodiscs (lipid discs of cell membrane components bounded by amphiphilic polymer scaffold), both of 
which have been used successfully with A2AR (Jamshad et al, 2015; Bocquet et al, 2015). Nanodiscs contain 
additional protein material that may increase transverse relaxation to an extent that makes a protein observe 
NMR on isotope labelled material intractable, and therefore a 19F tagging approach may be advantageous 
when applied to these systems. Lipodiscs allow GPCRs to be investigated whilst retained within a small 
excerpt of membrane excised from the expressing cell which may arguably provide a more native-like 
environment. This technique could in principle be used for NMR studies of the A2AR in a native membrane 
environment from a mammalian cell expression system, which would be significantly more physiologically 
relevant than reconstitution in micelles. Tagging mammalian derived lipodisc-reconstituted GPCRs offers 
a more tractable approach than isotope labelling to study this family in the most native-like environment 
currently possible. Certain other members of the GPCR family rely exclusively on mammalian cell 
expression to produce sufficient amounts of protein for biophysical techniques. Expression of deuterated 
protein is not possible in these cell lines and therefore 19F tagging extends the application of NMR to these 
targets beyond mere ligand observed experiments.  
In this study a rationally designed novel tagging site on the A2AR is reported at Lys2095.70. The site location 
is based on the putative crystallographic differences induced with Cmpd-1 and ZM 241385 bound, in 




of the A2AR, carrying the novel mutation is compared with that of a mutant reported in the literature V229C 
(mutants referred to by single letter code for brevity), both in native membranes with the free cysteine and 
after tagging with BTFMA. 19F NMR spectra which support the literature resonance assignment for the 
V229C tagged mutant to inactive and partially active states are also reported alongside spectra for the novel 
tagged mutant (K209C), which likewise distinguishes active from inactive ligand-induced states based on 
chemical shift perturbation. In addition, in the presence of Cmpd-1, the K209C mutant reveals a novel 
inactive conformation of helix V, which remains unresolved by the literature V229C tagged mutant. 
The K209C tagged mutant of A2AR represents a unique tool enabling the further development of the Cmpd-
1 dual inhibitor series based on its novel mechanism of intervention in a manner not possible with the 
literature V229C mutation.  
We published our key findings from this chapter (Landin et al, 2019). 
Expression and Purification of A2AR 
An expression protocol in human embryonic kidney (HEK) cells and purification by immobilised metal 
affinity chromatography (IMAC) for the A2A receptor was optimised on a green fluorescent protein (GFP) 
fusion construct (designed by Lisa Joedicke, UCB, Slough)) cleavable by tobacco etch virus (TEV) protease 
(Fig. 1.8). 
The full construct runs low at 48 kDa (actual MW: 67 kDa). After TEV protease cleavage GFP-His10 runs 
at 28 kDa (close to actual MW), whereas A2AR runs at around 30 kDa (actual MW: 38 kDa). After a negative 
purification, the identity of the A2AR was 
validated by tryptic cleavage digestion and liquid 
chromatography/mass spectrometry 
(LC/MS)(the MS instrument was operated by 
Rebecca Burnley, UCB, Slough). The results are 
shown in Figure 1.9. Sufficient cleavage 
fragments were observed to identify the protein 
as the A2AR.  
After this validation experiment, a construct 
with a cleavable N-terminal twin-StrepII binding 
(tStrep) tag and cleavable C-terminal His10 tag 
was designed (by Lisa Joedicke, UCB, Slough)) 





Figure 1.8 SDS PAGE of the A2AR-TEV-GFP-His10 
construct before and after cleavage with TEV protease. 
GFP-His10 and A2AR appear in the second fraction before 





The new tStrep A2AR construct (full sequence in methods) was expressed, purified, and analysed by SDS 
PAGE (Figure. 1.10(A))(full details in methods). The new tStrep-TEV-A2AR-TEV-His10 construct ran as 
two main bands with an additional band or double band at ~50 kDa corresponding to a potential SDS 
stable dimer. The lower of the two bands was probably due to some undesired cleavage of the tStrep tag, 
since this band can be visualised with an anti-His mouse antibody, but was lost when the sample was 
purified with streptactin resin (Figure 1.10(B)). The SDS-stable dimer was, however, still present. 
The tagging protocol used in this study involved a thiol-tag reaction with the A2AR bound to the IMAC 
column. To test that this protocol did not result in significant loss of yield it was carried out on a V229C 
mutant described in the literature (generated by site-directed mutagenesis) (Ye et al, 2016). The A2AR was 
purified by IMAC and incubated with tagging reagents on the column after washing, but before elution. 
Figure 1.9 Sequence fragments identified by LC-MS of A2AR tryptic digest are enclosed in boxes, with cysteines 
forming potential disulphide bridges highlighted in yellow and potential cleavage sites highlighted in blue. The 
sequences shown in red appear as loops in crystal structures. The identified fragments confirm the identity of the 
protein as the A2AR. This mass spectrometry instrument was operated by Rebecca Burnley (UCB, Slough). 
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Figure 1.10 (A) Anti-His HRP-conjugated western blot of fractions from an A2AR IMAC purification. The 
elution shows a double band of A2A at ~30 kDa and a possible SDS-stable dimer at ~50 kDa. (B) SDS PAGE 
image of a streptactin purification of the new construct. The lower band of the double is not present in the final 















The IMAC column flow through (FT) from each 
washing and tagging step of the process was analysed by 
SDS PAGE and the results are shown in Figure 1.11. 
No bands consistent with A2AR were present in any of 
the wash or tagging fractions, indicating that the tagging 
protocol did not affect adhesion of the protein to the 
IMAC resin. After tagging the A2AR was eluted, 
desalted, cleaved with in-house TEV protease, and 
negatively purified yielding a single band, consistent 
with pure A2AR. The remaining protein material on the 
column from the negative purification was consistent 
in mass with uncleaved A2AR and TEV protease. 
The protocol described in this Figure was initially used 
with the tag bromo-trifluoroacetone (BTFA), and was 
subsequently applied to BTFMA.  
 
MD Simulations of the A2AR 
With expression of the receptor validated the next step was to identify potential tagging sites to distinguish 
different ligand classes. An in silico approach was used to identify potential mutation sites for 19F tagging 
of the A2A receptor to follow its conformational changes by NMR. 
Preliminary 125 ns MD simulations (full details in methods) were carried out on coordinates of the A2A 
constructed from antagonist and agonist bound crystal structures [PDB: 5IU4; 2YDO]. The simulated 
coordinates were constructed to include intracellular loop 3 and helix 1, which were not present in their 
entirety in the crystal structure due to fusion proteins or poor electron density, but were built into the 
coordinates sets with a combination of Modeller (Sali and Blundell 1993) and coordinates from the 
antagonist bound structure 3VG9 (Hino et al, 2012). 5IU4 was chosen as the antagonist coordinate set due 
to its high resolution and 2YDO was chosen as the agonist coordinate set as it contains the native ligand, 
adenosine. It was assumed that A2AR would not switch from an agonist to antagonist (or vice versa) 
conformation on this timescale. This assumption was supported by root mean squared deviation (RMSD) 
comparison between the 2YDO and 5IU4 derived structures across the 125 ns trajectories, which 
maintained a constant RMSD relative to each other of around 2.5 Å (Fig. 1.12). Residues that maintained 
distinct conformations between the two simulations were identified by comparing different regions of the 
receptor against each other more closely (Fig. 1.13). 
 
 
Figure 1.11 Coomassie-stained SDS PAGE of 
A2AR tagging fractions. A band consistent with 
pure, cleaved A2AR is present in the final elution 
with no significant impurities whilst some remains 
uncleaved as seen (from continued cation affinity) 






These simulations indicated that the terminus of helix 1 and ICL3, between helices 5 and 6, were likely the 
most appropriate parts of the protein to tag. RMSD deviation of these regions between same the agonist 
and antagonist trajectories were extracted for a more detailed comparison and the results are shown in 
Figure 1.13. The RMSD between the trajectories remained above 2 Å for the majority of the simulated time 
in helix 1 and ICL3. As a comparison the RMSD of helix 4 (a relatively constant parts of all A2A structures 
used here as a benchmark) remained within 1 Å between the two trajectories throughout the simulation. 
Comparisons between the structures of the above protein regions are shown in Figure 1.14. 
To identify suitable residues in these regions for mutation and tagging, sequence alignments of A2AR and 
its orthologues and paralogues were prepared using ClustalΩ (Madeira et al, 2019) and are shown in Figures 
1.15 and 1.16 respectively. It was hypothesised that residues with a greater degree of sequence conservation 
between homologues would be more likely to affect protein stability or function if mutated. Therefore, 
residues with poor sequence conservation between homologues were preferred for mutation. Helix I 
(residues 1-33) shows less sequence conservation at the N-terminus than other regions indicating that these 
residues might be mutated and tagged without impairing function. ICL3 and the adjacent portions of helices 
V and VI (residues ~200-240), are well conserved across orthologues. As ICL3 is known to be the G-
protein binding site, a greater degree of sequence conservation is expected as the GPCR family signals by 
a conserved pathway. These alignments indicate that sequence conservation between orthologues (which is 
much greater than between paralogues) is not necessarily critical to ensure that functional protein can be 
produced as Val2296.31 has been modified previously in the literature, albeit without direct validation of  the 
preservation of ligand binding (Ye et al, 2016). The sequence alignments of paralogues in Figure 1.16 
demonstrate that across the adenosine receptor family each of the 3 investigated residues vary. Val2296.31 is 
replaced by other hydrophobic residues in other adenosine receptors, whereas Met41.30 and Lys2095.70 may 
A      B 
               
Figure 1.12 (A) RMSD deviation between the agonist and antagonist bound trajectories of the A2AR. There is a 
stable difference of over 2 Å between the two trajectories throughout (B) Overlay of ribbon representation of 
A2AR coordinates from simulations from agonist (red) and antagonist (blue) structures after 125 ns simulation in 




be replaced by residues with very different properties (such lysine -> glutamine). These data indicate that 














Figure 1.13 Residues from (A) helix I and (C) IV and 
(B) ICL3 were compared over the 125 ns simulations. 
Both helix I (A) and ICL3 (B) have an RMSD between 2 
and 3 Å between the two simulations. It may be possible 
to use tags at these positions to observe conformational 
changes in the receptor in response to different ligands. 
Helix IV is positioned behind helix III away from the 
binding cavity and is a good negative control 
representing a part of the protein which does not vary 
between the two simulations. 
 
 
A    B    C 
 
Figure 1.14 Overlays of ribbon representations of A2AR agonist (red) and antagonist (blue) coordinates after 125 
ns simulation in an artificial lipid bilayer. (A) Helix I exhibits a small deviation between agonist and antagonist 
trajectories (B) ICL3 composed of helices V and VI move outward on agonist binding and retain this deviation 
over the course of a simulation suggesting that a modification at K209 on helix V may distinguish between 
different ligand-bound complexes (C) Helix IV is included as a negative control that exhibits very little or no 






Comparisons of the MD trajectories suggested that the residue Lys2095.70 could be used to distinguish 
agonist from antagonist forms of the receptor as seen in Figure 1.14, it is also situated in a region of the 
receptor sequence that is not well conserved between paralogues (Figure 1.16). The fact that a residue may 
be different in a closely related protein implies that the presence of a specific amino acid at this location is 
unlikely to be essential for the protein fold and stability of the 7-TM bundle. After reviewing these data, it 
was hypothesised that Lys2095.70 may, by its position on helix V, distinguish the binding of other antagonists 
from Cmpd-1 in addition to distinguishing the binding of agonists and antagonists, and this became the 




sp|P30543|AA2AR_RAT        ---MGSSVYITVELAIAVLAILGNVLVCWAVWINSNLQNVTNFFVVSLAAADIAVGVLAI 57 
sp|Q60613|AA2AR_MOUSE      ---MGSSVYIMVELAIAVLAILGNVLVCWAVWINSNLQNVTNFFVVSLAAADIAVGVLAI 57 
sp|P46616|AA2AR_CAVPO      ---MSSSVYITVELVIAVLAILGNVLVCWAVWINSNLQNVTNYFVVSLAAADIAVGVLAI 57 
sp|Q6TLI7|AA2AR_HORSE      MPTVGSLVYIMVELAIALLAILGNMLVCWAVWLNSNLQNVTNYFVVSLAAADIAVGVLAI 60 
sp|P29274|AA2AR_HUMAN      MPIMGSSVYITVELAIAVLAILGNVLVCWAVWLNSNLQNVTNYFVVSLAAADIAVGVLAI 60 
sp|P11617|AA2AR_CANLF      MSTMGSWVYITVELAIAVLAILGNVLVCWAVWLNSNLQNVTNYFVVSLAAADIAVGVLAI 60 
sp|P30543|AA2AR_RAT        NFFAFVLLPLLLMLAIYLRIFLAARRQLKQMESQPLPGERTRSTLQKEVHAAKSLAIIVG 235 
sp|Q60613|AA2AR_MOUSE      NFFAFVLLPLLLMLAIYLRIFLAARRQLKQMESQPLPGERTRSTLQKEVHAAKSLAIIVG 235 
sp|P46616|AA2AR_CAVPO      NFFAFVLVPLLLMLGIYLRIFLAARRQLKQMESQPLPGERTRSTLQKEVHPAKSLAIIVG 237 
sp|Q6TLI7|AA2AR_HORSE      NFFACVLVPLLLMLGVYLRIFLAARRQLKQMETQPLPGERARSTLQKEVHAAKSLAIIVG 240 
sp|P29274|AA2AR_HUMAN      NFFACVLVPLLLMLGVYLRIFLAARRQLKQMESQPLPGERARSTLQKEVHAAKSLAIIVG 240 
sp|P11617|AA2AR_CANLF      NFFAFVLVPLLLMLGVYLRIFLAARRQLKQMESQPLPGERARSTLQKEVHAAKSLAIIVG 240 
 
Figure 1.16 Partial sequence alignments of A2AR orthologues with residues investigated for mutation highlighted 
in yellow (The UniProt Consortium, 2019). Met41.30 (by human numbering) was not conserved in horse A2AR and 
so may be suitable for mutation. Lys2095.70 and Val2296.31 were each conserved across related mammals indicating 
that their identity was important for function, but given the successful study using a mutation at Val2296.31 this 
level of conservation may still allow for point mutations. 
Figure 1.15 Partial sequence alignments of A2AR paralogues with residues investigated for mutation highlighted 
in yellow (The UniProt Consortium, 2019). None of the highlighted residues are conserved across adenosine 
receptor paralogues, however the equivalents of V2296.31 are invariably hydrophobic residues. Suggesting that its 
properties are most crucial to the function of the receptor. 
sp|P0DMS8|AA3R_HUMAN       MPNNSTALSLANVTYITMEIFIGLCAIVGNVLVICVVKLNPSLQTTTFYFIVSLALADIA 60 
sp|P30542|AA1R_HUMAN       ---MPPSISAFQAAYIGIEVLIALVSVPGNVLVIWAVKVNQALRDATFCFIVSLAVADVA 57 
sp|P29274|AA2AR_HUMAN      ------MPIMGSSVYITVELAIAVLAILGNVLVCWAVWLNSNLQNVTNYFVVSLAAADIA 54 
sp|P29275|AA2BR_HUMAN      -----MLLETQDALYVALELVIAALSVAGNVLVCAAVGTANTLQTPTNYFLVSLAAADVA 55 
sp|P0DMS8|AA3R_HUMAN       RNKLSLNLSN---SKETGAFYGREFKTAKSLFLVLFLFALSWLPLSIINCIIYFNG---- 257 
sp|P30542|AA1R_HUMAN       RKQLNKKVSAS--SGDPQKYYGKELKIAKSLALILFLFALSWLPLHILNCITLFCPSC-- 263 
sp|P29274|AA2AR_HUMAN      RRQLKQMESQPLPGERARSTLQKEVHAAKSLAIIVGLFALCWLPLHIINCFTFFCPDC-S 263 
sp|P29275|AA2BR_HUMAN      CRQLQRTEL----MDHSRTTLQREIHAAKSLAMIVGIFALCWLPVHAVNCVTLFQPAQGK 265 
Potential Modification:● Positive Charge:● Negative Charge● 




To further investigate the potential 19F tags to distinguish between antagonist receptor conformations the 
BTFMA tag was built onto coordinate sets of the A2AR [PDB: 5IU4; 5UIG]. Solvent exposure is a likely 
mechanism for chemical shift changes of the tag between different conformational states (Ye et al¸ 2016). 
Therefore simulations of each mutant (V229C and K209C) starting from the coordinates of the A2AR with 
the ligands ZM 241385 and Cmpd1 [PDB: 5IU4; 5UIG respectively] were run for 625 ns each and the 
solvent exposure of the 19F atoms in each frame was plotted as shown in Figure 1.17. The solvent exposure 
of the 19F tags should be considered in a purely qualitative and comparative context as the 
palmitoyloleoylglycerophosphoethanolamine (POPE)/palmitoyloleoylglycerophosphocholine (POPC) 
/cholesterol membrane simulated in the MD system is different from both a more complex physiological 
membrane and from the membrane mimetic, lauryl maltose neopentyl glycol (LMNG) amphipol, used 
during in vitro experiments. With this caveat, the comparison indicates that the shift in 19F solvent exposure 
between ligands is greater with the tag at K209C on helix V than at V229C on helix VI. The 19F atoms on 
the K209C tag are able to sample conformations with solvent exposures of >100 Å2 in the Cmpd-1 bound 
coordinates, these conformations are not populated to the same degree from the ZM 241385 coordinates. 
The modal solvent exposure populations of the 19F atoms on the V229C tag change from 61-80 Å2 to 51-
70 Å2 based on which ligand is bound, whereas the modal solvent exposure of the tag on K209C changed 
from 51-70 Å2 to 91-110 Å2. These observations support the hypothesis that K209C can distinguish Cmpd-
1 binding from ZM 241385 binding better than a tag at V229C due to the more solvent exposed 

















Figure 1.17 Histograms of the solvent exposure of the 19F atoms on the simulated trifluoromethyl groups of the 
BTFMA tag. When bound to V229C the most populated solvent exposed conformations are between 60 and 80 
Å2 for the standard antagonist ZM 241385 and between 60 and 70 Å2 for Cmpd-1. When bound to K209C the 
most populated solvent exposed conformations are between 50 and 70 Å2 for ZM 241385 and between 90 and 
110 Å2 for Cmpd-1. From the large shift towards being able to sample more solvent-exposed conformations we 
may hypothesise that Cmpd-1 would be likely to cause a greater chemical shift change to a 19F tag attached to 




Radioligand Binding Assays 
The overarching aim of this study was to observe functionally relevant states of the A2AR by NMR. It is 
therefore essential that modifications, in this case point mutations, made to the receptor can be confirmed 
not to interfere with its function. It is also necessary to confirm that the micelle-reconstitution and 
purification protocol does not disrupt the fold and function of the A2AR. Therefore, three types of 
radioligand binding assay were carried out: Saturation binding experiments, IC50 experiments and 
displacement experiments on purified protein. These assays used the selective A2A antagonist ZM 241385, 
originally developed at Zeneca (Poucher et al, 1995). ZM 241385 has itself been used to investigate the 
effect of A2AR antagonists in general on dopamine levels using in vivo models of Parkinson’s disease 
(Gołembiowska et al, 2009), but is not itself currently used as a therapeutic for this indication. Saturation 
binding experiments were carried out on samples of membrane expressing A2AR to fit a saturation binding 
curve. The binding of radioactive ZM 241385 tends towards a maximum (Bmax) as all the A2AR sites are 
filled and the curve is fitted to the equation Y=Bmax×x /(KD+x). This allows the apparent KD (the 
concentration of ligand where half the receptor is in the bound state) to be calculated as an inverse measure 
of the strength of binding of the ligand. As this property is already well documented, binding of the ligand 
ZM 241385 serves here as a measure of how similar the mutants are to each other and to wt A2AR. If the 
point mutations do not significantly alter the KD, then it is reasonable to assume that the receptor’s 
properties are the same in general. IC50 experiments are specific to the set of conditions under which they 
are measured and determine the concentration of ligand required to remove half of a protein’s activity in a 
given situation. In this case, we calculate IC50s of the ligands competing ZM 241385 out of the A2AR 
binding pocket which gives a comparative measure of the properties of the ligands and the different A2AR 
constructs under the conditions we tested them. The amounts of [3H] ZM 241385 that remains bound to 
the membrane embedded A2AR over a range of increasing concentrations of a competitor ligand, is fitted 
to a logarithmic curve, and the IC50 is found at its inflection point. The displacement experiment is more 
conveniently carried out than competition experiments on purified protein samples, but is less precise as 
the desalting columns used to separate bound from unbound ligand are less reliable than the plate harvester 
used for in-membrane experiments. This experiment determines if there is significantly more bound 
radioligand, and therefore functional A2AR, in a test sample relative to a control sample, where a large excess 
of non-radioactive competitor is present. The advantage of this experiment is that the receptor is subjected 
to identical assay conditions to those used in the NMR experiment.  
Saturation binding experiments were carried out in two different buffers (Fig. 1.18). The buffer reported 
by PerkinElmer (chosen as they are prominent suppliers of A2A and associated reagents) was found to 




Saturation binding experiments with this buffer were carried out on HEK membranes that had expressed 
wild type protein, the V229C mutant (Ye et al, 2016) and the K209C mutant reported here (Fig. 1.19). 
Calculated apparent KDs from these results were not within a range that could be reliably ascertained from 
these data. Furthermore, the wild-type (wt) construct appeared to show reduced binding affinity as 
compared to the mutants. Therefore, a further saturation binding experiment was carried out on the wt 






Figure 1.18 Identical saturation binding experiments were carried out in radioligand buffer A (Jaakola et al, 2008) 
and radioligand buffer B (PerkinElmer, 2009). Buffer B was selected for use from this experiment as there was 
greater differentiation between specific and non specific binding. Membrane protein X is a non-GPCR protein 




The extended range of measured concentrations allowed an apparent KD of 11 nM to be calculated. This 
was around fivefold higher than the 2 nM value reported in the literature (Jaakola et al, 2010). The buffer 
from PerkinElmer used in the experiments of Figures 1.18 did not contain Na+ ions which are known to 
be negative allosteric modulators of class A GPCRs (Katrich et al, 2014). Since the ZM 241385-bound 
conformation of the A2AR is stabilised in the presence of bound Na+ ions then a sub optimal Na+ ion 
content may cause a lower proportion of a given concentration of ZM 241385 to be bound in the A2AR, 
thus shifting the point where half of the receptor would be occupied towards an apparently higher ZM 
241385 concentration. To test if the lower apparent KD was due to a lack of Na+ ions, the buffer was 
changed to one containing 100 mM NaCl (Uustare et al, 2005) and the experiment was repeated (Fig. 1.21). 
A KD of 9 nM was calculated from these data, which was still above the 2 nM reported in the literature 
(though this difference may not be formally significant) (Jaakola et al, 2010), and was also not significantly 
different from the previous experiment. One possible explanation is that literature values were derived from 
experiments on adenosine deaminase-treated membranes which removed the endogenous agonist, 
adenosine and allowed higher affinity binding of ZM 241385 to be measured. Here it was not necessary to 
characterise any ligands de novo with determination of absolute KD values, it was sufficient to compare the 
relative affinities in our system and to determine if the cysteine mutants display altered activity. Therefore, 
competition experiments were performed, from this point on, in the higher NaCl buffer.  
The IC50 of ZM 241385 in homologous competition was calculated for each of the wt, V229C and K209C 
constructs directly in the HEK membranes expressing them (Fig. 1.22). The IC50 of ZM 241385 was 22 
nM, 17 nM and 11 nM for Wt, V229C and K209C respectively. These values are very comparable and with 
 
Figure 1.19 Specific [3H] ZM 241385 binding to 
membranes from HEK cells expressing dual affinity tagged 
A2A construct with one of two cysteine mutations compared 
to the truncated wild type construct (n=3). All curves show 
an apparent KD at least tenfold higher than the reported 
values from the literature, with the mutant’s possessing 
apparent KDs of V229C: 76 nM, 25 nM – undefined 95% 
confidence interval; K209C: 11 nM, 5 – 35 nM 95% 
confidence interval; the wild type construct did not possess 
a calculable KD. These graphs where fitted to the single site 
binding equation (Y= Bmax*x/(Kd + x)) and further 
assumes a large excess of ligand to target. The error bars 
show the standard error of the mean. 
 
Figure 1.20 Specific [3H] ZM 241385 binding to 
HEK membranes expressing dual tagged affinity 
tagged wt construct (n=3). Apparent KD: 11 nM, 5-
25 nM 95% confidence interval. These graphs 
where fitted to the single site binding equation (Y= 
Bmax*x/(Kd + x)) and further assumes a large 
excess of ligand to target. The error bars show the 




significant overlap of their standard errors of the mean, giving support to transferability of results from 
mutant to wt protein. 
These data suggest that one may legitimately draw 
inferences about the wt receptor from experiments on 
the cysteine mutant constructs as the variation between 
the IC50s is smaller than or of a similar size to the 
standard errors of each experiment. Subsequently it was 
determined by radioligand binding experiments on 
purified and tagged receptor that both mutant constructs 
were active when reconstituted in LMNG/CHS micelles 
and tagged with BTFMA (Fig. 1.23). The NMR 
experiments could therefore proceed with confirmation 
that the receptor was still active in the final samples.  
  
Figure 1.21 Specific [3H] ZM241385 binding to 
HEK membranes expressing dual affinity tagged 
A2AR wt construct in an NaCl-containing buffer 
(n=3). The apparent Kd was 9 nM, 5 – 17 nM 
95% confidence interval. Fitting method as 
above. 
A                       B 
  
Figure 1.22 (A) Homologous competition curves of [3H] ZM 241385 for the two tagged constructs and wt A2AR 
(n=3). These fits used the equation for competition binding at one site (Y = Ymin + (Ymax-Ymin)/(1+10^(x-
log(IC50))) and the error bars are standard deviations of the mean. (B) Chart of calculated IC50’s of each mutant. 
The error bars are the fitting errors for each curve and are consistent with there being no significant difference 
between the curves. The IC50 of ZM 241385 was 22 nM, 17 nM and 11 nM for Wt, V229C and K209C 
respectively. The error bars are the standard errors of each fit.  
A                  B 
  
Figure 1.23 Specific and non-specific binding of [3H] ZM 241385 to purified and tagged receptor with the 
mutations (A) V229C and (B) K209C normalised in both cases to specific binding. Both mutants still have 




19F NMR of Tagged A2AR 
With the functionality of the K209C and V229C mutants verified, 19F NMR experiments were carried out 
to characterise the responses of helices V and VI to different ligands. The chemical environment of the tag 
changes as the protein populates conformational states in different proportions, resulting in the 19F spins 
becoming more or less shielded in different states and so their chemical shift changes. BTFMA has been 
chosen as our tag since an investigation of several commercially available tagging compounds (Ye et al, 
2015) revealed that BTFMA was the most sensitive to changing solvent polarity. 
To ensure that meaningful conclusions could be 
drawn from the 19F experiments, spectra were 
collected with the antagonist caffeine and agonist 5'-
N-Ethylcarboxamidoadenosine (NECA) (the 
structures of which are shown in Figure 1.24) in 
addition to ZM 241385 and Cmpd-1. NECA is 
included to demonstrate that the BTFMA tag can 
distinguish between inactive and active states of the 
receptor as this structural transition is the most studied 
and well characterised, thus validating the 19F tagging 
data (Xu et al, 2011; Lebon et al, 2011). Caffeine is 
chosen as an additional antagonist to ZM 241385 to 
verify that the 19F data reports on a similar 
conformation for antagonists in general, but a distinct 
conformation for Cmpd-1. 
The NMR experiments were conducted on BTFMA-tagged samples of the V229C (Ye et al, 2016) and our 
K209C mutants as discussed previously in Figure 1.17. The initial 19F NMR experiment was an attempt to 
reproduce the antagonist to agonist shift reported in the literature (Ye et al, 2016). A2AR V229C was tagged 
on IMAC resin and cleaved, samples were then desalted into buffer A and 5000 scans of 1D 19F data were 
collected. The high number of scans carried out allowed the A2AR to be studied at very low protein 
concentrations (20 μM) improving its stability and economising on purification reagents. Figure 1.25 shows 
spectra of A2AR in solution with 10 mM of the antagonist ZM 241385 (hereafter always in blue) and 4 mM 
NECA (hereafter always in red). Prosser and co-workers report an inactive ensemble at -61.08 ppm and an 
active ensemble at -61.60 ppm. These data by contrast show main peaks at -61.72 ppm and -61.80 
respectively for ZM 241385 and NECA. There are two similarities to the published spectra: The main 
agonist peak is shifted upfield relative to the antagonist (but only slightly), and there is a peak around 60.5 
ppm that Prosser and co-workers ascribe to non-specific tagging (Ye et al, 2016) .  
 
Figure 1.24 Structures of the A2AR antagonist 
caffeine (top) and the A2AR agonist NECA (bottom) 




To ascertain which peaks were due 
specifically to protein bound tags, the 
antagonist-bound sample was incubated at 
25°C for 36 hours to allow aggregation of 
functional A2AR reducing the corresponding 
signals and run again for 5000 scans, the 
resultant spectrum is shown in Figure 1.26.  
The peak at -61.72 had decreased in intensity 
significantly over this time period, suggesting 
that it was due to the A2AR aggregating over 
time and becoming invisible to NMR. The 
other peaks at -60.5, -61.62, and -61.85 on the 
other hand persisted in intensity over the 
course of the experiment. This strongly 
suggests that they were due to material which 
remained in solution after the A2AR has 
aggregated and unfolded, and are therefore 
artefacts. The protocol was amended in such 
a way that the tagging reactions still proceeded 
for ~18 hours, but with extensive washing to 
remove free tag whilst the A2AR was retained 
on the IMAC resin. Furthermore, in case 
glycerol could have caused the major peaks to 
be shifted from the literature values it was 
omitted in the final buffer (hereafter buffer 
SG) for the next tagging experiment. 
The A2AR was tagged with the modified 
protocol and further NMR experiments were acquired with ZM 241385, caffeine, NECA and UCB’s 
proprietary ligand Cmpd-1 (Fig. 1.27). These data are very similar to that reported in the literature. The 
signal observed with 100-fold or greater concentration of antagonist relative to protein, appears close to 
the -61.08 ppm reported for the putative S1-2 inactive ensemble (Ye et al, 2016). The sample with 20-fold 
agonist present relative to protein shows a peak at -61.55 ppm which is close to the 61.60 reported for the 
putative S3 partially active state. The slight variations may be due to our 10-fold lower LMNG 
 
Figure 1.25 1D 19F NMR spectra of A2AR V229C tagged with 
BTFMA in solution with antagonist ZM 241385 (blue) and 
agonist NECA (red). The agonist spectrum was broader than 
that of the antagonist which could be due to the sampling of 
a broader range of active and partially active conformational 
states on differing timescales than occurs with the antagonist. 
Though different these spectra did not confirm the tagging 
experiments from the literature (Ye et al, 2016). 
 
Figure 1.26 1D 19F spectrum of BTFMA-tagged A2AR 
V229C after 36 hours at 25°C. The peaks 60.5 ppm and 61.85 
ppm did not decrease in intensity suggesting that they were 
not due to tagged A2AR, as the A2AR is unstable at this 





concentration, differences in DMSO concentration, differences in observed vs modelled states or some 
combination of the above.  
 
These data largely confirm the observations reported in the literature around antagonist conformation and 
demonstrate that Cmpd-1 causes the tag on helix VI to adopt a conformation which is not distinguishable 
from two other known antagonists as the main peak does not move away from -61.06 just like ZM 241385. 
On the other hand, the APO spectra reported in the literature could not be reproduced, as protein was too 
unstable to yield significant signal in our experiment in the absence of ligand, it is hypothesised that this is 
due to lower detergent concentration used in this work. Therefore, samples of our K209C tagging site on 
helix V were prepared and tagged in the same way, and an identical set of experiments were run (Fig. 1.28).  
The new K209C tagging site shows a reversal in the direction of the shifts between agonist and antagonists 
compared with the V229C site. Here the agonist shifts the tag signal downfield relative to antagonist and 
Cmpd-1 shows an upfield shift relative to the other two antagonists. This strongly implies that helix V 
samples a different conformation when Cmpd-1 binds to the receptor when compared with the other 
antagonists, and furthermore that this conformation is not detectable by the previously reported tag on 
helix VI. The main peak in the spectrum of A2AR with Cmpd-1 is broader than those from the A2AR with 
caffeine or ZM 241385. This may be due to the alternative inactive state existing in an intermediate exchange 
regime, causing line broadening, or that this peak represents the average of several unresolved states. 
 
Figure 1.27 1D 19F NMR spectra of A2AR V229C tagged with BTFMA in solution with antagonist ZM 241385 
(Blue), antagonist caffeine (Black), antagonist Cmpd-1 (Lime), and agonist NECA (Red) normalised by peak 
height. The antagonist peaks all appear around -61.06 ppm (putative S1/2), whereas the agonist peak appears at -




Further dynamics experiments could distinguish these interpretations, but either interpretation points to 
the presence of at least one alternative inactive conformation of the receptor.  
 
In parallel with this work 12 μs of MD simulations and Markov state modelling of the A2AR were carried 
out by Dr Silvia Lovera as discussed in our publication (Landin et al, 2019). These simulations categorised 
conformations of the A2AR bound to Cmpd-1 into five macrostates. Macrostates four and five (shown in 
Figure 1.29) are conformations of the ligand that are correlated with the outward movement of helix V. 
Macrostate four closely resembles the crystal structure, but macrostate five exhibits a more extreme outward 
movement of helix V concomitantly with the adoption of a metastable ligand binding site outside of the 
main orthosteric binding pocket. In combination these conformational states cause the outward helix V 
motion observed in the 19F NMR experiments. The presence of only one resolved peak in the Cmpd-1 
bound spectrum is consistent with the macrostates being in fast exchange on the NMR timescale resulting 
in a single peak, distinguishable from those of other antagonists. The importance of Cmpd-1’s structure in 
forming the allosteric macrostate five interaction is demonstrated by chemical analogues with alternative 
methoxy substitutions, whose A2AR selectivity is abolished (Sun et al, 2017). The importance of allosteric 
sites in ligand selectivity has been seen more broadly in the field, such as in the case of the M2 muscarinic 
 
Figure 1.28 1D 19F NMR spectra of A2AR K209C tagged with BTFMA in solution with antagonist ZM 241385 
(Blue), antagonist caffeine (Black), antagonist Cmpd-1 (Lime), and agonist NECA (Red). The agonist sample 
shows a peak at around -60.09 ppm, the antagonists from the literature show a peak at -61.13 and Cmpd-1 shows 




acetylcholine receptor (Haga et al, 2012). Residues important to allosteric binding to the M2 receptor have 
been identified and can mediate ligand selectivity for the M2 as opposed to the M4. 
As stated above it was hypothesised that the concentration of LMNG/CHS used may influence the 
proportion of the receptor that populates different states, with our spectra appearing to show more of the 
inactive ensemble than those of Prosser and co-workers (Ye et al, 2016) . It should be noted at this juncture 
that detergent concentration is a difficult parameter to measure and to control. Although buffers used in 
membrane protein structural biology include a nominal detergent concentration this very often does not 
reflect the actual concentration that is present in the final sample. Two of the most recent NMR 
investigations of the A2AR (Eddy et al, 2018; Ye et al, 2016) report that sample concentration was the last 
step in their preparation protocol, being required to deliver a sample suitable for NMR. A potential pitfall 
of this method is that detergent/CHS molecules may exist as stable, empty micelles which cannot pass 
readily through a concentrator membrane and therefore become more concentrated concomitantly with 
the protein when using a spin concentrator. As a result, the detergent concentration may be higher than its 
nominal value. A further complication is that no convenient methods for detergent quantification on a par 
with protein quantification exist at present. Therefore, detergent concentrations may vary between 
experiments from different protein preparations without this being readily ascertainable. More recent work 
by the previously mentioned Prosser group (Ye et al, 2018) uses dialysis as the last step prior to NMR which 
 
Figure 1.29 Representations of extracellular portion of A2AR showing macrostates five (light grey) and four (lime) 
causing the A2AR to adopt a conformation with an outward movement of helix V that was evidenced by the shift 
observed in the 19F tag on K209C (out of frame below image). Cmpd-1 leaves the orthosteric pocket in macrostate 
five, which further increases the outward movement of helix V. In combination these states result in the alternative 




would bring the detergent concentration back down to its nominal value. In this study, sets of K209C 
spectra (including Figure 1.29) have been collected from samples of the same protein prep to ensure a 
constant detergent concentration even if the absolute value is unknown.  
To further investigate the effect the effect of varying detergent on our data, NMR experiments comparing 
A2AR K209C spectra with bound ZM 241385 and Cmpd-1 were collected with additional detergent added 
after the protein was concentrated for NMR. These data are shown in Figure 1.30. Increasing 
concentrations of detergent cause the peak from the Cmpd-1 bound receptor to move towards (but not 
quite reach) the peak of ZM 241385-bound receptor.  
A variety of explanations for this may be suggested. It may be that the downfield shifted (less negative ppm 
values) signal represented a more detergent-exposed tag and that, therefore, the addition of more detergent 
into the solution causes the coalescence of solvent-exposed shifts into the detergent-exposed spectral region 
as the entire solvent environment becomes more homogeneously detergent-like. One other hypothesis is 
that it is not the detergent that is influencing the receptor, but the cholesterol. MD simulations have found 
both in the A2AR and other receptors that several cholesterol binding sites exist on the outer face of the 7-
TM bundle (Genheden et al, 2017). Since cholesterol is likely to be concentrated as detergent micelle 
concentration increases it would be consistent with these data to infer that the increased cholesterol 
concentration in the NMR samples causes the receptor not to adopt the abnormal conformation of helix 
V to the same degree.  
 
 
Figure 1.30 Spectra of A2AR K209C tagged with 
BTFMA in different concentrations of LMNG/CHS 
(left to right +0.01% LMNG, +0.075% LMNG, 
+0.15 LMNG) CHS was always at 1/5th concentration 
by mass of LMNG. The initial concentration of 
detergent before addition of further detergent is 
unknown, but constant throughout the experiment. 
ZM 241385 spectra are shown in blue and Cmpd-1 in 





There may be other explanations of these data or the above hypotheses may each be true to some degree. 
Further experiments would need to be designed and carried out to discriminate between these possibilities. 
What is clear, however, is that the detergent environment selected for biophysical experiments in drug 
discovery targeting GPCRs have a profound effect on the outcome. If the detergent environment selected 
favours an inactive or active state, then the opposing effects of ligands may be supressed to the point that 
they cannot be observed. 
In conclusion these data strongly support the existence of an additional inactive conformation of helix V 
that is more heavily populated in the presence of the putative allosteric ligand reported by Sun et al. These 
measurements are made in solution at physiological ionic strength and close to physiological temperature, 
without any fusion or insertion modifications to the protein. Although not explored further in this work, 
the K209C tagged A2A mutant is a useful tool for further development of novel ligands derived from Cmpd-
1; by enabling direct assessment of their allosteric effect on helix V conformational sampling, the K209C 
tagging site may bridge the gap between ligand binding and antagonistic function. It is also hoped that these 
data will encourage the further use of rationally designed 19F tagging of novel sites in less tractable target 





Materials and Methods 
Turnitin note: These methods build heavily on our publication of this work (Landin et al, 2019) 
and my previous progress monitoring reports for this PhD as they refer to the same published 
experiments that we carried out. Co-authors and collaborators are acknowledged in-text, in the 
acknowledgements section, and in this section where work was carried out jointly. 
Talon Superflow Resin, HisTrap HP columns GE Healthcare 
[3H] ZM241385 10-50 Ci/mmol, 1 mCi/ml, Ethanol:H20 1:1 Biotrend (ART-0884-50) 
Expifectamine 293 Transfection kit, iblot Gel transfer stack, SeeBlue 
protein ladder, Peroxidase-conjugated anti-His antibody, Nco1, Xho1, 
DNA digestion and ligase buffer, T4 DNA ligase 
ThermoFisher Scientific  
Protease Inhibitor Cocktail Tablets Roche 
Lauryl Maltose Neopentyl Glycol >98% purity Anatrace 
Cholesteryl Hemisuccinate >99% purity Avanti 
Theophylline >99% purity, Caffeine >99% purity, N-
ethylcarboxamidoadenosine >98% purity, ZM241385 >98% purity, 
Deuterium Oxide >99% purity, Deuterium-matched Shigemi tube 
SigmaAldrich 
2-Bromo-N-[4-(trifluoromethyl)phenyl]acetamide >99% purity Apollo Scientific 
50 kDa Protein Spin Concentrator Amicon 
Glass Fibre Filters PerkinElmer 
4-12% Bis-Tris Gradient Gels NuPAGE 
A2AR Constructs (vector was a proprietary UCB HEK293 cell expression vector):  
The constructs consist of residues 1-316 of the wild type sequence with an N154Q mutation to remove a 
putative N154 glycosylation site. The mutants to be used for 19F tagging contained one of the mutations 
K209C and V229C each. The constructs contain an N-terminal tStrep tag and C-terminal TEV-His10. All 
sequences for initial constructs were ordered from DNA 2.0 (As it was called then). Cysteine mutations 
were introduced using a Quickchange Lightening mutatgenesis kit (Agilent). The linkers are commercially 
recommended sequences. The constructs were designed and ordered by Lisa Joedicke, UCB (Slough). 
























1 mg DNA per litre of cells was transfected into expiHEK 293 cells at 2.5*106 cells/ml using standard 
protocols for ThermoFisher Scientific’s Gibco ExpiFectamine 293 transfection kit. Enhancers 1 and 2 from 
the kit were added 16-18 h after transfection as per manufacturer’s protocol. Cells were grown at 37 °C in 
75% humidity, 8.0% CO2 and shaking at 120 min-1. The expression was harvested at 48 h after transfection. 
Cells were harvested by centrifugation (4000 g, 20 min, 4 °C), flash frozen and stored (-80 °C) until use. 
Membrane Preparation:  
Membranes were prepared by resuspension in ice-cold lysis buffer (25 mM HEPES, 1 mM 
ethylenediaminetetraacetic acid (EDTA), 100 µM theophylline, pH 7.4 +protease inhibitor cocktail (PIC)) 
and two passes through a continuous cell disruptor (11.0 kpsi, 4 °C). Debris was removed by centrifugation 
(7000 g, 20 min, 4 °C). Membranes were spun down (187945 x g, 1 h 30 min, 4 °C), washed by re-suspension 
in ice-cold high salt buffer (25 mM HEPES, 500 mM NaCl, 1 mM EDTA, 100 µM theophylline, pH 7.4 
+PIC), spun down again (187945 x g, 1 h 30 min, 4 °C) and re-suspended in ice cold storage buffer (PBS, 
10% glycerol, 100 µM theophylline, pH 7.4, +PIC), before being flash frozen and stored. 
A2A Purification and Tagging:  
The membranes were solubilised (0.5% LMNG, 0.1% CHS, 3 h, 4 °C) at 5 mg/ml total protein 
concentration determined by bicinchoninic acid assay (BCA). Insoluble matter was removed by 
ultracentrifugation (187945 x g, 1 h, 4 °C) and the supernatant was incubated with 1.2 ml buffer-equilibrated 
(50 mM HEPES, 300 mM NaCl, 10% glycerol + 0.01% LMNG + 0.002% CHS, 4 °C, pH 7.4)TALON 
Superflow bead slurry per litre cell expression for the total amount of membranes used overnight. The 
flow-through (FT) was separated on a 2 ml gravity flow column. The resin was washed with 10 CV buffer 
A (50 mM HEPES, 100 mM NaCl, 10% glycerol + 0.01% LMNG + 0.002% CHS, 4 °C, pH 7.4), 10 CV 
buffer B (50 mM HEPES, 800 mM NaCl, 20 mM imidazole, 10 mM MgCl2, 10 % glycerol + 0.01% LMNG 




°C) and the buffer was removed immediately at the end of the incubation and washed with 20 CV buffer 
A. The beads were incubated with 100 µM BTFMA (6 h, 4 °C), then with 150 µM fresh BTFMA (overnight, 
4 °C) and washed with 10 CV buffer A (50 mM HEPES, 100 mM NaCl, 10% glycerol + 0.01% LMNG + 
0.002% CHS, 4 °C, pH 7.4). Protein was eluted with 8 CV buffer E (50 mM HEPES, 100 mM NaCl, 10% 
glycerol, 200 mM imidazole, 4 °C, pH 7.4), concentrated as required (50 kDa cut-off, Amicon) and desalted 
in a 3 ml PD10 column (GE Healthcare). 
TEV Digest:  
The protein was treated with in house TEV protease (1:1 TEV to A2AR mass ratio, 4 h, 4°C) and 
subsequently incubated on 1 ml equilibrated TALON Superflow bead slurry per mg TEV overnight and 
the FT containing A2A was collected. A2A was desalted into buffer SG (50 mM HEPES, 100 mM NaCl, 0.01 
% LMNG, 0.002% CHS, pH 7.4). 
SDS PAGE:  
All gels were Bis-Tris 4 - 12 % gradient gels run in MES (ThermoFisher) under reducing conditions. A2A 
receptor was visualised by InstantBlue Coomassie stain (Expedeon) (> 1 h) with SeeBlue ladder or prepared 
for western blot by transfer to a polyvinylidene difluoride membrane on a gel transfer stack by standard 
protocols for iBlot (Thermo) kit (7 min). Western blots were visualised by Anti-His Peroxidase-conjugated 
monoclonal mouse antibodies (1:4000 dilution). 
Coordinate Preparation for MD 
MD coordinates were generated from crystal structures with the antagonist ZM 241385 [PDB: 5IU4], the 
agonist NECA [PDB: 2YDO] or the novel UCB antagonist Cmpd-1 [PDB: 5UIG] (Lebon et al 2011; Segala 
et al, 2016; Sun et al, 2017). Any cytochrome fusion proteins in ICL3 were removed and loops consisting of 
the physiological sequences were introduced. For antagonist-bound coordinates the ICL3 coordinates were 
derived from an antagonist bound structure with ICL3 present [PDB: 3VG9], with the surrounding residues 
aligned to those in the coordinate structures.  For 5UIG and 2YDO there are no analogous ICL3 structures 
and so the loop was built using Modeller (Sali & Blundell 1993). All thermostabilising mutations in the 
crystal structures were reverted to the physiological sequence.  The simulations were carried out in a 
POPC:POPE:cholesterol artificial bilayer in a ratio of 5:5:1 built by the CHARMM-GUI tool (Jo et al, 2009). 
The 19F tag was built on using Chimera and hydrogen atoms consistent with pH 7 were added by 
CHARMM-GUI with the protein coordinates in the lipid bilayer generated by insertion. The protein 
coordinates were parameterised by the forcefield Amber 14SB and the lipid coordinates were parameterised 
using lipid14 in LEaP (Maier et al, 2015; Dickson et al, 2014). The simulation box had a length and width of 
85 Å in the plane of the bilayer and a height perpendicular to the bilayer of 120 Å. The system was solvated 
in water and 0.15 M NaCl. ZM 241385, NECA and Cmpd-1 were parameterised with the generalised Amber 





Simulations were run using a 2 fs timestamp with minimisation over 10 000 steps. Heating was carried out 
in two runs, from 0 to 100 K over 5 ps followed by 100 to 303 K over 100 ps. The box was equilibrated in 
10 500 ps runs. Simulations were run for 125 ns each using the Langevin thermostat and Monte Carlo 
barostat. To generate full 625 ns data for each coordinate set the fresh trajectories were generated by 
applying the minimisation and heating steps described to the coordinates at 30, 60, 90 and 120 ns from the 
first 125 ns simulation and then running those for a further 125 ns. The trajectories were analysed using 
CPPTRAJ (Roe & Cheatham, 2013). 
Radioligand Binding Assays on Membranes: 
Membranes were prepared as for purification but without the inclusion of theophylline in the storage buffer. 
Membrane samples containing 10 µg total protein in 200 µl as calculated by (BCA) were incubated with a 
dilution series of [3H]ZM 241385 with a final concentration of 0.1% DMSO in Jaakola et al’s buffer (50 mM 
Tris-HCl, 10 mM MgCl2, 0.5 mM EDTA, pH 7.4), PerkinElmer’s buffer (50 mM Tris-HCl, 0.5% BSA, pH 
7.4) or Uustare et al’s buffer (20 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl2, 1mM EDTA, pH = 7.4) as 
specified for 1 hour at room temperature (n = 3). To measure non-specific binding duplicate samples (n 
=2) were incubated in the same way with the addition of 20 µM ZM 241385.  The reaction was rapidly 
stopped by washing with 50 mM Tris (pH 7.4) in a Skatron 1450 Microbeta Trilux onto glass fibre filters 
which were counted in a Perkinelmer Micro 96 plate reader. 
Radioligand Binding Assays on Purified Receptor:  
Purified A2AR in buffer SG was incubated at 0.02 mg/ml with 50 nM [3H] ZM 241385 (n = 3) for 1 hour 
at room temperature and desalted before being counted in a PerkinElmer Tricarb 2910 TR Liquid 
Scintillation Analyser. Non-specific binding was measured by replicates of this experiment incubated with 
the addition of 20 µM ZM 241385 (n= 3) which were desalted and counted in the same way.  
19F NMR:  
Samples of cleaved and tagged A2A were made up at a concentration of 20 µM (measured by BCA) in buffer 
SG with 2% DMSO and the relevant ligand in a Shigemi tube. Samples were doped with 10% D2O.  All 
experiments were run on a Bruker AVIII HD spectrometer operating at a magnetic field strength of 14.1 
T equipped with a 5 mm QCI-F Helium Cooled Cryoprobe. The experiments were run detecting 19F with 
a spectral width of 138 ppm, 490 ms acquisition time, a recycle delay of 1 s, 15 000 scans, at a temperature 
of 298.2 K and processed with 15 Hz of line broadening. Chemical shift referencing was based on the 














The lipocalin protein family is a diverse set of proteins that exhibit an eight-stranded beta-barrel fold, and 
bind physiological ligands and a variety of exogenous drug-sized small molecules (Du et al, 2015; Masi et al, 
2016). Retinol binding protein 4 (RBP4), also called plasma retinol binding protein, is a well-studied member 
of this family displaying the archetypal eight-stranded beta barrel structure which is shown in Figure 2.1 
(Cowan, Newcomer & Jones, 1990).  
RBP4 carries retinol from the liver to 
peripheral tissues whilst preventing its 
oxidation (Masi et al, 2016). The 
importance of the lipocalin in this 
process can be seen in RBP -/- knockout 
mice that can develop normal vision with 
a diet sufficiently high in retinol, but 
unlike RBP+/+ cannot maintain normal 
retinal function after three weeks of a 
low-retinol diet (Quandro et al, 1999). 
Retinol levels in the liver remain high in 
RBP -/- knockout mice on a low retinol 
diet, indicating that RBP is critical for 
the mobilisation of retinol stores to 
peripheral tissue via the blood. 
Other members of the lipocalin family 
bind exogenous ligands. A striking 
example of a lipocalin exhibiting this 
property is the histamine binding protein 
(HBP2_RHIAP) of the tick Rhipicephalus 
appendiculatus (Shown in Figure 2.2). This 
protein possesses a lipocalin fold and 
binds two histamine molecules in its 
cavity with sufficient affinity to 
outcompete the histamine receptors of 
the tick’s host thus supressing the host’s 






Figure 2.1 Ribbon representation of RBP4 in complex with all-
trans retinol [PDB: 1RBP]. The ligand binding pocket is formed by 
an 8-stranded β-barrel (Cowan, Newcomer & Jones, 1990). 
Figure 2.2 Ribbon representation of histamine binding protein 
[PDB: 1QFV]. Two histamine molecules are present in the 




The human α-1-acid glycoproteins are the lipocalins that are the subjects of this study and possess binding 
activity against a broad range of exogenous ligands (Masi et al, 2016). These proteins are coded by the genes 
orosomucoid 1 and orosomucoid 2 to produce the F1/F2/S (AGP1) or A (AGP2) variants of α-1-acid 
glycoprotein respectively (Luo et al, 2015). AGP1 and AGP2 are also referred to as Orm1 and Orm2 
respectively and their sequences are shown in Figure 2.3. There are around twenty amino acid differences 
between the two protein variants depending on the alleles compared. AGP1’s three allelic variants differ by 
two amino acids (Q20 in variant F1 and F2, R20 in variant S; V174 in variant F1 and S, M174 in variant 
F2) (The Uniprot Consortium, 2019). 
 
AGP consists of 183 amino acids and adopts a lipocalin type fold based around an archetypal 8-stranded 
β-barrel structure. The protein is present in blood plasma at a concentration of ~2 µM and binds small 
molecule drugs such as methadone and endogenous ligands such as serotonin thus acting as a transporter 
(Masi et al, 2016). It has immunosuppressive activities that have been observed in cancer (Elg et al, 1997) 
and neuroinflammation (Jo et al, 2017). Although these physiological effects of AGP2 have been observed 
the link between the binding of natural ligands and AGP2 function is not understood (Bteich, 2019). 
In addition to the immunomodulatory effects of AGP there is interest in the function and properties of 
both variants as they affect the volume of distribution of many therapeutics. Volume of distribution (VD) 
is the theoretical volume of blood that would be required to hold an administered dose in its entirety at the 
blood plasma concentration.  VD is therefore a measure of drug binding to blood plasma. This can have a 
marked effect on the in vivo efficacy of a particular drug. For instance, the anti-cancer drug Imatinib (IMT) 
has been shown to enter cells at a reduced concentration in the presence of an elevated concentration of 
AGP (Gambacorti-passerini et al, 2003) and has been found to bind both AGP variants (with KDs of  1.25 
and 50 µM for the S and A variants respectively) in vitro (Fitos et al, 2006). 
AGP1      MALSWVLTVLSLLPLLEAQIPLCANLVPVPITNATLDQITGKWFYIASAFRNEEYNKSVQ 42 
AGP2      MALSWVLTVLSLLPLLEAQIPLCANLVPVPITNATLDRITGKWFYIASAFRNEEYNKSVQ 42 
 
AGP1      EIQATFFYFTPNKTEDTIFLREYQTRQDQCIYNTTYLNVQRENGTISRYVGGQEHFAHLL 102 
AGP2      EIQATFFYFTPNKTEDTIFLREYQTRQNQCFYNSSYLNVQRENGTVSRYEGGREHVAHLL 102 
 
AGP1      ILRDTKTYMLAFDVNDEKNWGLSVYADKPETTKEQLGEFYEALDCLRIPKSDVVYTDWKK 162 
AGP2      FLRDTKTLMFGSYLDDEKNWGLSFYADKPETTKEQLGEFYEALDCLCIPRSDVMYTDWKK 162 
 
AGP1      DKCEPLEKQHEKERKQEEGES 183 
AGP2      DKCEPLEKQHEKERKQEEGES 183 
Figure 2.3 Sequence alignments of AGP1 variant F1 and AGP2 variant A. The F2 and S variants of AGP1 differ 
by Q20R and V174M respectively. Residues 1-18 (yellow) are cleaved to make the mature form of the protein and 




Past X-ray crystallographic structural studies have focused on establishing the fundamental properties of 
AGP1 and AGP2 that determine their different ligand binding specificities. In 2008 the crystal structure of 
AGP1 (Figure 2.4(A)) was solved (Schönfeld et al, 2008) and it was followed in 2011 by the structure of 
AGP2 (Figure 2.4(B)) (Nishi et al, 2011). The structure of AGP2 was solved in the ‘free’ state to 2.10 Å, in 
complex with PEG, and also in complex with three ligands to a similar resolution: Disopyramide (DSP), 
amitriptyline (AMT) and chlorpromazine (CPZ). The AGP2 structures revealed that the protein had a 
smaller ligand binding pocket compared to that of AGP1, thus explaining AGP1’s increased binding 
promiscuity. These structures also showed that certain ligands that were not specific for either variant (such 
as CPZ) bind via interactions to the conserved Phe-49 and hydrophobic Phe-112/Leu112 residues. 
Specificity for AGP2 is conferred by the replacement of the sterically occluding Phe114 in AGP1 by the 
smaller Ser114, which can mediate hydrogen bonds to the ligand, in AGP2.  
 
The structural studies of the AGP variants have not, however, yielded data on their binding to some of the 
most medicinally important ligands. IMT (mentioned above) is an inhibitor of the break point cluster-
Abelson (Bcr-ABL) tyrosine-kinase that is constitutively active and created by a fusion of part of 
chromosome 9 onto chromosome 22. BCR-ABL produces a constitutive signal that drives cell growth and 
can be a key oncogenic marker (Savage and Antman, 2002). The existing structure of AGP1 has been used 
to conduct a molecular docking study on the binding of IMT to AGP1 as shown in Figure 2.5 (Fitos et al, 
2012), however no experimental studies have confirmed the in silico results. This author wishes to thank 
Dr Ilona Fitos and Dr Agnes Simon for sharing the ligand coordinates from their docking study by private 
communication.  
In the case of AGP2 the tightest known binders are derivatives of the natural product staurosporine, first 
isolated in 1977 (Omura et al, 1977). The 7(R)-hydroxylated derivative of straurosporine, UCN-01 shown 
A      B          
 
Figure 2.4 (A) AGP-1 [PDB: 3KQ0] in complex with dihydroxypropyl acetate (Tris buffer) (B) AGP-2 [PDB: 
3APV] in complex with AMT revealing a highly similar architecture to that of AGP-1 with the AMT ligand binding 




in Figure 2.6, was subsequently found to be a 
potent specific inhibitor of the protein kinase 
C (PKC) family, inhibiting all of it members 
to some degree, but PKCα most strongly 
(Mizuno et al, 1995).  
The PKC family of proteins consists of 8 
members all of which are promiscuous 
protein kinases. The PKC family are targets 
for therapeutic areas such as cardiovascular 
disease, autoimmune disease, and cancer 
(Mochly-Rosen, Das and Grimes, 2012). 
PKCα signalling is associated with cell 
proliferation making its inhibition a potential 
route to treat cancer. They each consist of 
regulatory region and a catalytic region. The 
regulatory region mediates intramolecular 
interactions that are relieved by binding to the 
activatory ligand diacyl glycerol (PKCα, 
PKCβΙ, PKCβΙΙ and PKCγ also require 
calcium binding for activation). The kinase 
region, and in particular its ATP binding site, is 
the target for a number of clinical compounds 
including UCN-01.  
Following the interest in UCN-01 as a PKC 
antagonist it was found that the compound can 
also affect cell cycle control in two separate 
ways: Abrogating the G2/M checkpoint (Bunch 
and Eastman, 1996) and by arresting cells in G1 
phase (Akiyama et al, 1997). 
The abrogation of the G2/M checkpoint can 
be employed to increase the toxicity of DNA 
damage agents by a mechanism described 
schematically in Figure 2.7. When the cell 
suffers DNA damage during or immediately 
following DNA replication the cell cycle may be halted before mitosis by the set of proteins forming the 
G2/M checkpoint. In the absence of this checkpoint DNA damage that would normally have been repaired 
 
Figure 2.6 The structure of UCN-01. This hydroxylated 
analogue of staurosporine has been investigated as a cancer 
treatment due to its inhibitory activity against a broad range 
of kinases. 
 
Figure 2.5 AGP-1 [PDB: 3KQ0] with imantinib docked into 
the binding pocket. The binding pocket is the same as that 
found with other ligands with the terminal biaryl in a similar 
position to the heterocycles of AGP2 ligands in that protein. 
This author thanks Dr Fitos and Dr Simon (Hungarian 
Academy of Sciences, Budapest) for sharing the docked 
coordinates from their publication (Personal 




by the cell can prove fatal as the cell attempts to complete mitosis with damaged DNA. Cancer cells are in 
general more susceptible to DNA damaging agents due to their higher rate of proliferation and genomic 
instability and so DNA damaging agents have been longstanding cancer treatments. By preventing DNA 












UCN-01’s effect on the G2/M checkpoint is mediated by inhibition of checkpoint 1 (Chk1) kinase (Graves 
et al, 2000). A subsequent crystal structure, shown in Figure 2.8, of Chk1 kinase revealed the binding of 
UCN-01 in the catalytic ATP binding site of the kinase (Zhao et al, 2002). 
Curiously, the other effect of UCN-01 is to arrest cells in G1 phase, preventing the transition into S-phase 
(Seynaeve et al, 1993). This effect is mediated by the product of the retinoblastoma gene, a tumour 
suppressor. The retinoblastoma protein inhibits transcription of S-phase promoting genes, but is itself 
inhibited by phosphorylation. UCN-01 maintains retinoblastoma protein in an active non-phosphorylated 
state by an unknown mechanism and so prevents cell cycle progression to S-phase (Akiyama et al, 1997). 
This effect of UCN-01 provides an opportunity to target cancer cells, which have frequently lost 
retinoblastoma protein function (Dick and Rubin, 2013). A potential method to enhance the efficacy of 
cytotoxic anti-cancer treatments is shown schematically in Figure 2.9. By arresting predominantly healthy 





















Figure 2.7 (A) If a cell’s DNA is damaged (for example by a cytotoxic agent such as cisplatin) during proliferation 
the G2 checkpoint prevents entry into mitosis to allow the DNA to be repaired. (B) In cultured cells UCN-01 is 





The strategy shown in Figure 2.9 was recently 
shown to be effective in a human xenograft 
murine model of breast cancer at improving 
the tolerated dose of the cytotoxic agent 5-
fluorouracil (Mull et al, 2020). 
Clinical trials on UCN-01 have investigated its 
potential as a treatment for lymphomas 
(National Cancer Institute, 2017) and as a dual 
therapy with topotecan to treat ovarian 
cancer (Welch et al, 2007). The former study 
was terminated due to funding issues and the 
latter failed to demonstrate sufficient efficacy. 
Given the drastic effect of AGP2 on UCN-01 pharmacokinetics, it is worthwhile to investigate this 




The underlying interest in UCN-01 as a cancer therapy makes understanding its molecular interaction with 
AGP timely. This understanding could, for example, open opportunities to modify UCN-01 in a way that 
eliminates AGP2 binding without affecting the interaction with its kinase targets. This might subsequently 
have an important effect on the compound’s therapeutic potential. Furthermore, the structural information 
gained from this study may be used to inform future drug discovery efforts to avoid creating compounds 
with high affinity for AGP. 
 
Figure 2.8 The structure of Chk1 kinase in complex 
with UCN-01 [PDB:1NVQ]. Inhibition of this kinase 
prevents G2/M checkpoint cell cycle arrest. 




























No G1 arrest 
in absence of  
retinoblastoma 
protein activity
Figure 2.9 (A) Healthy cells are arrested in G1 phase and so are not as sensitive to cytotoxic agents 
targeting DNA replication. (B) Retinoblastoma protein-deficient cancer cells are not arrested in G1 and 




This chapter describes optimisation of bacterial expression and purification of recombinant AGP2 which 
has led to the production of milligram quantities of pure 15N labelled and 15N/13C dual-labelled AGP2. 
Isotope-labelled AGP2 was subsequently used to generate multi-dimensional NMR spectra which were 
sufficient for assignment of the protein backbone and significant portion of the side chains. These data 
were followed by a crystal structure of AGP2 in complex with UCN-01, characterising for the first time 








Trial Expression of AGP2 in Origami 2 Cells 
The initial aim was to establish a robust in-house protein expression system that could be used for 
producing isotopically labelled AGP2. AGP2 is a eukaryotic protein containing 2 disulphide bonds and is 
extensively glycosylated in vivo, with glycans making up as much as 45% of its mass (Masi et al, 2016). E. coli 
lack the endomembrane systems of eukaryotes to assist in disulphide bond formation and are not capable 
of producing eukaryotic glycosylation patterns, however previous crystallographic studies on both AGP 
variants have successfully produced sufficient folded protein that bound to known ligands in prokaryotic 
expression hosts and so these problems were not perceived to be insurmountable (Shönfeld et al, 2008; 
Nishi et al, 2011). 
For previous structural studies, AGP2 was expressed in the cytoplasm of Origami B cells (Nishi et al, 2011). 
Origami cells carry mutations in the thioredoxin reductase (trxB) and glutathione reductase (gor) genes 
(Merck, 2019); this results in a more oxidising cytoplasmic environment than that of wt E. coli cells or those 
of other expression strains facilitating disulphide bond formation. This approach allowed Nishi et al to 
produce pure protein at a final working concentration of 18 mg/mL from which it follows that they must 
have been successful in producing protein quantities on the order of 2 mg to carry out any significant 
condition screens (one 96-well screen would require 1.7 mg of protein assuming 1 µl drops of protein were 
used) . A 50 µl sample of 1 mM AGP2 would be sufficient on the instrument available for this study (see 
methods) and would require 1.1 mg of AGP2. It was therefore concluded that an approach similar to that 
of Nishi et al might be successful. 
AGP2 expression was first attempted using Origami 2 cells. This cell line is closely related to the cell strain 
used in the literature (differing in antibiotic resistance markers), making it a logical starting point (Nishi et 
al, 2011). Full-length (1-183) and short (1-175) versions of AGP2 were synthesized in a pMA-T vector 
(Thermo Fisher) and transferred by restriction cloning into a pET28 vector. The shortened version was 
purchased in case a smaller construct was necessary to facilitate NMR assignment later in the project. The 
crystal structures [PDB: 3APU; 3APV; 3APW; 3APX] indicate that residues after 175 do not form part of 
the main protein structure and are likely to be dispensable without affecting the protein fold. The AGP2 
constructs and pET28 receiver vector were cleaved by Nco1 and Xho1 in a double digestion as shown in 
the gel image in Figure 2.10. AGP2 was extracted from the gel and ligated into the pET28 receiver vector 
and amplified in the high copy number strain NEB5α (New England Biolabs). The integrity of the full 
length AGP2 construct was confirmed by forward sequencing prior to transformation into the Origami 2 
cells. AGP2 was expressed and purified from the soluble cell lysate by IMAC. The results were analysed by 








Very little if any AGP2 was detectable on the Coomassie-stained SDS PAGE, but after anti-His Western 
blotting a significant band consistent with the expected mass was observed. Given that other bands of 
similar intensity to the putative AGP2 band were observed in the SDS PAGE analysis and the total protein 























Figure 2.10 Agarose gel of double 
digestion of AGP2 constructs and the 
pET28 expression vector. Clear bands are 
shown for the AGP2 full and short 
constructs consistent with the expected 
sizes of 557 bp and 555 bp respectively. 
pET 28 migration was consistent with the 
empty vector size of 5231 bp. 
Figure 2.11 SDS PAGE visualised with Coomassie stain 
(left) and horseradish peroxidase (HRP) linked anti-his 
antibody after western blotting (right). A very faint band 
may be detectable by Coomassie staining the identity of 







Cloning and Expression of New AGP2 Constructs 
The initial expression of AGP2 in the pET28 vector in Origami2 cells did not produce protein in sufficient 
quantity for efficient purification and subsequent biophysical or NMR studies. Consequently, new 
expression vectors were explored in efforts to produce sufficient quantities of protein; three strategies were 
chosen: 
• Expression of AGP2 in the bacterial periplasm in a pET26 vector 
• Expression of AGP2 in the bacterial cytoplasm with the solubility-enhancing tag N utilisation 
substance A (NusA) using the pETM60 vector which incorporates a TEV cleavage site for post 
expression removal of the NusA 
• Expression of AGP2 in the bacterial cytoplasm with an N-terminal His6 tag in a pOPINF vector 
These strategies may each respectively be justified as follows: 
• Expression in the bacterial periplasm allows the protein to fold in a more oxidising environment 
assisting in disulphide bond formation, and has been applied successfully to express AGP1  
(Schönfeld et al, 2008). 
• Expression of recombinant protein with a NusA fusion, is an established method to improve both 
protein solubility and stability. The NusA protein works by recruiting bacterial chaperones and 
increasing the solubility of the fusion construct (De Marco et al, 2004). 
• Expression of recombinant protein with an N-terminal His6 tag rather than a C-terminal addition 
has been shown to improve expression in some cases (Park et al, 2015) 
To carry out these strategies the three new constructs first had to be generated. 
Generation of 3 New Constructs for Fresh Expression Strategies – pET26, pETM60 and pOPINF 
The full AGP2 construct was inserted into the pET26 and pETM60 vectors by restriction enzyme cloning 
techniques, as before with the pET28 vector, using the Nco1 and Xho1 restriction sites, and ligation with 
T4 ligase. The double digestion of the AGP2 construct and the pET26 and pETM60 vectors are shown in 
Figure 2.12. A strong band was present at around 550 kb in each of the AGP2 donor digestions indicating 
that the construct was cleaved out of the pMA-T vector and strong bands were present at above 5.0 kb in 
the receiver vector digestions indicating that these vectors had been successfully cut and may receive the 
AGP2 construct. AGP2 was prepared for insertion into the pOPINF vector by PCR addition of adaptor 
sequences (5’ AAGTTCTGTTTCAGGGCCCG, 3’ ATGGTCTAGAAAGCTTTA) across a screen of 5 
temperatures as shown in Figure 2.13. A band of around 550 kb, consistent with the AGP2 construct, was 
present amplification in the range of temperatures tested. These data indicated that all of the temperatures 
used were suitable. The AGP2 PCR product was inserted into cut pOPINF by homologous recombination 




After verification by sequencing AGP2 expressions were carried out for each of these constructs. 
  
 
Periplasmic Expression of AGP2 in pET26  
pET26-AGP2 was expressed in BL21 (DE3) cells and a standard periplasmic compartment purification 
protocol was carried out as shown in the SDS PAGE image of Figure 2.14 and in the UV trace of the 
IMAC protocol in Figure 2.15. This involved applying hypoosmotic and hyperosmotic buffer to the cells 
to cause the outer membrane of the cells to rupture and release the recombinant AGP2 into the buffer 
solution (Schönfeld et al, 2008). 
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Figure 2.12 Agarose gel of duplicated double 
digests of AGP2 in pMA-T, pET26 and 
pETM60. Clear bands are visible for the vectors 
and AGP2 inserts 
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Figure 2.13 Agarose gel of the AGP2 
construct amplified and modified to contain 
pOPINF adapter sequences by PCR across a 
range of temperatures (in °C) 
Figure 2.14 Coomassie-stained SDS PAGE of an expression of pET26-AGP2. There is no significant band at 







There was no evidence of a significant 
band at the expected mass (~ 23 kDa) in 
the SDS PAGE nor any significant UV 
absorption consistent with bound protein 
in the IMAC elution. As there was no 
evidence of AGP2 expression the pET26 





Cytoplasmic Expression of NusA-AGP2 Fusion Protein in pETM60 
NusA is a highly soluble 50 kDa protein that was expressed upstream of the N-terminus of AGP2 in this 
construct to assist in the expression of soluble AGP2. Expression and purification of AGP2 with the NusA 
solubility enhancing tag in the pETM60 vector was carried out and the results were analysed by SDS PAGE 
as shown in Figure 2.16. A significant band consistent with the expected mass of the construct (~75 kDa) 
was visible in each of the crude insoluble and soluble cell fractions. The IMAC UV trace (Figure 2.17) 
 
Figure 2.15 UV absorption (280 nm) trace from IMAC 
fractionation of the pooled hyperosmotic and hypoosmotic 
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Figure 2.16 Coomassie-stained SDS PAGE of NusA-AGP2(arrow) IMAC purification. There is 




showed a large peak (above the limit of the 
instrument’s UV absorbance detection) in the 
protein elution. The five fractions I8-I12 of this 
peak are shown in the SDS PAGE and the same 
band as in the crude fractions at ~75 kDa consistent 
with NusA-AGP2 was visible.  
Subsequently the NusA-AGP2 fusion was treated 
with in-house TEV protease for 16 hours at 4 °C or 
room temperature and the resulting protein samples 
were compared to His-AGP2 prepared insolubly 
(see next section). The results were analysed by SDS 
PAGE as shown in Figure 2.18. The previously 
observed band at 75 kDa corresponding to NusA-
AGP2 was replaced by a band around 50 kDa, 
consistent with cleaved NusA. A small band also 
appeared at around 25 kDa consistent with cleaved 
AGP2-His6 strongly suggesting that the NusA-
AGP2 protein was successfully cleaved in both 
reaction conditions. 
To separate AGP2-His6 from NusA, gel filtrations 
were carried out on TEV cleavage products of 
NusA-AGP2 in the presence or absence of a 
cystamine-cysteamine redox shuffle to allow disulphide bond exchange (Figure 2.19). In both cases 
significant peaks were observed between an elution volume of 100 and 150 ml-post injection consistent 
with aggregated protein. Small peaks (A7 and C1 in Figure 2.19) were observed consistent with monomeric 
protein, however SDS PAGE analysis (shown in Figure 2.20) indicated that the aggregate peaks were 
composed of NusA and AGP2 cleaved from each other, whereas the fractions consistent with monomeric 
protein (A7, C1) were composed only of NusA. 
From these data it was concluded that whilst NusA successfully brought AGP2 into solution it was 
nevertheless either improperly folded or partially denatured and therefore aggregated when NusA was 





Figure 2.17 UV absorption trace from IMAC of 
NusA-AGP2 expressing BL21 lysate. 
 
Figure 2.18 Coomassie-stained SDS PAGE image of 
AGP2 samples compared with NusA-AGP2 before 







Although insoluble AGP2 was produced using the pETM60 vector a full protocol to express insoluble 
AGP2 was developed using the pOPINF vector instead, as the smaller N-terminal His6 tag expression 
theoretically should consume fewer cellular resources than expressing a full 55 kDa NusA fusion partner 






Figure 2.19 UV absorption (280 nm) trace of two in-series gel filtrations of NusA-AGP2 cleavage products 
with redox shuffle (0-200 ml) and without redox shuffle (200-400 ml). 
 












Figure 2.20 Coomassie-stained SDS PAGE of NusA-AGP2 cleavage gel filtration. Bands consistent with NusA 
are present in both the load and monomeric fractions, but bands for cleaved AGP2 are only present in fractions 




Cytoplasmic expression of His6-AGP2 in pOPINF 
AGP2 inserted into the pOPINF vector was expressed 
in BL21 cells and the lysate fractions were analysed by 
SDS PAGE as shown in Figure 2.21. A clear band at the 
expected mass (~23 kDa) was visible in the insoluble 
fraction of the lysis. This result was consistent with 
AGP2 being produced as in insoluble inclusion bodies. 
The putative AGP2 inclusion bodies were purified by an 
inclusion body prep, solubilised in 10 M urea buffer, and 
reduced in preparation for refolding by rapid dilution in 
1M arginine containing buffer. The refolded preparation 
was concentrated, and folded protein was separated 
from aggregate by gel filtration as shown in Figure 
2.22(A). The inclusion bodies, refold mixture, and gel 
filtration peak were each analysed by SDS PAGE as 















Figure 2.21 Coomassie-stained SDS PAGE of 
pOPINF-AGP2 expressed in BL21 cells shows a 
clear band in the insoluble lysate fraction 
consistent with AGP2 inclusion bodies 
 
A        B       
 
                                                     
                
Ladder 
Insoluble Fraction 
Washed Inclusion Bodies Concentrated Refold Gel Filtration Peak 
Figure 2.22 (A) Refolded inclusion body prep was separated by gel filtration and a peak UV peak 
at 280 nm consistent with monomeric protein was observed at an elution volume of 202 ml-post 
injection, but further validation of identity and correct folding was necessary. (B) Coomassie-stained 
SDS PAGE of the concentrated gel filtration peak compared with the inclusion bodies before gel 











To confirm the identity of AGP2, the monomeric protein was analysed by intact mass spectrometry and 
the resultant spectrum is shown in Figure 2.23. The expected mass of the AGP2 construct, assuming cellular 
cleavage of the N-terminal methionine, is 23626 Da, however a peak of mass 23529 Da was dominant in 
the de-convoluted spectrum. 
 
Sequence verification of the pOPINF construct revealed an R->G mutation. This mutation accounted for 
the mass discrepancy as the mutated construct would yield AGP2 protein with expected mass of 23527 Da 
which was consistent with the observed mass of 23529 Da. These data confirmed pOPINF-AGP2 as the 
expression vector of choice for further protein expression. 
Optimisation of pOPINF-AGP2 Expression 
A replicate of the pOPINF AGP2 homologous recombination insertion, confirmed by N-terminal 
sequencing to lack the R->G mutation, was chosen to express a fresh sample of AGP2. The construct was 
expressed in BL21 cells and inclusion bodies were prepared as previously. The protein from the inclusion 
bodies was refolded by rapid dilution in 1 M arginine-containing buffer, concentrated, and refolded protein 




Figure 2.23 Deconvoluted (top) and raw (bottom) spectra of concentrated monomeric protein from gel filtration 
in electrospray M/S. The main peak at 23529 Da is consistent with a mutated form of the desired construct 














By way of comparison pOPINF-AGP2 was also transformed in SHuffle® (New England Biolabs) cells. 
This strain is related to the Origami strain, but in addition to the mutations in the thioredoxin reductase 
(trxB) and glutathione reductase (gor) genes the SHuffle® strain contains a constitutively expressed 
chromosomal copy of DsbC – a disulphide bond isomerase (New England Biolabs, accessed 2019). DsbC 
is usually expressed in the bacterial periplasm, but in this strain DsbC lacks a signal sequence and so is 
retained in the cytoplasm where it can assist in refolding of incorrectly oxidised disulphides. 
SHuffle® cells were grown in rich media and AGP2 was purified by IMAC from the soluble lysis fraction 
as shown in Figure 2.25. The IMAC elution profile showed 2 distinct peaks and SDS PAGE analysis 
indicated that the second peak contained a protein of a mass consistent with that His6-AGP2 (~24 kDa). 
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Figure 2.24 (A) UV (280 nm) trace of gel filtration of refolded AGP2 showing a dominant peak consistent with 
monomeric protein. (B) Coomassie-stained SDS PAGE of the AGP2 refold and gel filtration peaks. A significant 






To verify the identity of AGP2 expressed from the pOPINF in both BL21 cells and SHuffle® cells both 
were analysed by mass spectrometry and the spectra are shown in Figure 2.26. A main peak of mass 
23626 Da was observed for each sample. This is consistent with the calculated mass (23622 Da) of the 
AGP2 construct assuming N-terminal cleavage of methionine. It was therefore concluded that the construct 
had been successfully expressed in both systems. The 4 Da mass discrepancy may be the result of the 
sample containing reduced disulphides and so further mass spectrometry data was needed to verify whether 
this is the case and the refolding conditions may need to be adjusted. 
Although the mass spectrometry data demonstrated that the major peak in each sample was consistent with 
AGP2 there was also evidence from the SDS PAGE analyses of impurities being present. 
The analysis of the AGP2 inclusion body prep and refold in Figure 2.26 showed that there were impurities 
carried through to the final sample and therefore the inclusion body prep was modified to include further 
wash steps with high salt buffer to facilitate dissociation of soluble protein loosely associated with the 
insoluble fraction. 
To further clean AGP2 produced in the shuffle cell expression, an ionic exchange purification was carried 
out and the results are shown in Figure 2.27. The purity of the AGP2 fraction was improved by the protocol, 
but it failed to remove the impurities at ~45 kDa and ~18 kDa which co-eluted with AGP2 and so this 
purification step was deemed to be sub-optimal, given that some loss of yield would be likely. As the 
insoluble AGP2 from the inclusion body preparation could be cleaned more easily by additional wash steps 
of the insoluble material the refolding protocol was taken forward for isotope labelling. 
 
Figure 2.25 (A) UV (280 nm) trace of IMAC purification of AGP2 from the soluble lysate. (B) Coomassie-
stained SDS PAGE of the SHuffle® cell lysis fractions and IMAC fractions. A band consistent with His6-AGP2 
is observed in fraction E12 










Figure 2.26 (A) Deconvoluted (top) and raw (bottom) electrospray M/S spectra of AGP2 expressed in Shuffle 
cells with an additional peak at 23723 Da (+98 Da), which is consistent with a sulphate/phosphate adduct (B) 
Deconvoluted (top) and raw (bottom) electrospray M/S spectra of AGP2 expressed in BL21 cells. In both cases 
the major peak was observed at 23626 Da which is close to the calculated mass of 23622 Da. Further, a peak at 
~+40 Da was observed which could correspond to a K+ adduct. Other peaks were observed at >24000 Da, and 
were most likely impurities requiring more stringent purification to remove.  
Figure 2.27 (A) UV (280 nm) trace (blue) of NaCl anionic exchange purification with an NaCl elution gradient 
(green) of AGP2 expressed in shuffle cells. (B) Coomassie-stained SDS PAGE analysis of the ionic exchange 
purification. The protocol was successful in removing some impurities, but significant impurities co-eluted with 
AGP2. 
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Expression and Optimisation of Isotopically labelled AGP2 for NMR Studies Using the 
Refolding Strategy 
AGP2 was expressed in BL21 cells grown 
in rich media and subsequently exchanged 
into minimal media with 15NH4Cl as its 
nitrogen source. Inclusion bodies of 
AGP2 were purified with a more stringent 
washing protocol compared with the 
initial rich media test growths in efforts to 
remove soluble impurities; the results are 
shown in Figure 2.28. 
A dominant band at around 23 kDa was 
again observable by SDS PAGE. The 
inclusion bodies were solubilised in 8 M 
urea solution and rapidly refolded in 1 M 
buffered arginine as previously. Folded 
AGP2 was separated from misfolded 
protein and impurities by gel filtration and 
analysed by SDS PAGE and the results 

























Figure 2.28 Coomassie-stained SDS PAGE of AGP2 
inclusion body preparation. The indicated band runs at 
around 23 kDa as expected and the additional wash steps 
successfully removed some soluble impurities.  
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Figure 2.29 (A) UV (280 nm) trace of AGP2 purification from rapid dilution refold. The main peak at around 
204 ml post-injection was consistent with folded AGP2 (B) Coomassie-stained SDS PAGE analysis of rapid 
dilution refold gel filtration purification. The main peak from the gel filtration (centred on I11) was significantly 





The purified AGP2 from the gel 
filtration was concentrated and 
exchanged into 10 mM 
Na2HPO4/NaH2PO4 buffer at 
pH 7.4. A 15-N-1H heteronuclear 
single quantum coherence 
(HSQC) transverse relaxation-
optimised spectroscopy 
(TROSY) dataset was collected 
on a 16.4 T (700 MHz 1H observe 
frequency) NMR instrument 
equipped with a 1.7 mm 
cryogenically cooled TCI probe 
and the resulting spectrum is 
shown in Figure 2.30. The 
dispersion of the H-N peaks is 
indicative of folding, though 
further evidence from better-
resolved spectra and CD 
spectroscopy came later. This 
spectrum and all subsequent NMR spectra were collected by Dr Chris Williams (University of Bristol), 
whom this author wishes to acknowledge and thank. 195 peaks were expected based on the construct 
sequence, but only 119 could be confidently identified. This could result from exchange broadening 
indicative of conformational flexibility in certain regions of the protein or possibly aggregation. Low 
intensity signals were not included in the peak count, as at this stage it was not possible to rule out that 
these might correspond to incorrectly folded protein.  
 In efforts to further improve the NMR a fresh sample was prepared for which spectra were to be generated 
with an excess of AMT, which is a known binder with a KD of 300 nM (Hervé et al, 1998), in an attempt to 
rigidify the protein, reduce exchange broadening and thereby improve signal resolution. The UV trace of 
the gel filtration is shown in Figure 2.31. 
 
15N Chemical Shift/ppm   
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Figure 2.30 1H-15N TROSY-HSQC solution spectrum of 130 μM apo-
AGP2 at pH 7.4 in 10 mM Na2HPO4/NaH2PO4 buffer. Significant peak 
dispersion was observed consistent with the present of folding protein. 119 
significant peaks were counted; this count is substantially lower than the 
expected 195 peaks expected for this construct and so it was concluded 






The refold yielded a peak consistent with monomeric AGP2 at around 195 ml post-injection which was 
concentrated as required and exchanged into 10 mM Na2HPO4/NaH2PO4 buffer for NMR. A TROSY 
HSQC spectrum was recorded of AGP2 at 300 µM with 3 mM amitriptyline and it is shown in Figure 2.32. 
The sample yielded a spectrum with 127 signals 
that could be counted with confidence 
indicating that AMT gave some improvement in 
spectral quality. It was therefore hypothesised 
that AMT caused AGP2 to become more rigid 
and conformationally homogeneous resulting in 
a signal count closer to that which was expected 
(195). Nonetheless only 65% of the expected 
peak count could be picked with confidence. It 
was therefore necessary to carry out further 
optimisation and gather titration data to validate 





 Figure 2.31 UV-trace (280 nm) of AGP2 gel filtration of rapid dilution refold. As previously a significant peak was 
observed consistent with monomeric AGP2. This run was carried out in a different column to previous 
preparations and so a peak consistent with monomeric AGP2 was observed at ~195 ml post-injection. 
 
15N Chemical Shift/ppm  
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Figure 2.32 1H-15N TROSY-HSQC solution spectrum of 
AGP2 at pH 7.4 in 10 mM Na2HPO4/NaH2PO4 buffer with a 
3 mM AMT and 300 µM AGP2. 127 signals were picked with 
confidence indicating that AGP2 was more conformationally 




Protein-observed Ligand Binding NMR Experiments at pH 6.0 
Fresh AGP2 was purified 
from a buffered arginine 
rapid dilution refolding 
protocol as previously and 
the UV trace of the gel 
filtration is shown in Figure 
2.33. In efforts to improve 
the spectra the NMR buffer 
pH was changed from 7.4 
to 6.0, to reduce signal 
broadening due to H+ - NH 
exchange. AMT was 
included in the NMR 
samples at ligand:protein molar ratios of 0:1, 1:1, 2:1 and 10:1 in order to confidently identify and track 
peak shifts. The TROSY HSQC spectrum of AGP2 with a 10-fold excess of amitriptyline is shown in 
Figure 2.34. Although less protein was used per sample than in previous spectra, resulting in fewer signals 
above the noise that could be confidently picked as AGP2 peaks, the relative spectral quality was improved 
by the addition of AMT with an additional 10% more signals being resolved than the spectrum of the apo 
protein at a constant concentration. Several signals appeared sharper and exhibited altered chemical shifts. 
Overlays of the AMT titration from apo to 1:1, 1:2 and 1:10 ratios of AGP2:AMT are shown in Figure 2.35. 
It was hoped that when the backbone chemical shifts have been fully assigned for the protein it would be 
possible to map the binding site onto the crystal structure based on minimal shift analysis and potentially 






Figure 2.33 UV-trace (280 nm) of AGP2 purification gel filtered directly into 






Figure 2.34 1H-15N TROSY HSQC spectrum of AGP2 (~200 μM) with a 10-fold molar excess of AMT collected 
at 700 MHz. At a constant protein concentration these conditions resulted in 99 significant peaks compared to 90 
peaks for AGP2 in the absence of ligand. 
 
Figure 2.35 1H-15N TROSY HSQC spectra panels of AGP2 with a ten-fold excess of amitriptyline (green), a two-
fold excess of amitriptyline (navy blue), a one-to-one ratio of amitriptyline (red) or without any ligand (cyan) 
collected at 700 MHz. Several changes in chemical shift between these spectra caused by the addition of the ligand 
AMT are visible. The reasonable spectral dispersion and combined with CSPs indicated that correctly folded 
protein with binding activity had been generated.  
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To enable backbone chemical shift assignment a double labelled sample of AGP2 was expressed in BL21 
grown in minimal media with 15NH4Cl and 13C-labelled glucose as sole nitrogen and carbon sources 
respectively. Double labelled AGP2 was purified by the same protocol as previously. To reduce spectral 
complexity the N-terminal His6 tag was cleaved with 3C protease (Generon) and untagged AGP2 was 
purified by a negative IMAC. The NMR sample was prepared at 0.5 mM AGP2 with a 5-fold excess of 
amitriptyline in phosphate buffer at pH 6.0. HNCA, HNCACB, HNCOCA and HNCOCACB data sets 
were collected and examples of the results are shown in Figure 2.36(A). HNCA experiments couple the 
amide proton with the alpha carbons of the same residue and that of the residue one position earlier in the 
sequence. HNCOCA experiments couple the amide protons to the alpha carbons of only the preceding 
residue. A combination of HNCA with HNCOCA experiments enable the sequential chemical shift 
assignment of the backbone Cα carbons corresponding to these signals. HNCACB and HNCOCACB 
experiments provide the same data as HNCA and HNCOCA experiments respectively, and in addition 
generate negative signals corresponding to beta carbons that may also be assigned by the same method. A 
representative set of assignment strips is shown in Figure 2.36(B). 
As the His6 tag had been cleaved only 179 signals were expected in the spectrum shown in Figure 2.36(A) 
and 134 were picked with confidence in the HSQC. With 75% of the expected peaks picked, this spectrum 























Figure 2.36 (A) 15N-1H TROSY HSQC spectrum of 0.5 mM AGP2 with a five-fold excess of amitriptyline; 134 
peaks could be picked confidently. (B) Four assignment panels showing HNCA(sky blue), HNCOCA(maroon), 
HNCACB(navy, orange negative), HNCOCACB (red, cyan negative). Two of the four residues could be assigned 




These initial datasets allowed approximately 10% of the residues to be assigned with confidence. Typically, 
these were polar residues in loop regions of the protein in the crystal structure [PDB: 3APV]. The signal 
intensity, particularly of β-carbons, was much weaker in spectral regions corresponding to the sequence 
that forms secondary structure in the crystal structure. Figure 2.36 (B) shows an example of declining signal 
both of β-carbon signals and some α-signal, in this case in the HNCOCA. The lack of β-carbon signals 
combined with the presence of many overlapping α-carbon peaks with similar shifts made further confident 
assignments impossible. Therefore, it became necessary to carry out further optimisation of the NMR 
conditions to deliver a data set of sufficient quality to allow complete assignment. As the samples at pH 6.0 
had not yielded spectra of sufficient quality further optimisation was performed at pH 7.4. 
NMR Optimisation 
Although AGP2 has only been crystallised with the weaker affinity ligands amitriptyline, disopyramide, and 
chlorpromazine (Nishi et al, 2011), that have KD’s of 0.3 µM, 0.4 µM and 1 µM respectively (Hervé et al, 
1998), AGP2 is also known to bind the staurosporine class of ligands more tightly. Staurosporine itself is a 
natural product from Streptomyces that was discovered over 4 decades ago (Furusaki, Hashiba and 
Matsumoto, 1978). Staurosporine and its derivative UCN-01 have KD’s to AGP2 of 88 nM and 3.5 nM 
respectively (Katsuki et al, 2004). It was hypothesised that a ligand that bound AGP2 more strongly than 
amitriptyline would further reduce the exchange broadening of signals by rigidifying the protein and yield 
better spectra. 15N-labelled AGP2 was expressed and purified by gel filtration as previously and the resultant 
UV trace is shown in Figure 2.37. Monomeric AGP2 eluted at around 190 ml post-injection, though in 
contrast to previous purifications significant UV signal was present between the void and monomeric 
AGP2 elutions suggesting that some improperly folded protein had been produced in this preparation.  
Nonetheless, the peak corresponding to monomeric AGP2 was exchanged into 10 mM 
Na2HPO4/NaH2PO4 buffer at pH 7.4 and HSQC data sets in the presence and absence of an excess of 
staurosporine and the spectra are shown in Figure 
2.38. 123 peaks, out of the expected 195, were 
counted. An AGP2 sample from the same prep 
run without staurosporine resulted in an HSQC 
spectrum with only 65 significant peaks. Whilst 
this result demonstrated that staurosporine had a 
significant effect on the structure of AGP2 in 
solution each peak count was likely compromised 
by the poorer quality of the protein preparation 
indicated by Figure 2.37. Therefore, it was 
hypothesised that a fresh sample from a superior 
prep observed with a staurosporine compound 
would yield good data. 
 
Figure 2.37 UV (280 nm) trace of gel filtration of 
AGP2 refolded in arginine, significant signal was 
detected between the void volume at around 120 ml and 
the AGP2 peak at around 190 ml, this may indicate 






As described above the compound UCN-01 is a hydroxylated analogue of staurosporine and has a higher 
affinity for AGP2. Given the superior spectral quality of AGP2 in the presence of staurosporine relative to 
the apo sample of protein from the same preparation, it was hypothesised that UCN-01 as a stronger binder 
of AGP2 would produce further spectral improvements by forming more rigidifying protein-ligand 
interactions and so further reduce peak broadening that most likely stems from conformational exchange. 
Fresh 15N-labelled AGP2 was expressed and purified as previously and the N-terminal His6 tag was cleaved 
by in-house 3C protease. AGP2 was purified by negative IMAC and exchanged into 10 mM 
Na2HPO4/NaH2PO4 buffer at pH 7.4. A TROSY HSQC spectrum was acquired of the AGP2 sample with 
 
Figure 2.38 Overlay of 1H-15N HSQC spectra of AGP2 (180 µM) with 250 µM Staurosporine (orange) and with an 
equivalent DMSO concentration without any ligand (blue). 123 significant peaks are present suggesting that 
staurosporine stabilised a more structurally homogeneous conformation of AGP2 than was present in the spectrum 
of apo protein that only had 65 peaks. Several peak shifts on the addition of staurosporine are visible, but most peaks 
in the staurosporine-bound spectrum are not present in the apo spectrum suggesting that the corresponding parts of 




a 2-fold excess of UCN-01 and the resulting spectrum is shown in Figure 2.39. The spectrum was well-



























Figure 2.39 1H-15N TROSY-HSQC of AGP2 (0.5 mM) with 2-fold excess of UCN-01. 165 significant peaks 
were present out of a total 179 expected peaks collected at 700 MHz. Signals were well-dispersed strongly 




Purification of AGP2-trunc for NMR Studies 
To increase the likelihood of producing a complete set of assignments a modified pOPINF construct was 
produced by SDM removing ten C-terminal residues (AGP2-trunc). This sequence forms an alpha helix 
away from the binding pocket (Nishi et al, 2011), and so, although we had not confirmed this by a 
biochemical assay at this stage, it was reasonable to believe that its removal would not disrupt the binding 
activity of AGP2. The integrity of the construct was verified by sequencing and pure refolded protein was 
prepared from inclusion bodies by the same method as the full construct (Figure 2.40).  
The sample corresponding to the main SEC peak was cleaved by 
3C protease using the conditions for full-length AGP and analysed 
by SDS PAGE as shown in Figure 2.41. The hexa-his tag and 3C-
protease were removed by negative IMAC to yield the final 
sample. 
To verify the identity and oxidation state of the protein from the 
AGP-trunc refold ESI-MS was carried out on samples prepared 
for NMR as shown in Figure 2.42. The analysis yielded signals 
consistent with the cleaved construct. Further, acetylation ESI-
MS experiments were carried to demonstrate that the AGP2 thiol 
groups formed disulphide bonds. These experiments were carried 
out by comparing MS spectra of AGP2 exposed to the thiol 
capping reagent iodoacetaminde (IAA) in reducing and non-
reducing conditions. In non-reducing conditions IAA would not 
react with thiol groups involved in disulphide bonding, but if those cysteine residues had not formed 
 
Figure 2.40 (A) SDS PAGE gel of inclusion body preparation of AGP2-trunc. A band between 20 kDa and 25 
kDa is consistent with the new construct. (B) SEC trace (UV Absorbance 280 nm) of refolded AGP2-trunc 
inclusion bodies yields a peak at ~215 mL post-injection, consistent with folded AGP-trunc. 
 
Figure 2.41 SDS PAGE gel of AGP2-
trunc cleavage (3C) reaction. The 
protein was cleaved and yielded a band 
(lane three) consistent with pure 





disulphide bonds a reaction would occur. A positive control in reducing conditions demonstrated that when 
the protein disulphide bonds were broken by DTT before the addition of IAA the observed mass of the 
protein would increase due to IAA capping (Figure 2.42).  
 
To characterise the stability of the truncated construct, a thermal denaturation was performed and 
monitored by circular dichroism (CD) spectroscopy. This experiment was performed with both apo AGP-
trunc2 and AGP2-trunc in the presence of UCN-01 and the results are shown in Figure 2.43. The addition 
of UCN-01 resulted in a significant stabilisation of the protein with the melting temperature shifting by 
13.7 °C  from 61.9 °C to 75.6 °C. Thermal stabilisation is often used as an indicator of binding in small 
molecule screening as enthalpic interactions between protein and ligand often result in a raised melting 
temperature of the complex relative to apo protein (Pantoliano et al, 2001). The significant conformational 
stabilisation in these data is consistent with the high affinity binding of UCN-01 to AGP2 reported in the 
literature (Katsuki et al, 2004), and provides strong evidence that the truncated AGP2 construct retains 
strong ligand binding activity. The thermal stabilisation also supports rigidification as the mechanism of 
spectral improvement seen upon the addition of UCN-01 to AGP2 NMR samples. 
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Figure 2.42 Deconvoluted (top) and raw (bottom) ESI-MS spectra of purified 15N-labelled AGP2-trunc (A) 
Untreated AGP2-trunc yielded a peak at 20762 compared to the expected mass of 20769 assuming 100% 15N 
labelling. Given that isotope labelling is imperfect this discrepancy is acceptable (B) ESI-MS of AGP2-trunc 
treated with IAA without reducing power resulted in an unchanged spectrum with a peak at 20762, indicating that 
all four thiol groups were oxidised and in disulphide bonds. (C) Spectrum of AGP2-trunc reduced with DTT 
acted as a positive control with a mass increase of 231 to a total of 20922 Da corresponding to the addition of 
four 58 Da acetamide groups. The raw spectrum also showed a change to a more charged mass envelope due to 
the presence of additional ionisable amide groups from the assay and likely also from greater exposure of ionisable 






NMR optimisation of the AGP2-trunc Construct 
A fresh 15N-labelled sample of AGP2-trunc was prepared by the same method as for unlabelled material 
and a 1H-15N HSQC spectrum of isotopically labelled cleaved AGP2-trunc was recorded (Figure 2.44(A)). 
The sample was prepared at a 1 mM protein concentration with a 2-fold excess of UCN-01 and gave 
excellent peak dispersion and homogeneity. A sample of 15N-labelled full-length AGP2 was prepared as a 
comparison at the same concentration (Figure 2.44(B)). Amongst the peaks in common between the spectra 
no significant changes were present in the AGP2-trunc spectrum and so it was decided to proceed with the 
truncated construct to simplify assignments. 
To improve the spectra further, optimisations were carried out by varying pH. The amitriptyline-bound 
spectra referred to previously were acquired at pH 6.0, whilst the initial UCN-01 spectra were acquired at 
pH 7.4. Lower pH samples have the advantage of reducing the exchange of backbone amide hydrogen 
yielding sharper peaks, but a pH closer to 7.4 may be more likely to yield a more natively structured protein 
as this is the pH of serum. Therefore, pHs of 6.5 and 7.0 were screened by preparing fresh samples of 15N-
labelled AGP2-trunc. These pHs were chosen partly to remain above the theoretical pI of 5.46. 
A      B 
  
Figure 2.43 (A) CD melt curve of apo AGP2 (B) CD melt curve of AGP2 in the presence of the high-affinity 
binder UCN-01. There was a substantial increase in the melting temperature of the protein by 13.7°C  from 61.9°C 
to 75.6°C indicating that the ligand had a strong stabilising effect on the secondary structure of AGP2. 
Wavelengths between 185 and 250 nM were observed, and a global fitting algorithm (Global 3 v1.6.0.0 (Applied 
Photophysics)) was used to determine the overall fit. Each curve is based on one run. This author wishes to thank 





Figure 2.45 shows test HSQC spectra of AGP2-trunc at pH 7.0 (A) and pH 6.5 (B). This test demonstrated 
that superior spectra may be generated at pH 6.5 as 169 peaks could be counted out of an expected 169 
compared to 164 out of 169 at pH 7.0. Therefore, triple resonance spectra were recorded using the 
optimised conditions (10 mM NaH2PO4/Na2HPO4, 100 mM NaCl, pH 6.5) 
 
A      B 
 
Fig 2.44 (A) 1H-15N TROSY-HSQC spectrum of 1 mM AGP2-trunc with a 2-fold excess of UCN-01 at pH 7.4 
collected at 700 MHz. The peaks are well dispersed and 164 out of the expected 169 peaks were counted. (B) 
TROSY-HSQC collected at 700 MHz of comparative sample of full length AGP2 reveals few significant 
differences. 
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Figure 2.45 (A) 1H-15N TROSY-HSQC spectrum of 300 µM AGP2-trunc with a 3-fold excess of UCN-01 at pH 
7.0 collected at 700 MHz. 164 out of an expected 169 peaks could be counted. (B) 15N-1H TROSY-HSQC 
spectrum of 300 µM AGP2-trunc with a 3-fold excess of UCN-01 at pH 6.5 collected at 700 MHz. 169 out of an 





Full Backbone Assignments of AGP2-trunc 
To obtain full backbone assignments of the new protein construct additional HNCA, HNCACB, 
HNCOCA and CBCACONH spectra were recorded at 700 MHz with UCN-01 at pH 6.5. Figure 2.46 
shows the same putatively consecutive strips of signals that were partially assigned in previous amitriptyline-
bound spectra. The new conditions allowed additional Cα signals to be identified and assigned with 
confidence whilst the CBCACONH gave greater assurance to the assignments of consecutive residues. As 
this sample is at the same concentration and similar pH to that used previously with AMT bound, the 
increased ease of assignment is most likely due to the higher affinity of the ligand and decrease in spectral 
complexity from the truncated construct. Several regions of AGP2 contain repetitive hydrophobic 
sequences (most notably: Phe48-Phe49-Tyr50-Phe51 and Leu101-Leu102-Phe103-Leu104) of residues 
exhibiting very Cα/Cβ similar shifts. Consecutive pairs of identical residues with similar shifts were also 
present at many loci, further complicating assignment (e.g. Glu35-Glu36, Ser76-Ser77, Gly93-Gly94). In 
other stretches of sequence, the Cα and Cβ signals were challenging to assign due to a lack of signal. In 
addition to the Asn54-Glu57 region, Ile13-Leu18 and Lys120-Tyr127 could not be assigned immediately 
due to poor signal-to-noise in those stretches. The former of these regions was further complicated by 
Pro12. The issues with signal strength generally occurred around the transitions between secondary 
structure elements and loops. Ile13, Asn54 and Lys120 all occur around these transitions. The reason for 
the poor signal to noise ratio could be broadening from additional motion of the less rigid loops outside of 
secondary structure elements. These complexities could not be resolved with existing data and therefore 
further spectra were collected at 950 MHz (this author wishes to thank Christina Redfield (Oxford 
University, Biochemistry) who operated the instrument). In particular a CBCANH spectrum at the higher 
field was able to detect all the remaining Cβ signals and allowed a complete set of unambiguous backbone 
assignments to be obtained when used in conjunction with previously collected 700 MHz data. The 
CBCANH experiment yields positive peaks for Cα spins with the exception of glycine, which are negative 
along with all the Cβ peaks. The negative glycine peaks were particularly helpful to finally assign the 
Gly93/Gly94 loop, and other elements between two stretches of secondary structure.  Figure 2.47 shows 
how the improved sensitivity and dispersion of the higher field instrument revealed the Cβ peaks, that had 
previously not been visible above the noise, and so allowed the determination of a complete set of backbone 
assignments. In the 950 MHz data the newly observed Cβ peaks were weak relative to other 950 MHz Cβ 
peaks, but nonetheless strong enough to be used in unambiguous assignments. Assignments were further 
facilitated by a 3D 1H-15N HSQC-NOESY data set. The geometric disposition of residues in β-sheets in 
particular results in strong Hα NOE signals detectable from 1H-15N HSQC cross-peaks of succeeding 
residues. The extensive β-barrel comprising much of AGP2’s structure facilitated the identification of many 
residues based on these NOE peaks. 91 out of 172 Hα atoms were assigned particularly along the β-barrel, 
in regions such as Asp58-Gln66. The strong NOE signals between amide protons and i-1 Hα protons due 
to β-sheet geometry made these spins easy to identify and use as validation for backbone assignments where 






Figure 2.47 HNCA(sky blue), HNCOCA (maroon), HNCACB  (navy, orange negative) CBCACONH (red), 
CBCANH(pink, green negative) spectra of AGP2-trunc in complex with UCN-01. The CBCACNH collected at 
950 MHz yielded a drastic improvement in Cβ signal and allowing a complete set of backbone assignments to be 
determined.  
Figure 2.46 HNCA(sky blue), HNCOCA (maroon), HNCACB  (navy, orange negative) CBCACOHNH (red) 
spectra of AGP2-trunc in complex with UCN-01 at 700 MHz. Cα signals were maintained along further stretches 
of the backbone than in the amitriptyline bound samples. Additionally, more i-1 Cβ signals allowing the identities 
of connecting residues to be established with greater confidence. However, many Cβ signals were absent in the 





During assignment 38 residues, often in 
contiguous series, could be assigned to two 
separate but close chemical shifts. Met111 was 
one such example and is shown in Figure 2.48. 
The largest series of doubled peaks were residues 
Gln1-Leu8, Ser77-Gln82 and Ser89-Arg95. 
Gln1-Leu8 is in the randomly coiled N-terminal 
region, Ser77-Gln82 is in β-strand D and Ser89-
Arg95 is in the E-F β-hairpin. There is therefore 
no discernible connection between secondary 
structure and doubling. This effect was observed 
at 600 MHz, 700 MHz and 950 MHz and at pH 
6.5-7.4 in some, but not all spectra (For example 
Figure 2.49 shows a spectrum of AGP2 with 
UCN-01 that does not contain doubling). The 
cause of this doubling effect could not be 
identified and so in each case the major peak was 
assigned.  
98% complete backbone assignments of non-proline residues were obtained and are shown in Figure 2.49. 
A full assignment list is reported in the appendix a.1. The assigned HSQC spectrum is, as discussed in the 
introduction, a valuable tool in applying NMR to drug discovery. This HSQC spectrum with assignments 
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Figure 2.49 1H-15N TROSY-HSQC spectrum of AGP2 bound to UCN-01 at pH 6.5 with complete backbone 
assignments. Several peaks are only resolved at lower fields or display multiple peaks at higher field indicating that 
transitions between slow and medium exchange may occur at these field strengths (A) Complete spectrum with 
peripheral assignments (B) expanded central part of the spectrum with assignments. 
 
Figure 2.48 2 Sets of peaks in the HSQC (pink), HNCA 
(sky blue) and HNCOCA (brown) may be assigned to 





may now be used to characterise and compare ligand binding to AGP2 without the need for less consistent 
crystallography approaches that may fail for certain fragments or small molecules. 
UCN-01 Titration 
To further understand the effect of UCN-01 binding to AGP2, a titration experiment was carried out and 
the results are shown in Figure 2.50. TROSY-HSQC spectra of a sample of AGP2-trunc were collected at 
UCN-01 to protein ratios of 0:1, 1:1, 2:1 and 4:1. These data showed that UCN-01 induced a homogeneous 
bound conformation with very little change in the HSQC data above a stoichiometry of 1:1, as expected 
for a ligand with a KD on the order of 10-8 M. Therefore, an overlay of the spectra with a 2:1 ratio of UCN-
01 to protein and no ligand are shown in Figure 2.50. The data also revealed that the change between the 
ligand bound and apo form of AGP2 must be extensive as only a portion of the peaks were at a similar or 
identical chemical shift in each spectrum. The changes were sufficiently extensive to prevent 
straightforward transfer of backbone chemical shift assignments to the apo form from the bound form. 
 
Figure 2.50 1H-15N TROSY-HSQC AGP2-trunc collected at 700 MHz without ligand (red) and with a two-fold 
excess of UCN-01. The extensive shifts of backbone peaks and appearance of other from the noise indicate that 
a radical structural rearrangement occurs upon UCN-01 binding. Spectral changes were minimal upon increasing 
the UCN-01:AGP2 ratio above 1:1 indicating that the protein saturated with only a minimal excess of ligand as 
expected for a 10-8  M binder. Further, the spectral changes that occurred upon ligand binding were drastic, 




Numerous signals that were resolved in the ligand bound spectrum were missing in the apo-AGP2-trunc 
spectrum. Resonances in the apo spectrum were also generally broader, indicating that the structure as a 
whole was less conformationally homogeneous compared to UCN-01-bound protein. These data are 
consistent with past crystallography results as no truly apo form of AGP has so far been crystallised. AGP 
either crystallises as protein-ligand complexes with small drug molecules drugs of interest or, if none are 
present, crystallisation buffer components, such as polyethylene glycol, occupy the binding pocket 
suggesting that rigidification is critical for crystallisation. 
To map the most affected parts of the protein the apo and 2:1 UCN-01:AGP2 HSQC data were compared 
in a reverse minimal chemical shift approach. This approach was necessitated by the lack of backbone 
assignments for the lower quality apo spectra where many resonances were either missing, very weak or 
overlapped due to conformational flexibility. Using the fully assigned ligand bound spectrum the nearest 
signal in the apo spectrum was assumed to be its pair provided the peaks were within 0.1 ppm 1H and 0.68 
ppm 15N (weighting described in materials and methods). The effect of this method is to quantise CSPs 
into “more significant” or “less significant” categories. It should be noted that this method may yield some 
errors due to peaks in the apo spectrum by chance being closer to peaks in the UCN-01 bound spectrum 
that do not correspond to the same residues. Figure 2.51 shows a structure of AGP2 with residues that 
shift most significantly in the apo spectrum compared to the liganded spectrum highlighted in blue. 
Residues that are identifiable across the titration are shown in red. Significant shifts between the two forms 
are not confined to residues that are known to be important for ligand binding (such as Phe112), but also 
to residues that are distal to the binding site (such as Leu101), which is again indicative of extensive 
structural rearrangement.  
A striking feature of this shift map is the occurrence of strongly shifted residues along adjacent portions of 
β-sheet around the ligand binding barrel. The H-N pairs that are observed in the HSQC experiment also 
form the main H-bonding network that holds adjacent antiparallel β-strands together. These data therefore 
suggest that some deformation of the β-barrel architecture may occur in the apo form of AGP2 such that 
that the strands with the greatest proportions of shifted residues open to allow ligand entry into the binding 
site. Where possible, shift distances were plotted against residue number to give a quantitative measure of 
the difference (Figure 2.51 C). 
To validate these hypotheses would require unambiguous backbone assignments and NOE data for the 
apo form of AGP2. As noted, the shift map may be imperfect since some apo peaks may be mistakenly 
assigned to specific residues if they happen to move close to a peak from the liganded spectrum by chance. 
A full set of backbone assignments for the apo protein would also allow a quantitative analysis of peak 
shifts to be undertaken with confidence. The experiment could then be extended to understand the binding 















Figure 2.51 Colour map of AGP2 apo->UCN-01 bound titration data. Residues that are identifiable across spectra 
are coloured red, unidentifiable residues are coloured blue, proline residues are coloured black and peaks that are 
not visible at 700 MHz or are heavily overlapped are coloured pink. (A) The peaks of the β-barrel, particularly the 
87-101 β-hairpin, were significantly shifted in the apo spectrum relative to the liganded spectrum indicating that 
significant conformational changes occur in these parts of the protein. (B) The helices arranged around the β-
barrel do not exhibit many shifted peaks between the apo and liganded spectra indicating that they do not undergo 
significant structural changes during ligand binding. (C) To produce a quantitative map of chemical shifts, the 
distances between peaks assigned in the apo spectrum from those in the holo spectrum were plotted. When peaks 
could not be found in the apo spectrum a value of 0 was used. This chart also shows many of the largest shifts 





To further characterise the UCN-01-AGP2 complex experiments were carried out at 700 MHz to derive 
the T1 and T2 relaxation times and NOE contributions to ligand signals. The AGP2 concentration was 
750 μM with a three-fold excess of UCN-01. Each of these measures is linked to the motion of the protein. 
The best and worst exponential fits for the calculation of T1 and T2 time constants are displayed in Figure 
2.52, demonstrating that the experiments produced robust decay series for all residues. 
The calculated T1, T2 and NOE ratio parameters for each residue are displayed in Figure 2.53. The full 
relaxation parameter lists are displayed in appendices a.2-a.4. The termini have higher relaxation times and 
negative NOE ratios indicating independent mobility. The central residues of the protein have relatively 
uniform dynamics parameters with the exceptions of Asn34 and Leu104 that have elevated T2 parameters, 
potentially indicating some independent motion, but given the limited extend of these T2 deviations, further 
validation would be necessary. 
To calculate valid order parameters for AGP2 further data sets at other field strengths are required, but the 
relaxation data displayed here indicate that AGP2-trunc-UCN-01 adopts a uniformly rigid conformation 
along the entire chain with the exception of the termini, which are more mobile. It is likely that greater 
variation would be observed across the sequence of the apo protein if the difficulty in observing and 
assigning all of its peaks could be overcome. 
Though the relaxation parameters across the main body of the protein are relatively uniform there is a small 
amount of variation. Asn34 and Leu104, are have elevated T2 values at 118.6 ms and 83.4 ms respectively. 
These residues both occur close to secondary structure transitions between β-sheets and coiled residues, 
potentially implying additional motions due to conformational plasticity of the sheet structure. The termini 




UCN-01 complex is relatively rigid with only the termini able to be more flexible. Peaks that were 





Figure 2.52 Exponential fits with the lowest and highest standard deviation values of all the assigned peaks for 
both T1 and T2 calculations.  With all fits in between these extremes in their standard deviations these fits 










Figure 2.53 Dynamics data at 700 MHz T1 relaxation times for each backbone 15N spin by residue number, T2 
relaxation times for each backbone 15N spin by residue number, T1/T2 ratio, and NOE signal ratios for each 
backbone 15N spin by residue number. The secondary structure derived from the crystal structure (see below) is 
displayed above each chart. In each case the parameters are relatively uniform across the primary structure of the 
protein with parameters at the termini indicative of faster motion relative to the rest of the protein in those regions 




Figure 2.54 shows the structure of AGP2 (hot pink) with residues with low NOE and/or T1/T2 ratios highlighted 
(blue). As noted, the N and C termini of the protein show the most evidence of independent mobility, with NOE 
ratios turning negative and T1 and T2 values becoming more alike. In addition, residues 94-95 and residues 132-133 
also display NOE values below 0.7 and relatively low (<15) T1/T2 ratios. These residues occur between elements of 
secondary structure, with 94-95 between β-strands E and F, and 132-133 occurring immediately before helix #3. 
Combined with the drastic chemical shift changes that occur for signals corresponding to residues from the β-barrel, 
these data may indicate that, in the UCN-01-bound form, AGP2 is rigid around the ligand with some mobility in the 









Figure 2.54 Structure of AGP2 (pink) with residues that the data indicate are independently mobile highlighted 
(blue). Residues that may be more mobile occur around the more rigid secondary structure elements involved in 




Crystal structure of AGP2-trunc bound to UCN-01 
To further investigate the binding of UCN-01 to AGP2 co-crystallisation screens of AGP2 with UCN-01 
were prepared. These yielded conditions suitable for crystal generation from which X-ray data, diffracting 
at 1.82 Å was collected and the structure, which is shown in Figure 2.55, was solved by molecular 
replacement compared to AGP2 bound to PEG [PDB: 3APU]. The generation of the crystal structure was 
a joint effort with Sara Ryan (purified protein), Nahida Akter (set up crystal trays), Alice Bochel (handled 
and shot crystals), Chris Williams (solved structure), and this author (optimised construct, grew cells, 
prepared inclusion bodies, coordinated efforts) (all from the University of Bristol).  
The structural architecture of the protein is highly analogous to past structures of AGP and lipocalins in 
general (di Masi et al, 2016) with the same archetypal eight-stranded antiparallel β-barrel structure, labelled 
A-H in Figure 2.55. This β-barrel forms the main ligand binding pocket from its inward-oriented side 
chains. Three helices, labelled #1-#3(numbering from N-terminus) in Figure 2.55, are present in the 
structure. Helix #1 occurs before the β-barrel, helix #2 occurs between β-strands A and B and helix #3 
occurs after strand H. The previous structure of AGP2 exhibits another helix closer to the C-terminus after 
 
Figure 2.55 Crystal structure of UCN-01 (orange) in complex with AGP2 in its entirety from two faces (top) and 
viewed from two sides of the binding pocket (bottom). The β-sheets are labelled A-H as in published work (Nishi 
et al, 2011) and form a barrel consisting of antiparallel sheets. The pocket consists of aromatic side chains such as 
Phe49, a hydrogen bonding interaction from Glu64 and potential cation-π interaction from Arg90. For full table 




the β-barrel (Nishi, et al, 2011), but the truncated construct presented here does not have this feature. The 
UCN-01 binding pocket consists of hydrophobic interactions with Phe49, Phe51, and Phe112 as with past 
structures with other ligands (Nishi et al, 
2011). In addition, Glu64 forms a 
hydrogen bond to the 7(R) hydroxy group 
of UCN-01 and Arg90 may form a cation-
π bond to main plane of the aromatic ring.  
The observed secondary structure 
elements from the crystal structure were 
compared to those predicted by 
DANGLE (Cheung et al, 2012) from the 
chemical shifts of the assigned backbone 
spins at pH 6.5. The comparison is shown 
in Figure 2.56 and the DANGLE 
predictions are listed in appendix a.5.  
The secondary structure calculated for 
AGP2 based on backbone chemical shifts was broadly homologous to that of the crystal structure. One 
deviation was that the helical secondary structure around residue 9 was predicted by DANGLE, but is not 
observed in our crystal structure. By contrast past structures do exhibit helicity at these residues (Nishi et 
al, 2011).  
Given the limited extent of these predicted secondary structure elements it may not be reasonable to draw 
any conclusions from them. The secondary structure predictions from the backbone chemical shifts were 
almost identical to those observed in the crystal structure and so it is reasonable to believe that AGP2 
adopts a highly similar conformation in both the UCN-01 bound crystal and under our NMR conditions 
making the comparisons of inferences from both methods legitimate.  
Although solved at pH 7.4 the structure is highly homologous to previous AGP2 structures crystallised at 
pH 4.6 (Figure 2.57). The conformation of UCN-01 in the binding pocket is most similar to the drug CPZ. 
Both CPZ and UCN-01 are bound with aromatic ring systems in a similar plane (Figure 2.57 (A)) 
perpendicular to that of AMT and DSP (Figure 2.57 (C)+(D)). UCN-01 and CPZ are believed to bind to 
both AGP1 and AGP2 each with comparable affinity for the two AGP variants. In the literature the 
specificity of binding to one variant of AGP or the other is reported to be due to ligand interactions with 
Phe112 and Ser114 (residues for AGP2) (Nishi et al, 2011). In AGP1 Phe112 is replaced by Leu112 and it 
is possible that this more planar side chain may prevent AMT and DSP from binding in their preferred 
orientation by clashing with their ring systems. On the other hand, CPZ and UCN-01 may accommodate 
this change more easily as their aromatic systems allow more space between themselves and the backbone 
for the Leu112 side chain. Ser114 is replaced by Phe114 in AGP1 and is believed to clash with AMT and 
 
Figure 2.56 Comparison of secondary structure predicted from 
backbone chemical shifts using DANGLE (Cheung et al, 2012) 
with those observed from the crystal structure as analysed by 
STRIDE (Frishman & Argos, 1995) reveal broad similarity. The 
absence of the N-terminal helix in our crystal structure may be 
due to the effect of pH differences. Residues that were not visible 




DSP (Nishi et al, 2011). It is unclear from the structure whether this replacement is a specificity determinant. 
Mutagenesis experiments producing AGP1/2 hybrids in vitro or in silico may help differentiate which of 
these interactions are more essential.  
The interaction between Arg90 and the UCN-01 aromatic system is of interest as π-stacking interactions 
are observed more frequently in published structures than T-shaped π-cation interactions, such as the one 
observed here (Kumar et al, 2018). It is likely that a salt bridge with the Glu64 residue influences the 
orientation of Arg90, making it more likely to adopt the observed conformation. CPZ, which otherwise 
binds in a similar fashion to UCN-01, interacts with Arg90 by a more typical stacking interaction and 
concomitantly Glu64 also changes in orientation. The π-systems of the two other ligands, for which crystal 
structures have been solved, are oriented perpendicular to those of UCN-01 and CPZ and so further 
comparisons of Arg90-π interactions are unavailable. 
In addition to providing information on the specificity of AGP binding to various ligands these data also 
rationalise the affinities of staurosporine derivatives other than UCN-01 to AGP. The staurosporine ligands 
 
Figure 2.57 (A) Comparison of the binding of UCN-01 and CPZ to AGP2. The aromatic ring systems adopt a 
similar conformation along the same plane, but UCN’s larger size may produce additional stabilising hydrophobic 
interactions and the hydroxyl group may hydrogen bond with Glu64. These features may explain UCN-01’s higher 
affinity (B) Comparison of the binding of UCN-01 and DSP binding do AGP2. The aromatic groups of DSP are 
tilted perpendicular to UCN-01’s aromatic system. This feature may explain why UCN-01 may bind to both AGP1 
and AGP2 whilst DSP is specific to AGP2 (C) Comparison of the binding of UCN-01 and AMT to AGP2. As 
with DSP the aromatic groups of AMT are perpendicular those of UCN-01. Arg90 is therefore not able to form 
a cation-π interaction with the ring system unlike in the UCN-01 structure.  (D) Comparison of Phe112 
conformations between all existing AGP2 structures. The aromatic systems of nonspecific AGP1/2 ligands UCN-
01 and CPZ allow the Phe112 sidechain to move further into the binding pocket than it can with AGP2-specific 




(structures in Figure 2.58) that have been tested for AGP binding differ in the hydroxylation state and 
stereochemistry on the pyrrole ring.  
UCN-01 itself has a hydroxyl group on the same face of its aromatic system as the basic amine group. This 
hydroxyl is within hydrogen bonding distance (2.66 Å) to Glu64 in our crystal structure (shown in the 
bottom left panel of Figure 2.55) which may result in energetically more favourable binding. Staurosporine 
instead does not possess a pyrrole hydroxylation, which may explain its weaker affinity, lacking this 
enthalpic contribution. UCN-02, which has the reverse stereochemistry at the pyrrole ring has the weakest 
affinity of the 3 for AGP (Katsuki et al, 2004) and this may be due to the unfavourable position of the 
hydroxyl group in the hydrophobic pocket formed by Phe49 and Tyr127. 
 
Potential UCN-01 Modifications to Abolish AGP2 Affinity 
The interest in studying UCN-01’s binding to AGP2 stems from the potential to redesign UCN-01 in such 
a way as to maintain its affinity for its kinase targets whilst reducing its affinity to AGP2.  
As discussed in the introduction, UCN-01’s targets include the cell cycle proteins CDK1 and Chk1 for 
which high-resolution crystal structures have been determined. These two crystal structures of UCN-01 
with CDK1 and Chk1 together with the AGP2 structure provide a structural framework for rational 
chemical modification. 
Comparison of UCN-01 Binding to Chk1 and AGP2 
Figure 2.59 shows the structure of UCN-01 bound to Chk1 compared to the binding pocket of AGP2 
aligned to UCN-01’s conformation. 
A         B         C 
 
Figure 2.58 (A) Staurosporine (B) UCN-01 (C) and UCN-02. These compounds differ by the hydroxylation on 
the pyrrole ring. UCN-01 has a higher affinity (3.5 nM) for AGP2 than its analogues staurosporine (88 nM) and 
UCN-01 (676 nM). We can rationalise UCN-01’s higher potency based on our crystal structure as being due to 




The binding mode of the ligand to these two very different proteins has remarkable similarities, but also 
some differences that could potentially be exploited. UCN-01 has greater potency as a Chk1 inhibitor than 
staurosporine (Zhao et al, 2003) due to the presence of a hydrogen bonding interaction between the pyrrole 
hydroxyl group in UCN-01 and Ser147 in much the same way that UCN-01 forms a favourable interaction 
with Glu64 in AGP2. The effect of this modification on affinity for AGP2 appears more significant than 
for Chk1 (Katsuki et al, 2004), but nonetheless the commonality makes modification less promising than 
other moieties. 
The aromatic system forming the central core of UCN-01 forms hydrophobic interactions with non-polar 
residues in the binding pocket in both structures. In Chk1 these residues are Ala36, Val23 and Leu137. 
AGP2 uses a cation-π interaction between Arg90 and the ring on its basic face, but mainly hydrophobic 
interactions on the reverse face as with the Chk1 complex. 
Given the common importance of interactions of the hydroxy-pyrrole and central aromatic system the 
other parts of UCN-01 must be investigated for modification. Whilst in AGP2, UCN-01 is surrounded by 
a β-barrel, in Chk1 it is sandwiched between two β-sheets. It may therefore be possible to introduce 
substitutions on the UCN-01 aromatic system that protrude out of the sides of Chk1’s “sandwich” into 
space but which clash sterically with the sides of AGP2’s β-barrel. The positions of such potential 
substitutions are shown in Figure 2.60. 
 
A      B 
 
Figure 2.59 (A) Structure of the UCN-01-Chk1 binding pocket [PDB: 1NVQ]. The UCN-01 hydrophobic ring 
system is “sandwiched” in between hydrophobic residues of Chk1. The hydroxy-pyrrole group of UCN-01 forms 
a 2.86 Å hydrogen bond to Ser147. (B) UCN-01 forms extensive hydrophobic contacts to AGP2 as it does with 
Chk1 and a hydrogen bond from the hydroxy-pyrrole. The cation-π interaction to the aromatic system differs 




Modifications at one of these locations could 
serve a dual purpose of improving the solubility 
of UCN-01 whilst abrogating AGP2 affinity by 
appropriate selection of modifications. 
Figure 2.61 shows the structures of some 
potential modified UCN-01 analogues. 
Introducing -NO2 as a ring substituent may 
increase the steric bulk of the compound whilst 
improving solubility. An amidine -C(NH)(NH2) 
group would serve the same function to a greater 
degree by introducing a further basic group to 
the ligand. A carboxylic acid group may also  be 
considered for increased steric bulk, but with 
the added effect of making the compound a 
zwitterion at physiological pH which may 
further assist in abrogating AGP2 binding as AGP2 preferentially binds basic drugs (Hervé et al, 1998). 
Abrogating AGP2 affinity sterically is achievable with our knowledge of the crystal structure, but 
maintenance of Chk1 affinity is less certain. Preliminary in silico docking could be used at low cost to triage 
modifications likely to be effective, but ultimately synthesis of modified UCN-01 compounds and 





Figure 2.60 The indicated R groups could be substituted 
from -H to hydrophilic groups to abrogate AGP2 binding 
sterically and improve UCN-01’s solubility.  
A    B    C 
 
Figure 2.61 Potential substitution of an amidine group (A), nitro group (B) or carboxylic acid group (C) onto 
UCN-01. Modifications (A) and (B) would likely clash sterically with the 87-100 β-hairpin of AGP2 whilst 
protruding into solution when bound to Chk1 thus potentially making UCN-01 more specific for Chk1. 




Comparison of UCN-01 Binding to CDK2 and AGP2 
UCN-01’s cell cycle progression inhibition activity is largely due to its binding to CDK2. A comparison 
between binding of UCN-01 to CDK2 (Johnson et al, 2002) and AGP2 is shown in Figure 2.62.  
 
 
Similarly, to Chk1 binding, UCN-01 occupies a site between hydrophobic residues on either face of the 
aromatic system in the CDK2 binding cleft. In contrast to the binding mode of the compound in both 
AGP2 and Chk1 there are no hydrogen bond donors or acceptors proximal to the hydroxy-pyrrole group 
of UCN-01. This fact could be exploited to produce a modified compound whose affinity for AGP2 is 
abrogated. Some potential analogues are shown in Figure 2.63. 
Given the published data on the affinities of staurosporine 7-hydroxy analogues for AGP2 (Katsuki et al, 
2004) we may believe with a degree confidence that the proposed modifications to UCN-01 would reduce 
its affinity for AGP2. Less certain is whether affinity for CDK2 would be maintained. As with Chk1, in 
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Figure 2.62 (A) Structure of CDK2 in complex with UCN-01 [PDB: 1PKD]. As with Chk1 hydrophobic residues 
on either side of the aromatic system, in this case Val18 and Leu134, form binding contacts between ligand and 
protein. Unlike both AGP2 and Chk1 there are no residues near the hydroxy-pyrrole group to form H-bonds. (B) 
Our structure of UCN-01 in complex with AGP2 for comparison. Unlike CDK2 H-bonding from Glu64 to UCN-








Presented here is a novel method of producing folded AGP2 with ligand binding activity, 98% backbone 
assignments of the protein with relaxation parameters at 700 MHz, and a crystal structure of the important 
anti-tumour compound UCN-01 bound to AGP2.  
The protein expression and purification method represents an improvement in tractability over the 
published methods for generating pure recombinant AGP2 as it allows for expression of the protein in 
BL21(DE3) cells rather than cells specialised for cytoplasmic folding of disulphide bonded proteins.  
The NMR data are noteworthy as they indicate that AGP2 may be more disordered in the apo form than 
would have been assumed based on published crystal structures. The relaxation parameters, on the other 
hand, show that the main body of the protein displays mostly uniform dynamics when binding UCN-01 in 
solution. This rigidification is corroborated by CD data showing a significant increase in melting 
temperature upon ligand binding. NMR spectral quality is also considerably improved in the presence of 
UCN-01 relative to the apo form, consistent with conformational rigidification upon ligand binding. 
The crystal structure reveals the binding mode of the highest known affinity ligand for AGP2 and 
rationalises how the stereochemistry of the staurosporine pyrrole ring impacts binding affinity. These 
findings open new avenues for redesigning UCN-01 to maintain its anti-kinase activity whilst avoiding high-
affinity plasma binding. It may be that by circumventing AGP2 binding a modified UCN-01 may be a 
fruitful lead in oncology therapeutics.  
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Figure 2.63 Modified UCN-01 to remove its hydrogen bond donor capacity by replacing the hydroxy-pyrrole 
group with a methyl group (A), ethyl group (B), or methoxy group (C). Each of these modifications removes the 
capacity of UCN-01 to hydrogen bond to Glu64 in AGP2. (B)&(C) may also clash sterically with Glu64 or the β-




Materials and Methods 
Precision Protein Marker Biorad 
1 kB DNA Ladder Bioline 
Restriction Enzymes + reagents ThermoFisher 
T4 Ligase ThermoFisher 
KOD polymerase Novagen 
GenElute Gel Extraction Kit Sigma 
BL21 Competent Cells Novagen 
SHuffle® Competent Cells New England Biolabs  
NEB5α competent Cells New England Biolabs 
In-Fusion Cloning Enzyme Takara 
DNA Constructs ThermoFisher  
Amitriptyline >99% purity Biotechne 
Staurosporine >95% purity VWR 
UCN-01 >97% purity Sigma 
3C Protease  Generon 
15NH4Cl >99% purity Goss Scientific 
13C6H12O6 >99% purity Goss Scientific 
Sequencing  Genewiz 
Crystal Screen Molecular Dimensions 
 
Constructs and Vectors:  
Initial constructs ordered from ThermoFisher Geneart were named Full and Short containing residues 1-
183 and 1-175 of the mature protein, respectively. As in published crystallography work residue C149 was 
replaced with arginine to improved sample homogeneity. The restriction sites closest to the AGP2 sequence 
were Nco1 at the 5’ and Xho1 at the 3’ resulting in vector artefacts at either end. The final sequences were 












The constructs were ordered in the pMA-T vector 
The pET28 vector introduced MG as a vector artefact at the N-terminus and LE at the C-terminus followed 
by the His6 tag 
The pET26 vector introduced the PelB signal sequence (MKYLLPTAAAGLLLLAAQPAMA) at the N-
terminus for periplasmic secretion, MG as a vector artefact at the N-terminus and LE at the C-terminus 
followed by the His6 tag 
The pETM60 vector introduced the NusA sequence at the N-terminus followed by the NusA His6 tag and 
a TEV cleavage sequence ENLYFQS/GA and an MG vector artefact. At the C-terminus the vector 
contained the LE vector artefact and His6 tag 
The pOPINF vector introduced a start codon, an N-terminal His6 tag with and a linker to a 3C protease 
cleavage site. Together this sequence reads: MAHHHHHHSSGLEVLFQGP. As InFusion cloning does 
not rely on restriction sites the MG and SLE vector artefacts present in the classically cloned constructs 
were absent. 
The AGP2-trunc construct contained a stop codon replacing Glu173, but was otherwise unchanged from 
the full length pOPINF construct.  
Classical Cloning of AGP2: 
For cloning into pET28, pET26 and pETM60 AGP2 donor and receiver vectors was incubated with 5% 
each of Xho1 and Nco1 enzyme in FastDigest buffer for 2 hours at 37 °C and the fragments were separated 
on a 0.7% agarose gel. AGP2 construct and receiver vector were purified by GenElute gel extraction kit by 
manufacturer protocol. Ligations were carried out with T4 ligase by manufacturer protocol. Cloning 
product was transformed into high copy number 5α cells (NEB) by manufacturer protocols and pure DNA 
was obtained by miniprep kit (Sigma) by manufacturer protocols. 




Primers containing the pOPINF vector In-Fusion adaptor sequences (Fwd: aagttctgtttcagggcccg, Rev: 
atggtctagaaagcttta) and 30-40 bases of the AGP2 construct (ThermoFisher) were used to amplify the AGP2 
construct by PCR using KOD polymerase (Novagen) by commercial protocols. AGP2 was inserted into 
pOPINF by In-Fusion enzyme manufacturer protocols. Cloning product was transformed into high copy 
number 5α cells (NEB) by manufacturer protocols and pure DNA was obtained by miniprep kit (Sigma) 
by manufacturer protocols. 
Expression of AGP2 in Rich Media: 
Cells transformed with the vector containing AGP2 were precultured from single colonies in LB + selection 
marker for 16h and inoculated into LB/2YT growth media + 2% glucose w/v at a 1:100 volumetric ratio. 
Protein expression was induced at an OD of 0.7-1.0 with 0.25 mM IPTG for expression of inclusion bodies 
or 0.1 mM IPTG for soluble expression and the temperature was lowered to 30°C for 16 hours. Cells were 
harvested by centrifugation (6k rpm, 10 min, 4 °C) and stored (-20°C) until use. 
Expression of AGP2 in M9 by Media Exchange: 
Cells transformed with the vector containing AGP2 were grown as above in rich media to an OD of 1.0-
2.0. Cells were removed from the media by centrifugation (4 krpm, 10 min, 4°C), resuspended in sterile 200 
ml M9 (12.9 g Na2HPO4.6H2O , 3 g KH2PO4, 0.5 g NaCl, pH 7.0), removed from the M9 wash by 
centrifugation (4 krpm, 10 min, 4°C) and resuspend in 500 ml M9 per initial litre of rich media growth. 
Cells were maintained in M9 media (30 min, 37°C) to burn 14N. Carbon and nitrogen sources were added 
(made up to 25 ml H2O per litre expression, 2.5 % glucose w/v, MgSO4 (for 1 mM final), 1:1000 of final 
trace metals(20 mM CaCl2, 2 mM CoCl2.6H2O, 2 mM CuCl2.2H2O, 60 mM H3BO3.HCl, 10 mM 
MnCl2.4H2O, 2 mM Na2MoO4.2H2O, 2 mM Na2SeO3.5H2O, 2 mM NiCl2.6H2O, 2 mM ZnSO4.7H2O), 1 g 
15NH4Cl) and induced with 0.25 mM IPTG for expression of inclusion bodies or 0.1 mM IPTG for soluble 
expression and the temperature was reduced to 30°C. Cells were incubated for 16 hours and harvested by 
centrifugation (6k rpm, 10 min, 4 °C). Cell pellets were stored (-20 °C) until use. 
Expression of AGP2 in M9: 
Cells transformed with the vector containing AGP2 were precultured from single colonies in LB + selection 
marker for 16h and inoculated directly into M9 + carbon and nitrogen sources (made up to 25 ml H2O per 
litre expression, 2.5 % glucose (13C labelled or not as required) w/v, MgSO4 (for 1 mM final), 1:1000 of 
final trace metals, 1 g 15NH4Cl). Cells were grown to OD 0.3-0.6 and induced with .25 mM IPTG for 
expression of inclusion bodies or 0.1 mM IPTG for soluble expression and the temperature was reduced 
to 30°C. Cells were incubated for 16 hours and harvested by centrifugation (6k rpm, 10 min, 4 °C). Cell 
pellets were stored (-20 °C) until use. 




Cells were lysed in 20 mM Tris, 50 mM NaCl, 0.1 % CHAPS, pH 8.0 by Sonication in ice-ethanol bath (3 
times 5:10-on:off 2 min 30 sec, amplitude 80%). The lysate was clarified by centrifugation (14.5 krpm, 15 
min, 4°C). The soluble lysate was flowed through a 5 ml Ni-NTA column and washed with 20 mM Tris, 
50 mM NaCl, 10 mM imidazole, pH 8.0. Soluble AGP2 (for all constructs) was eluted with a 10 mM – 
800 mM imidazole gradient. Imidazole was removed by a gel filtration in S75 resin into 20 mM Tris, 150 
mM NaCl, pH 8.0. 
Preparation of AGP2 Inclusion Bodies: 
Cells expressing AGP2 were resuspended in 20 mM Tris, 50 mM NaCl, 1 mM EDTA, 1 mM benzamidine, 
pH 8.0 and lysed by sonication in ethanol-ice bath (2 times 5:15-on:off 2 min 30 sec, amplitude 75%). 
Insoluble material was separated by centrifugation (8700 rpm, 30 min, 4°C). The insoluble material was 
washed by sonication in lysis buffer as previously and removed from the soluble impurities by centrifugation 
(8700 rpm, 30 min, 4°C). 2 sonication-wash cycles as above were carried out in high salt buffer 20 mM Tris, 
500 mM NaCl, 1 mM EDTA, 1 mM benzamidine, pH 8.0. The washed inclusion bodies were separated by 
centrifugation (8700 rpm, 30 min, 4°C) and dissolved in minimal 8-10 M urea, 50 mM Tris, pH 8.5 + a few 
drops conc. NaOH. Solubilised inclusion bodies frozen until further use. 
Purification of AGP2 by Inclusion Body Rapid Dilution Refold and Size Exclusion 
Chromatography: 
AGP2 inclusion bodies were reduced with 10 mM DTT (1 hour, on ice). Insoluble debris was removed by 
centrifugation (15 krpm, 10 min). Reduced unfolded AGP2 was added dropwise to 1 M arginine, 
50 mM Tris, pH 8.5, 1 mM EDTA, 1 mM benzamidine, 3.5 mM cystamine, 6.5 mM cysteamine. The refold 
was incubated for 24-72 hours at 4°C. The refolded AGP2 was concentrated in a pressure cell on a 10 kDa 
membrane as required and monomeric protein was separated by gel filtered in S75 resin into 20 mM Tris, 
150 mM NaCl, pH 8.0 and concentrated as required by spin concentrator. 
Cleavage and Negative IMAC of AGP2: 
AGP2 solution (1-2 mg/ml) in 20 mM Tris, 150 mM NaCl, pH 8.0 was incubated (16 hours, room 
temperature) with a 10:1 mass ratio to in house 3C protease (stored in 20 mM Tris, 1 mM beta-
mercaptoethanol (BME), 150 mM NaCl, 50% glycerol w/v, pH 8.0). Following incubation, the cleavage 
reaction was passed through a 5 ml Ni-NTA column equilibrated in 10 mM Na2HPO4/NaH2PO4, 100 mM 
NaCl, pH 7.4. The negatively purified AGP2 was exchanged into 10 mM Na2HPO4/NaH2PO4, 100 mM 
NaCl, pH 7.4 in a spin concentrator and concentrated as required for further experiments. 
SDS PAGE Analysis: 
Gels were made up as 10% acrylamide (separating) and 4% acrylamide (stacking) in standard tricine buffer. 





AGP2 was exchanged into 20 mM NaP, 150 mM NaF, pH 7.2 by Zeba column. CD was run on an Applied 
Photophysics Chirascan instrument and the analysis was carried out with the instrument’s inherent software 
v. 4.7.0.194.  
NMR Experiments: 
All 700 MHz and 600 MHZ double resonance experiments (HSQC, and TROSY HSQC) and triple 
resonance experiments (HNCA, HNCACB, HNCOCA, HNCOCACB) were collected by Chris Williams 
using standard Topspin settings using a Bruker 16.4 T (700 MHz 1H observe frequency) spectrometer 
equipped with a 1.7 mm cryogenically cooled TCI probe in 90% H20, 10% D2O at 298 K. All spectra were 
analysed in CcpNmr analysis 2.4.2. AGP2 was observed in 10 mM NaH2PO4/Na2HPO4, 100 mM NaCl, 
with the ligand and pH specified in the relevant figure. 
950 MHz double and triple resonance experiments were collected by Christina Redfield using standard 
Topspin settings using an Oxford Instruments 22.3 T (950 MHz 1H observe frequency) spectrometer 
equipped with a high-sensitivity 5 mm cryogenically cooled TCI probe in 90% H2O, 10% D2O at 298 K. 
AGP2 was observed at a concentration of 1 mM protein, 2 mM UCN-01 in 10 mM NaH2PO4/Na2HPO4, 
pH 6.5, 100 mM NaCl. 
NMR Titration Chemical Shift Mapping 
In a reverse minimal shift approach, peaks in the apo spectrum were assigned based on their proximity to 
assigned peaks in the UCN-01 bound spectrum. Apo peaks closest to liganded peaks were assigned first 
and subsequently more distant apo peaks were assigned to the closest remaining unassigned UCN-01 peak 
provided that the peaks were closer than 0.1 ppm in the 1H dimension and 0.68 ppm in the 15N dimension. 
Heteronuclear shifts were weighted based on the respective ranges of assigned peak chemical shifts present 
in the two dimensions (1H:4.504, 15N:30.616) as described in published methods (Williamson, 2013). These 
ranges yielded a weighting of 0.147 1H ppm/15N ppm. All visible assigned peaks in the UCN-01 spectrum 
were greater than 5% of the height of the largest peak (His172) and so peaks in the apo spectrum were only 
counted if they were more than 5% of the height of the largest apo peak (putative His172). 
To produce the minimal chemical shift chart, all peaks in the apo spectrum that could be assigned based 
on the holo spectrum (including those further away than 0.1 ppm in the 1H dimension and 0.68 ppm in the 
15N dimension) were assigned to the same residue as the closest holo peak and the chemical shift distance 
between the two (with the H:N distance conversion as above) was plotted. 
Crystallisation of AGP2 and Structural Resolution 
AGP2-trunc (purified by Sara Ryan) was cleaved and crystal conditions were screened from Structure 1+2 
(Molecular Dynamics). The successful hit consisted of 0.5 mM AGP2 with a two-fold excess of UCN-01 














The studies of A2AR and AGP2 presented in this thesis are examples of two different approaches drawn 
from the NMR literature as discussed in the introduction. The techniques applied to the A2AR as a 
membrane protein are best compared to methodologies previously applied to the M2 proton channel and 
β2-adrenergic receptor, whereas the work on AGP2 bears more resemblance to that on the Bcl-2 family. In 
each case appropriate NMR techniques have been applied to understand the “jigglings and wigglings” 
(Feynman, 1963) of these proteins and how their motions affect drug discovery campaigns. 
19F Tagging of the A2AR in Context 
The 19F NMR study reported here extends the application of GPCR 19F tagging to investigate distinct 
antagonist-induced states and applies it to a novel ligand. 
GPCRs in general have been investigated by NMR, but their large size and the necessary presence of a 
detergent micelle to maintain their stability, make structure determination by solution state NMR extremely 
challenging. The application of uniform isotope labelling to understand GPCR biology has nonetheless 
been attempted in the past, in particular a study of the GPCR analogue sensory rhodopsin (pSRII) has been 
conducted. The structure of this 7-TM helical protein was solved by NMR (Gautier et al, 2010) 
demonstrating that the most in-depth NMR study of 7-TM proteins is in principle possible, but to this 
author’s knowledge it remains the only 7-TM helical protein the structure of which has been solved at 
atomic resolution by NMR. ssNMR is useful for larger systems such as genuine GPCRs by obviating the 
increased relaxation rate resulting from slow tumbling in solution. A structural model of the GPCR CXCR1 
has been determined using ssNMR (Park et al, 2012), just as ssNMR was used to probe the structures of 
the M2 channel. However, unlike the case of the M2, the determination of the CXCR1 structure relied on 
bovine rhodopsin as a topology template and cannot be considered a true de-novo NMR structure. The 
chemical shifts of the protein spins were used to generate structural restraints to produce structure 
fragments to be mapped onto the template. It is also the case that some reviewers have questioned whether 
the resolution of the CXCR1 structural model is sufficient for drug discovery applications (Latek et al, 2012). 
The difficulties encountered in generating full NMR models of GPCRs necessitates the application of 
alternative methods to probe their structures and the 19F study described in this thesis uses one such 
alternative method along with selective labelling.  
Selective labelling or tagging of other GPCRs have been employed as alternatives to full assignment of 
uniformly labelled proteins to overcome spectral complexity. Chemical shift changes in selectively labelled 
β1-adrenergic receptor were used to characterise the effects of multiple ligands on the receptor (Isogai et al, 
2016; Solt et al, 2018). The A2AR itself has also been studied by this method (Clark et al, 2017). Just as in a 
uniformly labelled sample, in selectively labelling GPCRs the isotope labels act as chemical shift probes, 
but with the identity of the peaks determined by mutagenesis.  
By contrast, the 19F tagging approach, whilst being constrained to reporting on one locus per experiment, 




media. Further, the precise location of the label is predetermined by the location of the point mutation and 
so no further deconvolution is necessary. 
For a research question that focusses on a specific part of the protein a single 19F probe may be sufficient 
to yield all the necessary information. In our case by tagging K2095.70 we were able to measure a response 
for both drug-sized small molecules such as Cmpd-1 and fragment sized caffeine. This single 19F probe was 
sufficient to address whether helix V adopts a different conformation when in complex with the Cmpd-1 
compared to those of other antagonists, negating the need for a full backbone chemical shift assignment. 
Given the commercially driven time pressures on drug discovery pipeline delivery in pharmaceutical 
companies, such considerations are of central importance to determine whether or not a method may be 
used.  
The key differences between past studies of β2-adrenergic receptor or A2AR (Liu et al, 2012; Ye et al, 2016) 
and this 19F study are that an alternative method of receptor inactivation was being investigated and that 
Cmpd-1 is a novel ligand that the study sought to characterise. Past studies have, by contrast, been 
concerned primarily with characterising different active states and have investigated the receptor rather than 
the ligand. It is hoped that this 19F study represents an extension of 19F NMR to address a broader range 
of questions than it has been applied to in the past. The study also advances the integration of non-standard 
NMR approaches to investigate the properties of lead compounds in drug discovery as some reviewers 
have noted (Gusach et al, 2020).  
Although our 19F tagging approach yielded the necessary supporting evidence on the movement of helix V, 
it did not provide structural detail on the conformation that was adopted. Selective labelling and tagging 
cannot yield the NOE constraints necessary for a de-novo structure calculation in the same way that full 
backbone and sidechain assignments of uniformly labelled protein can. However, recently selective labelling 
has also been used to glean structural information about the β2-adrenergic receptor by paramagnetic 
relaxation enhancement (PRE) (Imai et al, 2020). PRE causes increased relaxation rates of nuclei by the 
proximity of a paramagnetic centre, which allows some intramolecular distances to be determined. 
Paramagnetic tags may be chemically conjugated to a receptor in much the same way as 19F tags, via thiol 
bonds to introduced cysteine residues. If a more detailed study of the effect of Cmpd-1 on helix V were to 
be conducted then this approach would be applicable as the introduction of several A2AR cysteine residues 
for 19F tagging is already validated in terms of feasibility and impact on activity. Such a study could yield 
distance measurements allowing the movement of helix V to be quantified and so go beyond the qualitative 







Backbone Assignments of AGP2 in Context 
The investigation into the binding of UCN-01 to AGP2 was pursued using a very different NMR 
methodology to that used for the A2AR. The smaller size of AGP2 made classical NMR techniques, 
resembling those discussed for Bcl-2 in the introduction, possible and appropriate. The NMR work is 
nonetheless unorthodox in some ways.  
Whilst NMR data was being gathered the crystal structure of AGP2 bound to UCN-01 was solved revealing 
its binding orientation. In this regard the work is analogous to that on the M2 proton channel where the 
binding mode of ligands was determined by crystallography prior to or concomitantly with NMR, but as 
with these cases the adaptability of NMR allowed a more complete investigation of the backbone dynamics 
using the NMR assignments than is possible with crystallography alone. 
Neither in this study nor in previous AGP work has the crystal structure of AGP2 in the apo state been 
solved. The applicability of NMR to study apo AGP2 under a range of solution conditions is, therefore, 
important. In most CSP studies, as described for Bcl-2, the NMR assignments are determined for the apo 
protein and CSPs are measured by using this as a reference spectrum for comparison to the ligand-bound 
spectra which are not usually assigned. This work on AGP2 was carried out in the reverse order. This 
workflow was imposed by the dynamic nature of apo AGP2, evidenced by the loss of NMR signals due to 
intermediate exchange broadening such that assignment of the complete apo spectrum was not possible. 
Rigidification of the AGP2 on addition of the UCN-01 ligand yielded data of sufficient quality for full 
backbone assignments to be made. Therefore, parts of the AGP2 work may be considered to use a “reverse 
CSP” strategy, in that NMR can observe the apo form of the protein in a way that is not possible by 
crystallography, and allow inferences about the apo structure to be made based on the assigned ligand-
AGP2 complex. If a future drug discovery effort were to target the apo form of AGP2 for investigation, 
with an antibody for instance, NMR assignments of apo spectra would be highly valued. It may be possible 
to obtain apo AGP2 assignments by optimising spectral conditions for fresh 3D NMR experiments used 
in conjunction with the existing UCN-01 bound assignments, but the success of such an approach is not 
guaranteed. 
Future studies may also look at modifying UCN-01 to abolish affinity for AGP2 to yield a compound with 
more favourable pharmacokinetic properties. During such a process, the full backbone assignments offer 
the prospect of using HSQC spectra to triage a variety of UCN-01 analogues for AGP2 binding than by 
crystallography alone. The crystal structures reported to date have been solved in very different buffer 
conditions at pH 4.6 (Nishi et al, 2011) or pH 7.4 (this study). These facts indicate that crystallography may 
not be sufficiently reproducible to cover the broad range of ligands that NMR can handle with ease. The 
existence of a complete set of NMR backbone assignments for the UCN-01 bound form makes further 
NMR studies of new ligands relatively straight-forward, as those assignments may be transferred to recently 
collected spectra to analyse the binding of new ligands or redesigned UCN-01 derivatives. Future studies 




peaks that shift significantly in the ligand bound form. This would allow a more traditional CSP workflow 
to be adopted, even if some apo residues remain unassigned. 
Conclusion 
In conclusion protein observed NMR is a powerful tool in drug discovery that has been applied here to 
advance our understanding of inactive states of the A2AR and the binding of UCN-01 to AGP2. The power 
of 19F tagging has been extended to study the inhibitory action of a novel antagonist to a relatively 
intractable GPCR and classical isotope labelling techniques have been used to work backwards from ligand 
bound AGP2 to understand the apo form of that protein.  
It is hoped that this work extends the use of protein observed NMR to accelerate the delivery of novel 












































Residue H N C Ca Cb Cg Cd Ha Hb Hd 
None None None None None None None None None None None 
0Pro None None None 62.9 32.16 None None None None None 
1Gln 8.54 122.02 None 55.8 29.34 None None 4.26 1.92,1.99 None 
2Ile 8.17 124.55 None 58.62 38.63 17.25,26.82 12.85 4.43 1.81 0.78 
3Pro None None None 63.32 32.19 None None None None None 
4Leu 8.26 122.58 None 55.95 42.3 27.31 None 4.18 1.51,1.58 0.86 
5Cys 8.34 116.36 None 55.23 39.58 None None 4.42 2.94,3.21 None 
6Ala 8.14 125.25 None 54.79 18.65 None None 4.43 1.36 None 
7Asn 8.4 113.68 None 53.87 36.92 None None 4.58 2.92 None 
8Leu 7.28 120.58 None 53.85 40.94 27.5 24.56,26.13 4.31 1.53,1.58 0.60,0.70 
9Val 6.93 119.33 None 59.42 32.92 20.86,20.90 None 4.17 1.99 None 
10Pro None None None 63.09 32.52 None None None None None 
11Val 8.7 122.7 None 56.13 29.4 None None None None None 
12Pro None None None 62.7 31.99 None None None None None 
13Ile 9.23 125.07 None 61.77 37.98 None None None None None 
14Thr 7.9 117.36 None 59.31 72.12 None None None None None 
15Asn 9.27 121.08 None 56.54 36.84 None None 4.69 2.88 None 
16Ala 8.07 122.8 None 55.21 17.83 None None 4.25 1.37 None 
17Thr 7.77 119.13 None 66.66 68.01 None None 3.71 4.43 None 
18Leu 7.79 119.51 None 57.55 40.08 None None 4.26 1.32,1.39 None 
19Asp 8.23 121.41 None 58.26 39.64 None None 4.41 2.73,2.82 None 
20Arg 7.9 122.41 None 59.13 29.94 None None None None None 
21Ile 7.53 107.68 None 61.84 37.28 17.25,25.52 14.14 5 2.52 0.63 
22Thr 7.54 120.68 None 65.66 69.46 None None 4.11 4.46 None 
23Gly 8.59 115.63 None 44.18 None None None None None None 
24Lys 7.61 122.3 None 54.32 34.86 None None 4.45 1.08,1.18 None 
25Trp 8.34 127.88 None 54.61 34.29 None None 4.4 None None 
26Phe 9.35 116.47 None 56.73 41.28 None None 4.97 None None 
27Tyr 9.03 122.43 None 57.35 40.88 None None 5.74 None None 
28Ile 8.53 130.58 None 59.61 37.54 None None None None None 
29Ala 6.97 119.45 None 51.02 22.65 None None 5.07 0.88 None 
30Ser 8.82 110.94 None 58.87 65.81 None None 4.89 3.84,4.00 None 
31Ala 7.99 118.05 None 53.19 24.01 None None 4.49 1.21 None 
32Phe 8.75 114.19 None 56.19 44.82 None None None None None 
33Arg 9.11 119.7 None 57.4 30 None None None None None 
34Asn 6.63 117.72 None 54.91 41.19 None None None None None 
35Glu 9 130.25 None 59.95 29.51 None None None None None 
36Glu 8 120.29 None 60.3 28.52 None None None None None 
37Tyr 8.72 120.27 None 58.35 35.4 None None None None None 
38Asn 7.86 118.06 None 57.72 38.99 None None 4.55 None None 
39Lys 8.18 117.84 None 59.29 32.08 None None None None None 
40Ser 8.09 114.66 None 61.64 63.12 None None 4.18 3.66,3.77 None 
41Val 8.6 117.72 None 65.03 31.68 22.24,22.29 None 4.02 2.43 None 
42Gln 7.84 122.17 None 58.93 28.37 None None None None None 




44Ile 7.63 120.42 None 62.68 38.4 18.46 14.84 4.09 2.14 0.51 
45Gln 8.7 128.72 None 58.15 30.94 None None 4.44 None None 
46Ala 8.02 116.04 None 51.97 20.5 None None 5.08 1.68 None 
47Thr 10.41 None None 66.19 77.4 23.54 None None None None 
48Phe 8.81 123.78 None 55.71 42.22 None None 5.74 None None 
49Phe 9.08 116.92 None 55.57 42.18 None None 5.84 3.07,3.22 None 
50Tyr 9.29 117.02 None 56.44 42.22 None None 5.5 None None 
51Phe 9.2 120.36 None None 42.61 None None 5.96 2.88 None 
52Thr 8.9 118.12 None 59.92 70.74 None None 4.98 4.46 None 
53Pro None None None 63.3 33.47 None None None None None 
54Asn 9.17 122.91 None 52.55 38.06 None None 4.94 2.73,3.26 None 
55Lys 8.9 122.22 None 59.96 32.41 None None None None None 
56Thr 8 110.44 None 64.12 68.74 22.08 None None 4.27 None 
57Glu 7.18 118.92 None 55.53 30.84 None None None None None 
58Asp 7.79 117.79 None 56.1 37.99 None None 4.22 2.91,3.21 None 
59Thr 7.68 106.93 None 58.94 74.17 None None 5.57 4.34 None 
60Ile 8.76 118.34 None 60.9 42.48 17.86 14.13 4.21 1.35 0.15 
61Phe 8.42 129.27 None 57.07 39.51 None None 4.73 None None 
62Leu 8.98 135.38 None 53.59 44.96 None 24.67,25.31 5.49 1.32,1.73 0.49,1.16 
63Arg 8.03 123.99 None 55.57 33.38 None None 4.44 None None 
64Glu 8.87 126.62 None 56.07 34.73 None None 4.63 None None 
65Tyr 9.03 127.66 None 57.49 36.67 None None 4.65 None None 
66Gln 8.97 126.56 None 55.26 34.63 None None 5.11 None None 
67Thr 8.77 125.53 None 62.81 69.96 None None 5.52 None None 
68Arg 9 126.78 None 54.91 33.85 None None 5.07 None None 
69Gln 9.32 120.59 None 57.07 26.33 None None None None None 
70Asn 9.33 109.76 None 54.82 37.41 None None 4.13 2.88,3.07 None 
71Gln 8.04 118.3 None 54.52 32.99 None None None None None 
72Cys 8.56 119.75 None 56.13 43.89 None None None None None 
73Phe 10.04 132.72 None 57.97 40.71 None None 4.53 None None 
74Tyr 8.52 126.09 None 54.94 40.32 None None None None None 
75Asn 8.19 126.73 None 52.16 42.71 None None 4.43 2.22,2.30 None 
76Ser 8.04 117.39 None 55.81 65.92 None None 5.16 3.56,3.78 None 
77Ser 8.44 116.08 None 57.78 65.33 None None 4.58 3.65,3.68 None 
78Tyr 8.67 118.23 None 58.1 39.91 None None 5.29 None None 
79Leu 9.62 125.26 None 53.29 43.18 25.98 None 5.01 1.58 1 
80Asn 8.4 118.88 None 53.04 40.7 None None None None None 
81Val 8.02 120.75 None 61.49 33.54 None None None None None 
82Gln 8.64 129.52 None 55.45 25.65 None None 4.66 None None 
83Arg 8.73 121.99 None 61.96 34.8 None None None None None 
84Glu 8.96 117.06 None 59.42 28.78 None None 3.99 None None 
85Asn 7.32 114.9 None 52.76 39.3 None None 4.67 2.59,2.83 None 
86Gly 7.87 106.83 None 47.05 None None None None None None 
87Thr 7.5 107.68 None 58.45 73.05 None None None None None 
88Val 8.47 111.64 None 58.81 35.37 None None 5.17 None None 




90Arg 8.7 119.59 None 53.81 34.79 25.17 None None None None 
91Tyr 8.75 126.2 None 57.1 38.94 None None 5.02 None None 
92Glu 8.65 127.1 None 55.64 32.19 35.2 None 4.3 1.35 None 
93Gly 8.9 116.58 None 46.94 None None None None None None 
94Gly 8.29 106.15 None 45.11 None None None None None None 
95Arg 7.25 118.19 None 54.12 32.51 None None None None None 
96Glu 8.36 122.33 None 55.55 31.09 None None None None None 
97His 9.22 127.41 None 55.28 34.4 None None 4.8 2.62,3.02 None 
98Val 8.69 122.25 None 61.42 34.89 20.92,21.16 None 5.09 1.79 None 
99Ala 9.38 133.2 None 50.43 20.92 None None 5.07 None None 
100His 9.05 119.67 None 58.27 31.93 None None 4.52 None None 
101Leu 7.56 124.34 None 54.91 42.36 None None None None None 
102Leu 8.52 128.14 None 53.41 45.59 None None 4.59 1.36 None 
103Phe 8.29 117.47 None 57.11 41.97 None None 4.79 None None 
104Leu 9.07 124.74 None None None None None None None None 
105Arg 9.55 123.04 None 59.3 29.47 None None None None None 
106Asp 8.58 121.16 None 54.77 42.85 None None None None None 
107Thr 8.2 115.85 None 63.49 69.01 None None 4.35 4.55 None 
108Lys 8.94 124.28 None 55.75 31.23 None None 4.58 None None 
109Thr 7.2 105.61 None 59.49 72.71 None None 5.28 4.25 None 
110Leu 8.47 122.04 None 55.05 45.74 None None 4.26 0.58,0.76 None 
111Met 8.12 120.8 None 53.78 38.48 None None 5.61 1.93 None 
112Phe 8.44 119.19 None 52.21 39.16 None None 5.66 2.28,2.82 None 
113Gly 9.88 111.17 None 45.25 None None None None None None 
114Ser 9.12 123.96 None 59.11 65.59 None None 4.84 None None 
115Tyr 9.46 121.46 None 57.83 36.22 None None 4.42 None None 
116Leu None None None 58.14 42.08 None None None None None 
117Asp 8.61 113.65 None 53.44 40.47 None None 4.67 2.64,2.87 None 
118Asp 8.42 121.64 None 52.4 42.71 None None 4.79 2.42,3.02 None 
119Glu 8.46 126.66 None 56.92 28.93 None None None None None 
120Lys 7.68 115.24 None 56.82 32.44 None None None None None 
121Asn 7.48 114.99 None 54.33 45.02 None None None None None 
122Trp 7.7 120.52 None 55.88 30.55 None None None None None 
123Gly 8.65 104.73 None 47.42 None None None None None None 
124Leu 7.99 116.81 None 53.11 49.62 None None 5.57 1.43,1.49 None 
125Ser 8.54 111.9 None 56.26 65.66 None None None 3.11,3.61 None 
126Phe 8.43 124.71 None 55.72 42.61 None None 4.8 None None 
127Tyr 8.29 126.52 None 55.88 42.31 None None 5.15 None None 
128Ala 8.81 120.04 50.49 50.46 23.45 None None 5.47 1.37 None 
129Asp 8.36 120.31 None 54.46 40.26 None None 4.17 2.19,2.65 None 
130Lys 7.13 119.17 None 53.06 34.81 None None None None None 
131Pro None None None 62.76 30.1 None None None None None 
132Glu 6.54 115.9 None 54.71 31.8 None None 4.39 None None 
133Thr 8.21 113.02 None 59.64 71.62 None None 4.57 None None 
134Thr 8.59 112.37 None 60.21 71.48 None None 4.56 4.34 None 




136Glu 8.76 120.96 None 60.35 28.59 None None None None None 
137Gln 7.79 120.41 None 58.84 29.67 None None None None None 
138Leu 7.89 119.71 None 57 41.55 24.74 24.12 3.69 1.29,1.52 0.71 
139Gly 8.12 105.87 None 47.41 None None None None None None 
140Glu 7.32 120.1 None 59.92 30.49 None None None None None 
141Phe 6.82 121.89 None 59.47 36.85 None None None None None 
142Tyr 8.13 117.89 None 57.98 35.84 None None None None None 
143Glu 7.72 118.83 59.5 59.48 29.7 None None None None None 
144Ala 7.18 123.36 None 55.21 18.22 None None 3.87 1.2 None 
145Leu 7.69 118.24 None 57.79 40.66 None None None None None 
146Asp 8.02 119.33 None 57 39.4 None None 4.25 2.52,2.83 None 
147Cys 7.58 120.4 None 60.16 42.45 None None None None None 
148Leu 6.94 118.47 None 54.33 40.9 None 19.91,25.33 3.77 0.75,1.15 -0.67,0.07 
149Arg 7.69 114.17 None 56.96 26.59 None None None None None 
150Ile 7.47 122.06 None 58.55 39.87 16.54 14.14 4.52 1.31 0.75 
151Pro None None None 62.55 32.47 None None None None None 
152Arg 8.38 122.13 None 58.28 29.31 None None None None None 
153Ser 7.87 111.78 None 59.75 62.59 None None None None None 
154Asp 7.66 123.29 None 54.79 40.08 None None 4.8 2.59,2.93 None 
155Val 7.06 120.85 None 63.18 32.29 23.49,25.81 None 4 1.92 None 
156Met 9.09 128.4 None 54.36 34.11 None None None None None 
157Tyr 8.56 118.41 None 57 41.7 None None None None None 
158Thr 7.74 113.15 None 60.94 70.78 None None 4.32 4.4 None 
159Asp 8.55 122.37 None 52.67 41.77 None None 5.05 None None 
160Trp 9.2 126.4 None 59.1 30.32 None None 4.62 None None 
161Lys 8.09 116.77 None 58.04 30.93 None None None None None 
162Lys 8.02 117.31 None 55.06 33 None None None None None 
163Asp 7.08 118.27 None 56.93 42.54 None None 4.03 None None 
164Lys 8.55 123.85 None 53.37 34.39 None None None None None 
165Cys 9.26 117.85 None 54.34 43.73 None None None None None 
166Glu 11.04 129.36 None 62.56 34.49 None None None None None 
167Pro None None None 65.28 31.14 None None None None None 
168Leu 7.45 117.53 None 56.22 41.91 None None None None None 
169Glu 7.75 120.21 None 58.45 29.48 None None None None None 
170Lys 7.63 118.72 None 56.56 32.58 None None None None None 
171Gln 7.85 120.49 None 56 29.12 None None None None None 
172His 7.78 125.53 None 56.82 30.67 None None None None None 
-1Gly None None None None None None None None None None 
           

















1 1GlnN 1GlnH 859.12198 31.82894 0.39313 16 A exp(-Bx) 
2 2IleN 2IleH 763.47149 17.00943 0.59652 16 A exp(-Bx) 
3 4LeuN 4LeuH 804.17299 25.66784 0.3263 8 A exp(-Bx) 
4 5CysN 5CysH 783.05041 69.08604 0.31496 8 A exp(-Bx) 
5 6AlaN 6AlaH 883.89663 33.39728 0.22308 16 A exp(-Bx) 
6 7AsnN 7AsnH 923.57311 26.12459 0.33379 16 A exp(-Bx) 
7 8LeuN 8LeuH 1104.33927 21.12312 0.20719 16 A exp(-Bx) 
8 9ValN 9ValH 1043.75589 15.31983 0.21214 16 A exp(-Bx) 
9 14ThrN 14ThrH 1056.33767 19.99133 0.12588 16 A exp(-Bx) 
10 16AlaN 16AlaH 966.65201 106.5865 0.17738 8 A exp(-Bx) 
11 17ThrN 17ThrH 1001.85123 20.81529 0.32462 16 A exp(-Bx) 
12 18LeuN 18LeuH 1055.86121 25.61128 0.20761 16 A exp(-Bx) 
13 19AspN 19AspH 1057.47124 29.45026 0.4095 16 A exp(-Bx) 
14 20ArgN 20ArgH 1047.05207 14.61138 0.23155 16 A exp(-Bx) 
15 22ThrN 22ThrH 1047.3358 15.9004 0.24947 16 A exp(-Bx) 
16 23GlyN 23GlyH 1097.17985 23.35668 0.20054 16 A exp(-Bx) 
17 24LysN 24LysH 1112.09909 14.91411 0.23427 16 A exp(-Bx) 
18 25TrpN 25TrpH 1078.23693 27.53289 0.26535 16 A exp(-Bx) 
19 26PheN 26PheH 1116.95195 26.75038 0.19256 16 A exp(-Bx) 
20 27TyrN 27TyrH 1064.34591 31.39551 0.25269 15 A exp(-Bx) 
21 28IleN 28IleH 1061.89151 32.27857 0.14496 15 A exp(-Bx) 
22 29AlaN 29AlaH 1111.36457 15.32199 0.15997 16 A exp(-Bx) 
23 30SerN 30SerH 1072.1098 14.26158 0.17842 16 A exp(-Bx) 
24 31AlaN 31AlaH 1053.2487 33.92325 0.45326 16 A exp(-Bx) 
25 32PheN 32PheH 1174.15922 29.14129 0.28207 16 A exp(-Bx) 
26 33ArgN 33ArgH 1058.50824 24.20456 0.18386 16 A exp(-Bx) 
27 35GluN 35GluH 999.91044 27.03813 0.39548 16 A exp(-Bx) 
28 36GluN 36GluH 1152.31904 18.21528 0.32368 16 A exp(-Bx) 
29 37TyrN 37TyrH 1118.92798 23.65899 0.2702 16 A exp(-Bx) 
30 38AsnN 38AsnH 1191.48769 19.29484 0.2365 16 A exp(-Bx) 
31 39LysN 39LysH 1161.42742 12.76348 0.17221 16 A exp(-Bx) 
32 40SerN 40SerH 1154.40609 13.55528 0.17136 16 A exp(-Bx) 
33 41ValN 41ValH 1107.80131 32.90179 0.29341 16 A exp(-Bx) 
34 42GlnN 42GlnH 1022.20323 10.6005 0.17104 16 A exp(-Bx) 
35 43GluN 43GluH 1071.89154 17.74005 0.28745 16 A exp(-Bx) 
36 44IleN 44IleH 1126.21677 31.79105 0.49201 16 A exp(-Bx) 
37 45GlnN 45GlnH 1213.78226 31.02609 0.14172 16 A exp(-Bx) 
38 46AlaN 46AlaH 1096.33811 14.17035 0.19344 16 A exp(-Bx) 
39 48PheN 48PheH 994.78891 24.24085 0.30218 16 A exp(-Bx) 
40 49PheN 49PheH 974.92523 28.32263 0.32697 16 A exp(-Bx) 
41 50TyrN 50TyrH 1032.84423 20.26942 0.1415 16 A exp(-Bx) 
42 51PheN 51PheH 1089.11654 21.14562 0.17465 16 A exp(-Bx) 
43 52ThrN 52ThrH 1081.83033 47.85542 0.42083 16 A exp(-Bx) 




45 55LysN 55LysH 925.94503 41.46333 0.21332 16 A exp(-Bx) 
46 56ThrN 56ThrH 1022.08258 31.60084 0.39363 16 A exp(-Bx) 
47 57GluN 57GluH 995.33632 17.01003 0.27293 16 A exp(-Bx) 
48 58AspN 58AspH 953.68758 25.60208 0.40417 16 A exp(-Bx) 
49 59ThrN 59ThrH 958.24781 35.5037 0.59225 16 A exp(-Bx) 
50 60IleN 60IleH 1036.44421 23.68901 0.24234 16 A exp(-Bx) 
51 61PheN 61PheH 1018.84481 27.26469 0.30862 16 A exp(-Bx) 
52 62LeuN 62LeuH 965.61991 28.27951 0.26035 16 A exp(-Bx) 
53 63ArgN 63ArgH 1020.78527 40.61561 0.36182 16 A exp(-Bx) 
54 64GluN 64GluH 1048.67675 27.351 0.33645 16 A exp(-Bx) 
55 65TyrN 65TyrH 1045.01724 23.82829 0.19959 16 A exp(-Bx) 
56 67ThrN 67ThrH 1144.7636 30.89965 0.19613 16 A exp(-Bx) 
57 68ArgN 68ArgH 1072.95541 26.79116 0.6124 16 A exp(-Bx) 
58 69GlnN 69GlnH 1118.40614 15.51881 0.1939 16 A exp(-Bx) 
59 70AsnN 70AsnH 1118.98818 12.89404 0.17767 16 A exp(-Bx) 
60 71GlnN 71GlnH 1124.4119 17.60843 0.34087 16 A exp(-Bx) 
61 72CysN 72CysH 1185.1908 17.1268 0.26019 16 A exp(-Bx) 
62 73PheN 73PheH 1127.53563 24.93272 0.25168 16 A exp(-Bx) 
63 74TyrN 74TyrH 1128.40071 25.07425 0.25124 16 A exp(-Bx) 
64 75AsnN 75AsnH 957.19368 64.28379 0.98591 16 A exp(-Bx) 
65 77SerN 77SerH 972.88987 34.20306 0.44175 16 A exp(-Bx) 
66 78TyrN 78TyrH 1010.99481 12.11389 0.15444 16 A exp(-Bx) 
67 79LeuN 79LeuH 1070.65212 25.74016 0.17941 16 A exp(-Bx) 
68 80AsnN 80AsnH 1090.70155 38.60114 0.28337 13 A exp(-Bx) 
69 81ValN 81ValH 1109.511 34.20512 0.30113 16 A exp(-Bx) 
70 82GlnN 82GlnH 1130.29508 23.99932 0.2246 16 A exp(-Bx) 
71 83ArgN 83ArgH 1129.26169 25.28849 0.21639 16 A exp(-Bx) 
72 84GluN 84GluH 1020.54878 25.28199 0.31065 16 A exp(-Bx) 
73 85AsnN 85AsnH 1110.35487 25.862 0.29959 16 A exp(-Bx) 
74 86GlyN 86GlyH 1066.74478 35.79657 0.34402 16 A exp(-Bx) 
75 88ValN 88ValH 1051.94764 23.11589 0.18612 16 A exp(-Bx) 
76 89SerN 89SerH 1016.39323 28.92422 0.27166 16 A exp(-Bx) 
77 90ArgN 90ArgH 1093.04117 44.41905 0.32711 16 A exp(-Bx) 
78 91TyrN 91TyrH 1025.279 33.61423 0.40649 16 A exp(-Bx) 
79 92GluN 92GluH 1006.4884 30.97041 0.36581 15 A exp(-Bx) 
80 95ArgN 95ArgH 881.09439 21.797 0.50583 16 A exp(-Bx) 
81 96GluN 96GluH 1035.15257 22.69606 0.37396 16 A exp(-Bx) 
82 97HisN 97HisH 1010.59314 35.51851 0.33566 16 A exp(-Bx) 
83 98ValN 98ValH 1045.85387 40.48867 0.46938 16 A exp(-Bx) 
84 99AlaN 99AlaH 1040.56434 17.40843 0.16748 16 A exp(-Bx) 
85 100HisN 100HisH 1130.7395 22.4667 0.16754 16 A exp(-Bx) 
86 101LeuN 101LeuH 1049.6963 64.3161 0.3488 15 A exp(-Bx) 
87 102LeuN 102LeuH 1122.07749 27.92685 0.15901 16 A exp(-Bx) 
88 103PheN 103PheH 1120.33641 52.3439 0.35521 16 A exp(-Bx) 
89 104LeuN 104LeuH 1301.47507 36.75987 0.28535 16 A exp(-Bx) 




91 106AspN 106AspH 954.67309 49.40419 0.2583 8 A exp(-Bx) 
92 107ThrN 107ThrH 1030.83481 89.35354 0.31829 16 A exp(-Bx) 
93 108LysN 108LysH 994.82462 23.91572 0.21185 16 A exp(-Bx) 
94 109ThrN 109ThrH 1036.84623 34.78779 0.33301 16 A exp(-Bx) 
95 110LeuN 110LeuH 998.94332 36.86989 0.30939 16 A exp(-Bx) 
96 111MetN 111MetH 1016.82516 41.63924 0.33697 16 A exp(-Bx) 
97 112PheN 112PheH 1195.09556 24.7324 0.13041 16 A exp(-Bx) 
98 113GlyN 113GlyH 1123.23397 23.17653 0.1409 16 A exp(-Bx) 
99 114SerN 114SerH 1006.80018 35.15311 0.26671 16 A exp(-Bx) 
100 115TyrN 115TyrH 1051.89566 31.03686 0.27502 16 A exp(-Bx) 
101 117AspN 117AspH 1179.24966 26.14897 0.27365 16 A exp(-Bx) 
102 118AspN 118AspH 1106.20222 19.95265 0.26287 16 A exp(-Bx) 
103 119GluN 119GluH 1121.68627 23.272 0.31581 16 A exp(-Bx) 
104 120LysN 120LysH 1052.65543 12.13698 0.16368 16 A exp(-Bx) 
105 121AsnN 121AsnH 1164.16965 34.7817 0.24961 16 A exp(-Bx) 
106 122TrpN 122TrpH 1132.76041 21.59754 0.1962 16 A exp(-Bx) 
107 123GlyN 123GlyH 1018.42275 24.79435 0.24535 16 A exp(-Bx) 
108 124LeuN 124LeuH 1094.19548 20.0297 0.18695 16 A exp(-Bx) 
109 125SerN 125SerH 1031.09403 38.75211 0.28291 16 A exp(-Bx) 
110 126PheN 126PheH 1021.54411 39.65845 0.33438 16 A exp(-Bx) 
111 127TyrN 127TyrH 1147.45766 24.87868 0.14742 16 A exp(-Bx) 
112 128AlaN 128AlaH 1098.62612 36.18784 0.34955 16 A exp(-Bx) 
113 129AspN 129AspH 1076.28279 40.95373 0.38415 16 A exp(-Bx) 
114 130LysN 130LysH 1130.39317 23.11175 0.42162 16 A exp(-Bx) 
115 132GluN 132GluH 1141.60185 31.06778 0.51027 16 A exp(-Bx) 
116 133ThrN 133ThrH 1106.01891 18.47247 0.29113 16 A exp(-Bx) 
117 134ThrN 134ThrH 1027.89937 15.16915 0.20166 16 A exp(-Bx) 
118 135LysN 135LysH 956.56926 43.09572 0.17018 15 A exp(-Bx) 
119 136GluN 136GluH 893.43558 30.23463 0.42927 16 A exp(-Bx) 
120 137GlnN 137GlnH 1034.00314 29.5011 0.35145 16 A exp(-Bx) 
121 138LeuN 138LeuH 1031.26833 26.2903 0.3032 16 A exp(-Bx) 
122 139GlyN 139GlyH 1021.76842 14.8512 0.20998 16 A exp(-Bx) 
123 140GluN 140GluH 1033.92405 19.62802 0.19296 16 A exp(-Bx) 
124 141PheN 141PheH 1080.33327 29.26305 0.28023 16 A exp(-Bx) 
125 142TyrN 142TyrH 1139.01394 30.06257 0.29476 16 A exp(-Bx) 
126 143GluN 143GluH 1128.64111 43.72245 0.56257 16 A exp(-Bx) 
127 144AlaN 144AlaH 1197.44918 36.34605 0.36762 16 A exp(-Bx) 
128 145LeuN 145LeuH 1097.70535 17.28938 0.15399 16 A exp(-Bx) 
129 146AspN 146AspH 1040.21467 32.80543 0.43593 16 A exp(-Bx) 
130 147CysN 147CysH 1176.55292 13.50453 0.19165 16 A exp(-Bx) 
131 148LeuN 148LeuH 1219.53078 59.63689 0.42864 16 A exp(-Bx) 
132 149ArgN 149ArgH 997.24584 38.57424 0.54075 16 A exp(-Bx) 
133 150IleN 150IleH 1107.79789 31.42502 0.36583 16 A exp(-Bx) 
134 152ArgN 152ArgH 1032.47434 19.77193 0.27887 16 A exp(-Bx) 
135 153SerN 153SerH 902.26539 37.61458 0.5576 16 A exp(-Bx) 




137 155ValN 155ValH 1100.40167 12.58044 0.21836 16 A exp(-Bx) 
138 156MetN 156MetH 1102.124 26.94203 0.18325 16 A exp(-Bx) 
139 157TyrN 157TyrH 1204.84813 26.62456 0.27299 16 A exp(-Bx) 
140 158ThrN 158ThrH 1226.54766 25.81913 0.25353 16 A exp(-Bx) 
141 159AspN 159AspH 1062.65882 20.85341 0.20344 16 A exp(-Bx) 
142 160TrpN 160TrpH 1146.88491 17.14313 0.15476 16 A exp(-Bx) 
143 161LysN 161LysH 1103.35831 27.75991 0.39189 16 A exp(-Bx) 
144 163AspN 163AspH 1130.77888 13.36512 0.25731 16 A exp(-Bx) 
145 164LysN 164LysH 1095.04573 67.85179 0.36441 16 A exp(-Bx) 
146 165CysN 165CysH 1081.39635 21.11555 0.17952 16 A exp(-Bx) 
147 166GluN 166GluH 1028.61131 24.24302 0.13111 16 A exp(-Bx) 
148 168LeuN 168LeuH 1111.32374 32.83493 0.46251 16 A exp(-Bx) 
149 169GluN 169GluH 947.11388 16.0922 0.34129 16 A exp(-Bx) 
150 170LysN 170LysH 721.67647 16.46818 0.47189 16 A exp(-Bx) 
151 171GlnN 171GlnH 675.39407 31.07253 0.70257 16 A exp(-Bx) 














1 1GlnN 1GlnH 261.6321 21.50787 1.00611 14 A exp(-Bx) 
2 2IleN 2IleH 178.5108 3.4053 0.56335 14 A exp(-Bx) 
3 4LeuN 4LeuH 104.1699 2.26854 0.3639 13 A exp(-Bx) 
4 5CysN 5CysH 73.66543 3.55034 0.25994 10 A exp(-Bx) 
5 6AlaN 6AlaH 63.14315 2.50493 0.25626 10 A exp(-Bx) 
6 7AsnN 7AsnH 65.2203 1.92897 0.33976 11 A exp(-Bx) 
7 8LeuN 8LeuH 57.2266 1.66629 0.28939 11 A exp(-Bx) 
8 9ValN 9ValH 70.96355 1.74339 0.34034 11 A exp(-Bx) 
9 11ValN 11ValH 60.55606 2.71931 0.33785 12 A exp(-Bx) 
10 14ThrN 14ThrH 62.29549 2.14818 0.24332 11 A exp(-Bx) 
11 17ThrN 17ThrH 55.47479 1.0951 0.28874 11 A exp(-Bx) 
12 18LeuN 18LeuH 58.39489 1.47012 0.19802 9 A exp(-Bx) 
13 19AspN 19AspH 55.63047 1.01928 0.25639 12 A exp(-Bx) 
14 20ArgN 20ArgH 56.80683 1.18503 0.3244 11 A exp(-Bx) 
15 22ThrN 22ThrH 57.26078 1.37888 0.35325 11 A exp(-Bx) 
16 23GlyN 23GlyH 65.91523 1.7173 0.26781 12 A exp(-Bx) 
17 24LysN 24LysH 65.44115 1.33348 0.34258 11 A exp(-Bx) 
18 25TrpN 25TrpH 58.50076 1.22762 0.22725 11 A exp(-Bx) 
19 26PheN 26PheH 62.53853 1.81054 0.24723 11 A exp(-Bx) 
20 27TyrN 27TyrH 57.49354 2.28684 0.30316 9 A exp(-Bx) 
21 28IleN 28IleH 54.75278 1.15633 0.09777 8 A exp(-Bx) 
22 29AlaN 29AlaH 59.07761 1.93215 0.35695 11 A exp(-Bx) 
23 30SerN 30SerH 58.34967 1.23573 0.26765 11 A exp(-Bx) 




24 31AlaN 31AlaH 60.60607 0.80777 0.16779 11 A exp(-Bx) 
25 32PheN 32PheH 70.12457 1.78245 0.28602 11 A exp(-Bx) 
26 33ArgN 33ArgH 59.68319 1.52194 0.20408 10 A exp(-Bx) 
27 34AsnN 34AsnH 118.5667 2.17868 0.31935 14 A exp(-Bx) 
28 35GluN 35GluH 57.51344 1.34516 0.33372 11 A exp(-Bx) 
29 36GluN 36GluH 57.12051 1.36378 0.49561 12 A exp(-Bx) 
30 37TyrN 37TyrH 54.93617 0.66759 0.15578 11 A exp(-Bx) 
31 38AsnN 38AsnH 57.40002 1.07202 0.25802 11 A exp(-Bx) 
32 39LysN 39LysH 60.10143 0.97875 0.25199 11 A exp(-Bx) 
33 40SerN 40SerH 63.52428 1.6949 0.36828 11 A exp(-Bx) 
34 41ValN 41ValH 55.1858 1.16052 0.21263 10 A exp(-Bx) 
35 42GlnN 42GlnH 59.53113 0.87857 0.23907 11 A exp(-Bx) 
36 43GluN 43GluH 69.47868 2.20781 0.48966 11 A exp(-Bx) 
37 44IleN 44IleH 66.19206 3.05331 0.73651 12 A exp(-Bx) 
38 45GlnN 45GlnH 58.08748 1.29298 0.1286 10 A exp(-Bx) 
39 46AlaN 46AlaH 63.21534 1.62971 0.35465 12 A exp(-Bx) 
40 48PheN 48PheH 58.57069 1.39255 0.26577 12 A exp(-Bx) 
41 49PheN 49PheH 56.60452 1.66732 0.31799 10 A exp(-Bx) 
42 50TyrN 50TyrH 61.89362 2.2563 0.27137 11 A exp(-Bx) 
43 51PheN 51PheH 61.11202 1.14254 0.17404 10 A exp(-Bx) 
44 52ThrN 52ThrH 66.31957 1.50353 0.21374 11 A exp(-Bx) 
45 54AsnN 54AsnH 62.73361 1.40851 0.30556 11 A exp(-Bx) 
46 55LysN 55LysH 58.96963 2.48159 0.21887 10 A exp(-Bx) 
47 56ThrN 56ThrH 59.77342 1.43004 0.31271 11 A exp(-Bx) 
48 57GluN 57GluH 64.81675 1.44575 0.32867 11 A exp(-Bx) 
49 58AspN 58AspH 62.31768 1.55516 0.37038 11 A exp(-Bx) 
50 59ThrN 59ThrH 61.50757 1.96034 0.45391 12 A exp(-Bx) 
51 60IleN 60IleH 61.79601 1.1806 0.20058 11 A exp(-Bx) 
52 61PheN 61PheH 59.0928 1.37577 0.25624 10 A exp(-Bx) 
53 62LeuN 62LeuH 63.97755 2.09172 0.27171 12 A exp(-Bx) 
54 63ArgN 63ArgH 62.40883 2.12123 0.28472 11 A exp(-Bx) 
55 64GluN 64GluH 67.27715 2.80405 0.49282 11 A exp(-Bx) 
56 65TyrN 65TyrH 56.09401 1.53951 0.2387 11 A exp(-Bx) 
57 67ThrN 67ThrH 66.71972 1.96839 0.21526 11 A exp(-Bx) 
58 68ArgN 68ArgH 61.66375 0.83649 0.31468 11 A exp(-Bx) 
59 69GlnN 69GlnH 57.72985 1.96162 0.4737 11 A exp(-Bx) 
60 70AsnN 70AsnH 54.00573 1.49082 0.40783 10 A exp(-Bx) 
61 71GlnN 71GlnH 56.92716 1.26706 0.42836 11 A exp(-Bx) 
62 72CysN 72CysH 58.53246 0.98236 0.29251 11 A exp(-Bx) 
63 73PheN 73PheH 64.72539 2.22867 0.34983 11 A exp(-Bx) 
64 74TyrN 74TyrH 66.59218 1.73451 0.28638 12 A exp(-Bx) 
65 75AsnN 75AsnH 65.90558 2.58412 0.51014 12 A exp(-Bx) 
66 77SerN 77SerH 65.19692 1.00482 0.19125 11 A exp(-Bx) 
67 78TyrN 78TyrH 66.05402 0.4665 0.19009 12 A exp(-Bx) 
68 79LeuN 79LeuH 67.49571 1.83949 0.21423 11 A exp(-Bx) 




70 81ValN 81ValH 60.0555 1.66554 0.25981 11 A exp(-Bx) 
71 82GlnN 82GlnH 54.65678 1.47357 0.30779 11 A exp(-Bx) 
72 83ArgN 83ArgH 58.79123 1.54841 0.25919 11 A exp(-Bx) 
73 84GluN 84GluH 62.10538 2.08255 0.43984 11 A exp(-Bx) 
74 85AsnN 85AsnH 66.04556 1.5914 0.31192 11 A exp(-Bx) 
75 86GlyN 86GlyH 61.62388 1.69439 0.28377 12 A exp(-Bx) 
76 88ValN 88ValH 57.63888 1.97294 0.27954 10 A exp(-Bx) 
77 89SerN 89SerH 63.35658 1.45496 0.21961 12 A exp(-Bx) 
78 90ArgN 90ArgH 54.01744 1.33247 0.20761 10 A exp(-Bx) 
79 91TyrN 91TyrH 65.16303 1.15584 0.20493 12 A exp(-Bx) 
80 92GluN 92GluH 59.00442 1.26824 0.24706 11 A exp(-Bx) 
81 94GlyN 94GlyH 67.98614 2.62402 0.24887 12 A exp(-Bx) 
82 95ArgN 95ArgH 61.56223 0.69537 0.20017 12 A exp(-Bx) 
83 96GluN 96GluH 68.29342 1.49434 0.36126 11 A exp(-Bx) 
84 97HisN 97HisH 64.32766 1.24226 0.16645 10 A exp(-Bx) 
85 98ValN 98ValH 65.57148 1.68004 0.29699 12 A exp(-Bx) 
86 99AlaN 99AlaH 60.61592 1.77218 0.26854 12 A exp(-Bx) 
87 100HisN 100HisH 57.98147 1.43763 0.21293 10 A exp(-Bx) 
88 101LeuN 101LeuH 53.9086 1.69919 0.17024 9 A exp(-Bx) 
89 102LeuN 102LeuH 51.17312 2.16173 0.25192 10 A exp(-Bx) 
90 103PheN 103PheH 53.0026 2.22747 0.24261 7 A exp(-Bx) 
91 104LeuN 104LeuH 83.37568 3.16827 0.32936 11 A exp(-Bx) 
92 106AspN 106AspH 61.25367 1.81085 0.2465 11 A exp(-Bx) 
93 107ThrN 107ThrH 41.0751 1.67572 0.1304 6 A exp(-Bx) 
94 108LysN 108LysH 60.25907 1.24086 0.18274 11 A exp(-Bx) 
95 109ThrN 109ThrH 42.88128 1.66847 0.2844 9 A exp(-Bx) 
97 111MetN 111MetH 58.6915 2.28615 0.29346 10 A exp(-Bx) 
98 112PheN 112PheH 59.60741 1.48153 0.16493 10 A exp(-Bx) 
99 113GlyN 113GlyH 55.62553 1.30337 0.17389 11 A exp(-Bx) 
100 114SerN 114SerH 58.64507 2.33955 0.30175 10 A exp(-Bx) 
101 115TyrN 115TyrH 60.14963 1.18839 0.1821 11 A exp(-Bx) 
102 117AspN 117AspH 60.70734 1.85037 0.35075 12 A exp(-Bx) 
103 118AspN 118AspH 58.27062 0.88009 0.21027 11 A exp(-Bx) 
104 119GluN 119GluH 67.62772 3.03509 0.63535 11 A exp(-Bx) 
105 120LysN 120LysH 65.76314 1.65501 0.33027 11 A exp(-Bx) 
106 121AsnN 121AsnH 69.42959 2.19221 0.30399 11 A exp(-Bx) 
107 122TrpN 122TrpH 56.21889 4.67836 0.8415 11 A exp(-Bx) 
108 123GlyN 123GlyH 62.98822 2.24381 0.31859 10 A exp(-Bx) 
109 124LeuN 124LeuH 59.53938 0.90992 0.15485 10 A exp(-Bx) 
110 125SerN 125SerH 61.74846 2.07671 0.25343 10 A exp(-Bx) 
111 126PheN 126PheH 57.59295 1.35035 0.16907 8 A exp(-Bx) 
112 127TyrN 127TyrH 55.98289 1.40084 0.16442 11 A exp(-Bx) 
113 128AlaN 128AlaH 55.89388 1.1422 0.21675 12 A exp(-Bx) 
114 129AspN 129AspH 57.65147 1.75738 0.28659 10 A exp(-Bx) 
115 130LysN 130LysH 54.17866 0.88079 0.3078 11 A exp(-Bx) 




117 134ThrN 134ThrH 67.78292 1.24744 0.2512 12 A exp(-Bx) 
118 135LysN 135LysH 59.07886 2.93105 0.22159 9 A exp(-Bx) 
119 136GluN 136GluH 59.32664 1.29881 0.2724 11 A exp(-Bx) 
120 137GlnN 137GlnH 59.95629 1.43147 0.30078 11 A exp(-Bx) 
121 138LeuN 138LeuH 58.3088 1.21082 0.25015 11 A exp(-Bx) 
122 139GlyN 139GlyH 61.2646 1.74132 0.35533 10 A exp(-Bx) 
123 140GluN 140GluH 55.13054 0.69311 0.11854 10 A exp(-Bx) 
124 141PheN 141PheH 53.25469 1.35938 0.26544 10 A exp(-Bx) 
125 142TyrN 142TyrH 58.80486 1.02502 0.19838 10 A exp(-Bx) 
126 143GluN 143GluH 57.8807 1.04951 0.24295 11 A exp(-Bx) 
127 144AlaN 144AlaH 58.32467 1.55333 0.31553 11 A exp(-Bx) 
128 145LeuN 145LeuH 57.40867 1.11194 0.18177 10 A exp(-Bx) 
129 146AspN 146AspH 57.16081 1.10779 0.26467 12 A exp(-Bx) 
130 147CysN 147CysH 59.08766 2.56941 0.67056 12 A exp(-Bx) 
131 148LeuN 148LeuH 58.45939 1.10285 0.15701 10 A exp(-Bx) 
132 149ArgN 149ArgH 66.20049 1.30374 0.26538 12 A exp(-Bx) 
133 150IleN 150IleH 57.6814 0.70244 0.15236 11 A exp(-Bx) 
134 152ArgN 152ArgH 58.00401 1.34901 0.34863 11 A exp(-Bx) 
135 153SerN 153SerH 53.26337 1.33233 0.3244 11 A exp(-Bx) 
136 154AspN 154AspH 59.58501 1.57523 0.35299 11 A exp(-Bx) 
137 155ValN 155ValH 59.20227 1.47689 0.46305 11 A exp(-Bx) 
138 156MetN 156MetH 58.77794 1.80498 0.22837 11 A exp(-Bx) 
139 157TyrN 157TyrH 64.91125 0.95765 0.17194 11 A exp(-Bx) 
140 158ThrN 158ThrH 67.92969 1.26092 0.21472 11 A exp(-Bx) 
142 160TrpN 160TrpH 62.84437 1.82316 0.30507 12 A exp(-Bx) 
143 161LysN 161LysH 50.82732 1.20096 0.32893 10 A exp(-Bx) 
144 163AspN 163AspH 58.0513 0.79753 0.2874 11 A exp(-Bx) 
145 164LysN 164LysH 62.61586 2.15714 0.19016 11 A exp(-Bx) 
146 165CysN 165CysH 55.09495 1.54578 0.25741 11 A exp(-Bx) 
147 166GluN 166GluH 53.51348 2.95385 0.29264 8 A exp(-Bx) 
148 168LeuN 168LeuH 54.00145 1.51397 0.40327 10 A exp(-Bx) 
149 169GluN 169GluH 65.92344 1.52845 0.4569 11 A exp(-Bx) 
150 170LysN 170LysH 75.00925 1.1832 0.34117 13 A exp(-Bx) 
151 171GlnN 171GlnH 110.9374 3.17931 0.52198 14 A exp(-Bx) 
152 172HisN 172HisH 176.9233 16.33071 4.02174 14 A exp(-Bx) 
        























1  1GlnN,H  1GlnN,H 8.52865 8.52865 122.00439 122.00439 -0.65492 
2  2IleN,H  2IleN,H 8.15713 8.15896 124.60556 124.66503 0.06583 
3  4LeuN,H  4LeuN,H 8.26057 8.26195 122.6946 122.7095 0.46299 
4  5CysN,H  5CysN,H 8.33075 8.32975 116.34572 116.36701 0.63905 
5  6AlaN,H  6AlaN,H 8.11899 8.11864 125.23878 125.2361 0.69814 
6  7AsnN,H  7AsnN,H 8.40318 8.40202 113.80739 113.79387 0.73142 
7  8LeuN,H  8LeuN,H 7.28133 7.27923 120.74726 120.77003 0.80384 
8  9ValN,H  9ValN,H 6.91578 6.91273 119.34428 119.32208 0.73373 
9  11ValN,H  11ValN,H 8.6883 8.68759 122.87769 122.85667 0.60114 
10  14ThrN,H  14ThrN,H 7.88395 7.88403 117.61832 117.62439 0.92696 
11  17ThrN,H  17ThrN,H 7.75937 7.75899 119.16567 119.17239 0.81153 
12  18LeuN,H  18LeuN,H 7.74931 7.74855 119.73473 119.72714 0.8472 
13  19AspN,H  19AspN,H 8.23812 8.23845 121.50593 121.51871 0.8516 
14  20ArgN,H  20ArgN,H 7.89888 7.89783 122.52163 122.51956 0.82976 
15  22ThrN,H  22ThrN,H 7.54237 7.54082 120.7697 120.75874 0.83982 
16  23GlyN,H  23GlyN,H 8.59263 8.59236 115.78722 115.78719 0.83508 
17  24LysN,H  24LysN,H 7.60715 7.60584 122.42949 122.42506 0.929 
18  25TrpN,H  25TrpN,H 8.32662 8.3259 127.93154 127.91949 0.86019 
19  26PheN,H  26PheN,H 9.34628 9.34601 116.52196 116.52211 0.85452 
20  27TyrN,H  27TyrN,H 9.01695 9.0159 122.52772 122.52867 0.84185 
21  28IleN,H  28IleN,H 8.5134 8.51397 130.72025 130.72124 0.95896 
22  29AlaN,H  29AlaN,H 6.9532 6.95226 119.53614 119.51033 0.77096 
23  30SerN,H  30SerN,H 8.81157 8.81046 111.0602 111.05385 0.85751 
24  31AlaN,H  31AlaN,H 7.97778 7.97664 118.1066 118.09939 0.83682 
25  32PheN,H  32PheN,H 8.74839 8.74933 114.20418 114.20338 0.78941 
26  33ArgN,H  33ArgN,H 9.11534 9.11326 119.77212 119.77593 0.93646 
27  34AsnN,H  34AsnN,H 6.63181 6.63345 117.83251 117.84142 0.67927 
28  35GluN,H  35GluN,H 9.00263 9.00139 130.34142 130.33654 0.82553 
29  36GluN,H  36GluN,H 7.98628 7.98483 120.36285 120.35162 0.74468 
30  37TyrN,H  37TyrN,H 8.68953 8.68791 120.18157 120.1855 0.86296 
31  38AsnN,H  38AsnN,H 7.81806 7.81809 118.12672 118.12065 0.87477 
32  39LysN,H  39LysN,H 8.17409 8.17251 117.97516 117.98561 0.79132 
33  40SerN,H  40SerN,H 8.10331 8.10208 114.86783 114.87632 0.82999 
34  41ValN,H  41ValN,H 8.58425 8.58478 117.60378 117.61764 0.78361 
35  42GlnN,H  42GlnN,H 7.82492 7.82524 122.30046 122.29642 0.79987 
36  43GluN,H  43GluN,H 7.07779 7.07733 113.97642 113.99145 0.6841 
37  44IleN,H  44IleN,H 7.61631 7.61707 120.65724 120.66072 0.7309 
38  45GlnN,H  45GlnN,H 8.68692 8.68311 128.76561 128.76017 0.79534 
39  46AlaN,H  46AlaN,H 8.0203 8.01979 116.18532 116.16742 0.83679 
40  47ThrN,H  47ThrN,H 10.40517 10.40259 124.40581 124.40783 0.79674 
41  48PheN,H  48PheN,H 8.81286 8.81244 123.97204 123.9546 0.88449 
42  49PheN,H  49PheN,H 9.06262 9.06284 117.00597 117.00427 0.83367 
43  50TyrN,H  50TyrN,H 9.28471 9.28349 117.16297 117.17472 0.81799 




45  52ThrN,H  52ThrN,H 8.90865 8.9073 118.24146 118.24652 0.77942 
46  54AsnN,H  54AsnN,H 9.16185 9.16049 122.95396 122.9542 0.8218 
47  55LysN,H  55LysN,H 8.89956 8.90011 122.3406 122.32724 0.89335 
48  56ThrN,H  56ThrN,H 7.99668 7.99569 110.53209 110.53377 0.78034 
49  57GluN,H  57GluN,H 7.17671 7.17655 118.99511 118.9799 0.75282 
50  58AspN,H  58AspN,H 7.79487 7.79389 117.9032 117.90903 0.85192 
51  59ThrN,H  59ThrN,H 7.67894 7.67802 107.02745 107.02443 0.8684 
52  60IleN,H  60IleN,H 8.74409 8.74553 118.41949 118.42063 0.90256 
53  61PheN,H  61PheN,H 8.42859 8.42755 129.33673 129.3338 0.90264 
54  62LeuN,H  62LeuN,H 8.95943 8.95404 135.43843 135.42761 0.97786 
55  63ArgN,H  63ArgN,H 8.02478 8.02347 124.08449 124.07712 0.83205 
56  64GluN,H  64GluN,H 8.86967 8.86856 126.77262 126.7758 0.83868 
57  65TyrN,H  65TyrN,H 9.03234 9.03125 127.69617 127.68583 0.82732 
58  67ThrN,H  67ThrN,H 8.75271 8.7489 125.25716 125.23692 0.82672 
59  68ArgN,H  68ArgN,H 8.98401 8.9831 126.88061 126.8836 0.83416 
60  69GlnN,H  69GlnN,H 9.31396 9.31266 120.69066 120.67989 0.74069 
61  70AsnN,H  70AsnN,H 9.32339 9.32145 109.88507 109.88031 0.78998 
62  71GlnN,H  71GlnN,H 8.03736 8.03638 118.35246 118.35048 0.82888 
63  72CysN,H  72CysN,H 8.563 8.56276 119.84108 119.86107 0.72184 
64  73PheN,H  73PheN,H 10.03813 10.03724 132.8579 132.84176 0.90464 
65  74TyrN,H  74TyrN,H 8.51283 8.51248 126.19928 126.19835 0.93792 
66  75AsnN,H  75AsnN,H 8.18123 8.17976 126.85782 126.85782 0.82286 
67  77SerN,H  77SerN,H 8.43689 8.43598 116.22745 116.23993 0.84868 
68  78TyrN,H  78TyrN,H 8.64995 8.65046 118.24407 118.22644 0.83704 
69  79LeuN,H  79LeuN,H 9.61372 9.61167 125.38862 125.3926 0.8022 
70  80AsnN,H  80AsnN,H 8.41866 8.41779 118.85241 118.84955 0.89741 
71  81ValN,H  81ValN,H 8.00551 8.00432 120.84602 120.8538 0.87824 
72  82GlnN,H  82GlnN,H 8.63689 8.63486 129.57834 129.57754 0.8335 
73  83ArgN,H  83ArgN,H 8.72906 8.72705 122.04353 122.04442 0.91069 
74  84GluN,H  84GluN,H 8.95636 8.95515 117.15224 117.15142 0.79547 
75  85AsnN,H  85AsnN,H 7.31125 7.31051 114.96509 114.964 0.84541 
76  86GlyN,H  86GlyN,H 7.86147 7.86123 106.82649 106.81115 0.96923 
77  88ValN,H  88ValN,H 8.48066 8.4796 111.84189 111.8405 0.85786 
78  89SerN,H  89SerN,H 9.21505 9.21384 115.52098 115.52015 0.84118 
79  90ArgN,H  90ArgN,H 8.67886 8.67818 119.60378 119.60779 0.72538 
80  91TyrN,H  91TyrN,H 8.7559 8.75606 126.41546 126.39608 0.96115 
81  92GluN,H  92GluN,H 8.63393 8.63376 127.48134 127.48482 0.75653 
82  94GlyN,H  94GlyN,H 8.26075 8.25821 106.17317 106.18229 0.67733 
83  95ArgN,H  95ArgN,H 7.18612 7.18592 117.87983 117.87596 0.65331 
84  96GluN,H  96GluN,H 8.34263 8.34184 122.22439 122.21626 0.7251 
85  97HisN,H  97HisN,H 9.21713 9.21512 127.48812 127.47651 0.74872 
86  98ValN,H  98ValN,H 8.68856 8.68822 122.3821 122.38367 0.85785 































































113GlyN,H 9.88458 9.88419 111.37328 111.3742 0.8935 













































124LeuN,H 8.00293 8.00358 117.00779 117.05032 0.83014 






















































































































149ArgN,H 7.6942 7.69273 114.3033 114.31076 0.86683 





152ArgN,H 8.37825 8.37783 122.2277 122.23785 0.83939 










































































































Lower Chemical Shifts 
1 Gln 1 C -72.7305 135.0443 -40 -110 179.99 90 CA CB H HA N 
2 Ile 1 C -68.7511 140.7373 -50 -100 170 100 CA CB H HA N 
3 Pro 1 C -59.0506 140.3952 -40 -90 170 110 CA CB 
4 Leu None None None None None None None None CA CB H HA N 
5 Cys None None None None None None None None CA CB H HA N 
6 Ala 1 C -56.1963 -30.895 -30 -100 10 -60 CA CB H HA N 
7 Asn 1 C -72.7809 -13.7881 -40 -120 20 -50 CA CB H HA N 
8 Leu 1 H -90.7633 -4.96936 -60 -120 30 -40 CA CB H HA N 
9 Val 1 C -71.4673 137.2546 -40 -100 179.99 100 CA CB H HA N 
10 Pro 1 C -64.4339 135.5129 -40 -90 170 110 CA CB 
11 Val 1 C -106.268 118.1109 -60 -160 170 90 CA CB H N 
12 Pro 1 E -67.0671 141.9123 -40 -100 170 110 CA CB 
13 Ile 2 C -104.742 4.7427 -70 -120 20 -40 CA CB H N 
14 Thr 1 C -85.111 165.0008 -60 -120 -170 140 CA CB H N 
15 Asn 1 H -58.1936 -41.2099 -40 -90 -10 -70 CA CB H HA N 
16 Ala 1 H -64.8715 -37.2978 -40 -90 -20 -60 CA CB H HA N 
17 Thr 1 H -64.4555 -44.5175 -40 -90 -20 -70 CA CB H HA N 
18 Leu 1 H -64.7988 -39.8734 -40 -90 -20 -60 CA CB H HA N 
19 Asp 1 H -64.9154 -44.6427 -40 -90 -20 -70 CA CB H HA N 
20 Arg 1 H -64.8817 -39.831 -40 -90 -10 -70 CA CB H N 
21 Ile 1 H -86.3188 -4.14959 -60 -120 30 -40 CA CB H HA N 
22 Thr 1 C -55.3798 135.005 -40 -80 160 110 CA CB H HA N 
23 Gly 1 C 84.10316 -4.04445 110 50 40 -40 CA H N 
24 Lys 1 E -114.67 134.9023 -90 -140 160 110 CA CB H HA N 
25 Trp 1 E -134.571 154.4861 -100 -160 179.99 120 CA CB H HA N 




26 Phe 1 E -124.29 134.2781 -80 -160 170 100 CA CB H HA N 
27 Tyr 1 E -102.82 117.8697 -60 -140 150 90 CA CB H HA N 
28 Ile 1 E -96.022 118.7044 -60 -140 160 100 CA CB H N 
29 Ala 1 E -135.516 160.2638 -110 -170 -170 120 CA CB H HA N 
30 Ser 1 C -149.906 160.912 -60 -180 -170 120 CA CB H HA N 
31 Ala 1 E -149.298 160.6636 -90 -180 -170 120 CA CB H HA N 
32 Phe 1 E -136.013 159.7168 -100 -180 179.99 130 CA CB H N 
33 Arg 2 C -70.7123 -24.1753 -40 -100 10 -50 CA CB H N 
34 Asn None None None None None None None None CA CB H N 
35 Glu 1 H -57.2629 -41.1997 -40 -90 -10 -70 CA CB H N 
36 Glu 1 H -61.8618 -42.0272 -40 -90 -10 -70 CA CB H N 
37 Tyr 1 H -65.8807 -42.0445 -40 -90 -20 -60 CA CB H N 
38 Asn 1 H -56.8371 -44.9212 -40 -80 -20 -70 CA CB H HA N 
39 Lys 1 H -64.6634 -43.5748 -40 -90 -10 -70 CA CB H N 
40 Ser 1 H -62.5657 -43.0712 -40 -90 -20 -70 CA CB H HA N 
41 Val 1 H -64.6075 -42.9103 -40 -90 -10 -70 CA CB H HA N 
42 Gln 1 H -64.0057 -40.8634 -40 -90 -10 -70 CA CB H N 
43 Glu 1 H -75.2494 -34.9849 -50 -110 10 -60 CA CB H HA N 
44 Ile None None None None None None None None CA CB H HA N 
45 Gln 1 C -55.1759 -35.1237 -30 -90 0 -70 CA CB H HA N 
46 Ala 1 C -91.7667 3.52196 -60 -130 40 -30 CA CB H HA N 
47 Thr 2 C -74.7392 125.7425 -40 -130 179.99 100 CA CB H 
48 Phe 1 E -132.013 154.1935 -90 -160 179.99 110 CA CB H HA N 
49 Phe 1 E -133.883 150.9984 -90 -170 179.99 120 CA CB H HA N 
50 Tyr 1 E -125.565 145.7302 -100 -170 179.99 120 CA CB H HA N 
51 Phe 1 E -124.88 130.0311 -90 -150 160 110 CB H HA N 
52 Thr 1 E -116.86 130.9135 -80 -150 160 90 CA CB H HA N 
53 Pro 1 C -65.0603 151.1584 -40 -90 179.99 120 CA CB 
54 Asn None None None None None None None None CA CB H HA N 
55 Lys 1 H -56.6078 -33.2814 -30 -80 0 -70 CA CB H N 
56 Thr 1 H -65.3174 -27.071 -40 -90 0 -60 CA CB H N 
57 Glu 1 C -87.0695 -4.06324 -60 -130 30 -40 CA CB H N 
58 Asp 1 C 55.01026 44.98974 80 40 60 20 CA CB H HA N 
59 Thr 1 E -132.621 153.4544 -100 -170 179.99 110 CA CB H HA N 
60 Ile 1 E -120.072 127.7119 -80 -150 160 100 CA CB H HA N 
61 Phe 1 E -98.0343 117.34 -70 -140 150 90 CA CB H HA N 
62 Leu 1 E -115.219 138.4524 -80 -150 170 100 CA CB H HA N 
63 Arg 1 E -123.708 127.5574 -80 -160 170 100 CA CB H HA N 
64 Glu 1 E -114.267 134.2422 -80 -150 170 100 CA CB H HA N 
65 Tyr 1 E -118.002 127.4782 -80 -160 170 100 CA CB H HA N 
66 Gln 1 E -120.492 134.1842 -90 -160 179.99 100 CA CB H HA N 
67 Thr 1 E -108.563 124.4852 -80 -140 150 100 CA CB H HA N 
68 Arg 1 E -124.164 137.708 -80 -170 179.99 100 CA CB H HA N 
69 Gln 2 C -64.8949 -15.2949 -30 -100 10 -60 CA CB H N 
70 Asn 2 C -69.9162 -20.4834 -40 -100 10 -50 CA CB H HA N 




72 Cys 1 E -97.5529 118.6864 -50 -150 170 90 CA CB H N 
73 Phe 1 E -111.559 127.213 -70 -150 160 100 CA CB H HA N 
74 Tyr 1 E -123.22 125.2346 -90 -150 160 100 CA CB H N 
75 Asn 1 E -117.021 132.9381 -70 -150 170 100 CA CB H HA N 
76 Ser 1 E -118.844 137.1572 -80 -160 170 100 CA CB H HA N 
77 Ser 2 E -139.003 154.2987 -70 -180 -170 110 CA CB H HA N 
78 Tyr 1 C -71.9139 143.1241 -40 -120 170 110 CA CB H HA N 
79 Leu 1 C -114.563 140.2114 -50 -170 179.99 100 CA CB H HA N 
80 Asn 1 C -127.194 135.0366 -60 -160 170 90 CA CB H N 
81 Val 1 E -115.283 126.0413 -70 -150 160 100 CA CB H N 
82 Gln 2 C -65.4388 146.2681 -40 -110 179.99 110 CA CB H HA N 
83 Arg 1 H -55.0221 -34.9513 -30 -80 0 -60 CA CB H N 
84 Glu 1 H -64.9834 -24.9921 -40 -80 0 -50 CA CB H HA N 
85 Asn 1 C -85.0786 -3.17356 -60 -130 20 -20 CA CB H HA N 
86 Gly 1 C 85.19527 6.87491 110 40 60 -30 CA H N 
87 Thr 1 E -134.661 156.0381 -110 -160 179.99 130 CA CB H N 
88 Val 1 E -130.966 153.8473 -100 -160 179.99 120 CA CB H HA N 
89 Ser 1 E -127.174 145.9256 -100 -160 179.99 110 CA CB H HA N 
90 Arg 1 E -125.374 134.7661 -100 -160 160 110 CA CB H N 
91 Tyr 1 E -105.175 123.6615 -70 -140 150 100 CA CB H HA N 
92 Glu 1 E -119.728 141.4574 -60 -170 179.99 80 CA CB H HA N 
93 Gly 1 C 55.03506 41.53718 80 30 60 10 CA H N 
94 Gly 1 C 75.15846 14.55763 100 50 30 -20 CA H N 
95 Arg 1 E -124.034 143.2572 -90 -160 179.99 110 CA CB H N 
96 Glu 1 E -91.1225 134.7643 -60 -150 160 100 CA CB H N 
97 His 1 E -125.818 132.9947 -80 -160 160 100 CA CB H HA N 
98 Val 1 E -108.38 125.3725 -70 -150 150 100 CA CB H HA N 
99 Ala 1 E -121.602 131.9283 -90 -150 170 100 CA CB H HA N 
100 His 1 E -77.1068 136.1821 -50 -140 170 100 CA CB H HA N 
101 Leu 1 E -110.932 125.282 -70 -140 160 100 CA CB H N 
102 Leu 1 E -121.938 137.1655 -80 -160 179.99 100 CA CB H HA N 
103 Phe 1 E -114.993 134.0291 -80 -150 170 100 CA CB H HA N 
104 Leu None None None None None None None None H N 
105 Arg 1 C -62.8166 -27.3489 -40 -90 0 -70 CA CB H N 
106 Asp 1 C -71.313 -19.3067 -40 -120 30 -70 CA CB H N 
107 Thr 1 C -65.7655 143.4098 -40 -100 170 110 CA CB H HA N 
108 Lys 2 E -94.4642 135.0134 -40 -130 170 100 CA CB H HA N 
109 Thr 1 E -136.627 155.469 -100 -170 179.99 120 CA CB H HA N 
110 Leu 1 E -127.389 139.6829 -90 -160 170 110 CA CB H HA N 
111 Met 1 E -115.617 135.0257 -90 -160 179.99 100 CA CB H HA N 
112 Phe 1 E -120.005 133.0854 -90 -150 170 100 CA CB H HA N 
113 Gly 1 E -83.4809 133.1042 -50 -160 179.99 80 CA H N 
114 Ser 1 C -70.778 146.0134 -40 -100 179.99 110 CA CB H HA N 
115 Tyr 2 C -65.2954 145.1559 -40 -100 179.99 110 CA CB H HA N 
116 Leu 2 C -77.8672 -16.057 -40 -120 30 -50 CA CB 




118 Asp None None None None None None None None CA CB H HA N 
119 Glu 1 C -60.6778 -28.1812 -40 -90 10 -60 CA CB H N 
120 Lys 2 C -66.3325 -14.9175 -40 -110 20 -50 CA CB H N 
121 Asn None None None None None None None None CA CB H N 
122 Trp 2 C -91.0674 142.7728 -40 -180 -170 90 CA CB H N 
123 Gly None None None None None None None None CA H N 
124 Leu 1 E -142.208 155.4291 -110 -170 -170 130 CA CB H HA N 
125 Ser 1 E -127.322 146.0463 -100 -170 179.99 110 CA CB H N 
126 Phe 1 E -123.235 137.949 -100 -150 179.99 110 CA CB H HA N 
127 Tyr 1 E -125.14 153.9649 -100 -160 179.99 120 CA CB H HA N 
128 Ala 1 E -130.458 144.6134 -80 -180 179.99 100 C CA CB H HA N 
129 Asp 2 E -75.1419 135.9401 -40 -130 179.99 90 CA CB H HA N 
130 Lys 1 C -86.1345 136.4302 -40 -180 179.99 90 CA CB H N 
131 Pro 1 C -62.9018 144.0217 -40 -90 179.99 120 CA CB 
132 Glu None None None None None None None None CA CB H HA N 
133 Thr 1 E -116.267 127.4794 -90 -160 179.99 100 CA CB H HA N 
134 Thr 1 C -84.9932 165.0002 -60 -100 -170 150 CA CB H HA N 
135 Lys 1 H -63.6299 -39.7091 -40 -90 -10 -70 CA CB H N 
136 Glu 1 H -64.8832 -44.1474 -40 -90 -20 -70 CA CB H N 
137 Gln 1 H -64.6961 -43.6179 -40 -90 -10 -70 CA CB H N 
138 Leu 1 H -64.4116 -44.1623 -40 -90 -20 -70 CA CB H HA N 
139 Gly 1 H -64.9541 -35.9865 -40 -90 -20 -60 CA H N 
140 Glu 1 H -64.9402 -44.1876 -40 -90 -20 -70 CA CB H N 
141 Phe 1 H -64.8244 -42.479 -40 -90 -20 -70 CA CB H N 
142 Tyr 1 H -64.78 -39.6801 -40 -90 -20 -70 CA CB H N 
143 Glu 1 H -63.4772 -44.8985 -40 -90 -20 -70 C CA CB H N 
144 Ala 1 H -62.559 -41.5139 -40 -90 -10 -70 CA CB H HA N 
145 Leu 1 H -64.9052 -37.4784 -40 -90 -20 -60 CA CB H N 
146 Asp 1 H -64.9261 -44.1091 -40 -90 -20 -70 CA CB H HA N 
147 Cys 1 H -64.5569 -25.3932 -40 -90 0 -60 CA CB H N 
148 Leu 1 C -91.3622 2.17721 -60 -120 30 -30 CA CB H HA N 
149 Arg 1 C 57.33877 42.49221 80 40 60 10 CA CB H N 
150 Ile 1 C -84.2765 128.9212 -50 -140 170 90 CA CB H HA N 
151 Pro 1 C -63.7968 143.338 -40 -90 170 120 CA CB 
152 Arg 1 C -55.1946 -34.7466 -40 -90 0 -60 CA CB H N 
153 Ser 1 H -65.606 -14.5181 -40 -100 20 -50 CA CB H N 
154 Asp 2 H -85.3073 -4.91526 -60 -120 20 -40 CA CB H HA N 
155 Val 1 C -79.7523 132.1211 -50 -150 160 90 CA CB H HA N 
156 Met 1 E -94.8891 134.995 -60 -130 160 100 CA CB H N 
157 Tyr 1 E -138.322 153.6266 -90 -180 179.99 120 CA CB H N 
158 Thr 1 E -131.952 139.1649 -90 -160 170 100 CA CB H HA N 
159 Asp 1 E -122.368 130.3725 -70 -160 179.99 90 CA CB H HA N 
160 Trp 1 C -59.8106 -21.2774 -40 -90 10 -50 CA CB H HA N 
161 Lys 1 C -64.9952 -16.5539 -40 -90 10 -60 CA CB H N 
162 Lys 1 C -106.326 6.28499 -70 -130 40 -20 CA CB H N 




164 Lys 2 C -148.283 153.9789 -40 -180 -170 90 CA CB H N 
165 Cys None None None None None None None None CA CB H N 
166 Glu None None None None None None None None CA CB H N 
167 Pro 1 H -55.0322 -34.9561 -30 -90 0 -70 CA CB 
168 Leu 1 H -64.9687 -22.4049 -40 -90 0 -50 CA CB H N 
169 Glu 1 H -62.9338 -35.6323 -40 -90 0 -70 CA CB H N 






a.5 DANGLE predictions based on chemical shift assignments of AGP2 residues. 
 
a.6. Table of crystallographic parameters. This author wishes to thank Dr Chris Williams 
for carrying out the structure calculations 
 
Table 1.  Data collection and refinement statistics. 
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